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General introduction
Schizophrenia is a devastating psychiatric disorder aﬀ ecting about 1% of the world’s population throughout countries, cultural groups, and sexes (Jablensky, 
1997). In 1902, it was Kraeplin who ﬁ rst described the disease as dementia praecox, a 
term used to describe individuals who exhibited symptoms that involved severe mental 
deterioration from an early age. Later, Bleuler used the term schizophrenia to illustrate 
the theoretical rupture between thought, emotion, and behaviour (Bleuler, 1950). Today, 
schizophrenia is described as a psychiatric disorder characterised by abnormal mental 
functions and disturbed behaviour, mostly appearing after puberty as a diverse mixture 
of positive and negative symptoms, and cognitive impairment (Liddle, 1987). Positive 
symptoms involve loss of contact with reality, including paranoia, false beliefs (delusions), 
perceptual experiences not shared by others (hallucinations), or bizarre behaviours. 
Negative symptoms refer to diminished or absent basic emotional and behavioural 
processes, such as social withdrawal, reduced initiative, blunted aﬀ ect, anhedonia (lack 
of pleasure), and reduced speech. Th e cognitive impairments in schizophrenia include 
attention deﬁ cits, reduced learning and memory, and executive dysfunctions (for example 
abstract thinking or problem solving) (Mueser and McGurk, 2004).
In addition, schizophrenic patients have shown an increased risk of alcohol and drug 
problems (Regier et al., 1990), infectious diseases (such as hepatitis C and HIV 
infection) (Rosenberg et al., 2001), violent victimization (Walsh et al., 2003) and post-
traumatic stress disorder (Mueser et al., 2002), housing instability and homelessness 
(Susser et al., 1989), and negative emotions, such as anxiety (Huppert and Smith, 2001), 
depression (Addington et al., 1998), and hostility (Bartels et al., 1991). Th ese risks cause 
among patients an increased mortality risk of about 10% due to suicide, accidents, 
and illnesses such as respiratory and cardiovascular diseases (Brown, 1997; Inskip et 
al., 1998). Surprising is the observation that although schizophrenic patients are often 
heavy smokers, they show a reduced risk of developing lung cancer (de Leon et al., 1995; 
Harris, 1988).
Aetiology
To date, the understanding of schizophrenia remains very rudimentary. Many attempts 
have been made to ﬁ nd out more on the cause of this disease. Groups from all over 
the world have been performing studies at the molecular, cellular and anatomical level 
in search for deﬁ nitive genes or pathogenic molecular mechanisms, but thus far little 
progress is being made. Th e complex, diverse clinical phenotype and course of the disease 
tamper research progress, since they often result in inconsistent, or even contradictive 
ﬁ ndings. Th e eﬀ orts to identify the underlying mechanisms in schizophrenia can 
roughly be divided into three general lines of research. Th e ﬁ rst line of analyses focuses 
on the examination of the mechanism of action of the drugs that alleviate or mimic the 
Chapter 1
10
symptoms of schizophrenia. As a second approach, the neuro-anatomical abnormalities 
in the brains of schizophrenic patients are examined. And thirdly, the genetics of 
susceptibility for schizophrenia is analysed.
Drugs and neurotransmitters
Th e ﬁ rst discovered beneﬁ cial drug to treat schizophrenia was chlorpromazine in the 
early 1950s. Th is drug, a so-called neuroleptic, turned out to block the D2 subtype 
of dopamine receptor (Creese et al., 1976; Seeman et al., 1976). Indeed, many of the 
traditional antipsychotic drugs act by blocking the dopamine receptors in the brain. 
Conversely, amphetamine, which increases the dopamine levels in the synaptic cleft, 
was found to induce schizophrenic symptoms in humans (Davis et al., 1991). Both types 
of drug eﬀ ects led to the dopamine hypothesis of schizophrenia, which proposes that 
dysfunction in dopamine neurotransmission is the underlying cause of the symptoms 
of the disorder (Carlsson, 1988). More speciﬁ cally, a hyperactivity of mesolimbic 
dopaminergic neurons is suggested to produce the positive symptoms of schizophrenia 
such as psychosis. Several research groups have reported that the dopaminergic system 
is indeed aﬀ ected in schizophrenia (reviewed by Abi-Dargham, 2004; Laruelle et al., 
2003). In this respect, an important study by Abi-Dargham et al. (2000) has clearly 
shown that increased synaptic dopamine concentrations are apparent in the striatum of 
drug-free schizophrenic patients.
A drug that induces both positive and negative symptoms is phencyclidine (PCP or angel 
dust). In addition, it causes cognitive deﬁ cits seen in many schizophrenic patients (Javitt 
and Zukin, 1991). PCP appears to act predominantly on glutamatergic N-methyl-D-
aspartate (NMDA) receptors. Also two other NMDA receptor antagonists (ketamine 
and MK-801) produce schizophrenic symptoms, and antipsychotics (i.e. dopamine 
receptor antagonists) can reduce PCP-induced behaviour. Th is has led to the hypothesis 
that hypofunctioning of the NMDA receptors causes schizophrenia (Coyle, 1996; Olney 
and Farber, 1995). One aspect of the glutamate model that is still poorly understood is 
the observation of diﬀ erential eﬀ ects of short- and long-term administration of NMDA 
antagonists. Both regimens, however, can induce profound behavioural symptoms in 
rats and primates similar to those observed in schizophrenia in humans (reviewed by 
Jentsch and Roth, 1999).
Also the serotoninergic (5-HT) system has been frequently implicated in schizophrenia, 
based on the eﬀ ects of drugs like lysergic acid diethylamide (LSD) and mescaline (Costall 
and Naylor, 1995). Although these drugs cause psychedelic hallucinations, there is very 
little evidence of a primary dysfunction of the serotonergic systems in schizophrenia. 
Also, repeated administration of LSD leads to behavioural tolerance, which clearly 
diﬀ ers from the situation in schizophrenia (Braﬀ  and Geyer, 1980).
Neuroanatomical abnormalities
Brain abnormalities in schizophrenic patients have been extensively studied over the 
past century. Unfortunately, many of these studies failed, because drug treatments and 
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dietary abnormalities of schizophrenic may themselves have caused alterations in brain 
anatomy. Th e recent development of neuroimaging techniques such as magnetic resonance 
imaging (MRI), single photon emission computed tomography (SPECT), and positron 
emission tomography (PET) has given investigators a new set of tools that permit in vivo 
study of brain abnormalities. Consistent ﬁ ndings in the brains of schizophrenic patients 
are the increased ventricular size, and prominent alterations in the prefrontal cortex and 
hippocampus, whereby the ventricular size aberrations are already present at the onset of 
the disease symptoms (Weinberger et al., 1979). However, a signiﬁ cant overlap is found 
between the ventricular sizes in subjects with schizophrenia and controls, making this 
an ineﬀ ective anatomical diagnostic marker. Th e prefrontal cortex and hippocampus 
are two brain areas involved in emotional regulation and cognitive functions suggesting 
that psychotic symptoms observed in schizophrenia originate in these regions (Stevens, 
1973; Torrey and Peterson, 1974). Th e prefrontal cortex, one of the projectory regions 
of the dopaminergic pathway, has been associated with schizophrenia, based on clinical, 
neuropsychological and neuroimaging ﬁ ndings (reviewed by Knable and Weinberger, 
1997). Th e hippocampus is implicated due to a reduced size, shape and architecture, 
alterations in metabolic activity, and neurochemistry in schizophrenic patients (reviewed 
by Harrison, 2004). Still, these observations do not clearly indicate a general dysfunction 
of these brain structures, but rather imply subtle morphological, architectural and cellular 
changes aﬀ ecting the neuronal connectivity and pathways throughout the brain.
Genetic factors
Genetic studies on schizophrenia patients and their relatives have shown that the risk 
of developing the illness is progressively greater in relatives who are more genetically 
related to the person with schizophrenia (Figure 1). Th e analyses of monozygotic twins, 
who have 100% identical genomes, revealed that genetic factors appear to be important 
in the development of schizophrenia (a concordance rate of 48%), with heritability 
estimates of approximately 80-85% (Cardno and Gottesman, 2000; Sullivan et al., 
2003). Th e family studies also show that simple major gene eﬀ ects are unlikely. More 
likely, multiple susceptibility genes exist that act in concert. Th is makes schizophrenia a 
complex genetic disorder, not caused by a single gene and not showing simple Mendelian 
inheritance. Th e results of the monozygotic twin studies also demonstrated that genetics 
are not suﬃ  cient to explain the entire pattern of occurrence (Cardno et al., 1999).
Environmental factors
Next to the genetic component of schizophrenia, it has become apparent that 
environmental factors contribute to the risk of developing the disease. Numerous 
studies have reported an increased occurrence of stressful events during the pre- and 
perinatal periods in schizophrenic patients (reviewed by McDonald and Murray, 2000). 
Examples of such events are obstetric complications, prenatal exposure to infection, 
external toxins, malnutrition or maternal stress during pregnancy (Brown et al., 2001; 
Jones et al., 1998; Susser and Lin, 1992; van Os et al., 2000). Stressors occurring later 
in life can trigger the clinical manifestation of schizophrenia. It has been described that 
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up to 46% of patients underwent some stressful life event in the three months preceding 
the ﬁ rst occurrence of schizophrenic symptoms (Norman and Malla, 1993; Ventura et 
al., 1989).
 
Together, this forms the hypothesis that in schizophrenic patients a genetic susceptibility, 
together with stressful early-life events, results in neurodevelopmental impairment 
and aﬀ ects maturation of the brain, manifesting in disease symptoms during or after 
puberty and mostly persisting throughout the patient’s lifetime. Th is developmental 
aspect together with the long time interval until the onset of the ﬁ rst schizophrenic 
symptoms makes causal research very diﬃ  cult. In this respect, prospective studies of 
(future) patients would be most informative, but on the other hand extremely expensive 
and time consuming due to the large cohorts to be studied over a long period of time.
Approaches
With the completion of the human genome sequencing project by the International 
Human Genome Sequencing Consortium in April 2003 a new era has begun enabling 
researchers to identify many new genes. Th us far, consortium researchers have conﬁ rmed 
the existence of 19,599 protein-coding genes in the human genome and identiﬁ ed 
another 2,188 DNA segments that are predicted to be protein-coding genes (2004). 
However, it could be years before a truly reliable gene count can be assessed. Moreover, 
to date the function of many of these genes is still unknown.
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Figure 1. Genetic component to schizophrenia
Genetically related individuals show an increased risk of developing schizophrenia 
during their lives. Nevertheless, individuals with identical genomes (monozygotic 
twins) show a concordance rate of only 48%, indicating schizophrenia is not entirely a 
genomic disease. Adapted from Gottesman (1991).
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In the hunt for ﬁ nding genes that may cause schizophrenia, the human genome 
sequencing data could be used in so-called genome-wide linkage analyses. To date, 
numerous of such genome-wide scans of schizophrenics have together implicated much 
of the genome, although only a couple of regions reached accepted levels of statistical 
signiﬁ cance (Owen et al., 2004). Unfortunately, each of these regions implicated have 
been refuted in other studies by not revealing any linkage with the disease (reviewed by 
Harrison and Weinberger, 2005). Due to this inconsistency the genome-wide linkage 
analyses approach has still not resulted in the discovery of a causative genetic region. Th e 
ultimate validation of a linkage analyses will come from the discovery of a gene or genes 
within a linked region, including functional information.
One other way of exploiting the public genome databases in the search for the genetic 
component of schizophrenia, is the testing for allelic variants of candidate genes, usually 
single-nucleotide polymorphisms (SNPs), within or adjacent to a gene. Th e identiﬁ cation 
of an association of a SNP with schizophrenics compared to a suitable comparison group, 
could mean that the SNP is either causative or in linkage disequilibrium (LD). Also in 
this case, the identiﬁ cation of susceptibility genes for schizophrenia will not come from 
mere statistical analyses, but will require biological evidence that the genetic risk variant 
has impact on the pathogenesis of the disease (Page et al., 2003).
Such alterations in genetic build-up may ultimately result in changes in gene expression, 
as measured by altered mRNA or protein levels. In addition, factors other than genetic 
mutations could also aﬀ ect expression levels. Th erefore, screening for diﬀ erences at 
the RNA or protein level could be most informative in the search for susceptibility 
genes for schizophrenia. More recently, a new level has been added to the regulation 
of expression, termed epigenetics (Holliday, 1987). Th ese epigenetic factors (heritable 
factors without sequence variation, such as DNA methylation, histone acetylation 
and chromatin structure) are able to regulate gene activity and are also believed to be 
important in schizophrenia (Jaenisch and Bird, 2003; Petronis, 2004; Robertson and 
Wolﬀ e, 2000).
Expression analyses
Th e complexity of schizophrenia suggests that high throughput screening techniques, 
such as microarrays, may be well suited for identifying transcripts that are dysregulated 
in the disease state. High-density DNA arrays make it possible to monitor the expression 
levels of thousands of genes at a time. Other screening techniques such as diﬀ erential 
hybridisation, subtractive library construction, representational diﬀ erence analysis 
(RDA), suppression subtractive hybridisation (SSH), diﬀ erential display (Liang and 
Pardee, 1992), conventional cDNA array hybridisation, serial analysis of gene expression 
(SAGE) (Velculescu et al., 1995), and (real-time) RT-PCR all have serious limitations 
for large genome-scale expression studies, as they are expensive, technically diﬃ  cult and 
very labour intensive compared to the DNA microarray approach.
Th e two most widely used types of arrays to evaluate diﬀ erential gene expression are 
the cDNA and oligonucleotide arrays, such as those produced by Aﬀ ymetrix. Th ese 
oligonucleotide arrays are synthesised in situ and consist of multiple, yet distinct, short 
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nucleotide stretches (e.g. 25-mers) of individual genes. Perfectly matching oligos are 
aligned adjacent to a control probe containing a single-base mismatch to correct for 
non-speciﬁ c hybridisation. Alternatively, cDNA arrays consist of longer clone fragments 
(usually between 300 and 2000 bases) that are spotted on the array. Th is approach 
causes a greater ﬂ exibility and lower relative production cost, but it less suitable to detect 
speciﬁ c splice variants or gene family members (Figure 2).
In the analyses of expression proﬁ les (either at the RNA or protein level) several diﬃ  culties 
will be encountered. Firstly, the availability of post-mortem brain tissue is essential for 
expression studies. Th e cause of death, the age of the deceased, and interval between 
death and tissue storage or ﬁ xation are all complicating factors, which makes it almost 
impossible to ﬁ nd the perfect controls for proper expression analyses. Secondly, the 
(medical) history is likely to interfere with the experimental outcome. Each individual 
has a unique environment in which he or she grows up (family studies compensate in 
part for this). Furthermore, if a patient is on medication, the timing and dosage of the 
drugs can have a severe eﬀ ect on the expression of a gene. Th irdly, since schizophrenia is 
a neurodevelopmental disorder with causal implications for early-environmental factors 
and a long time interval until the onset of symptoms, it will be quite a challenge to ﬁ nd 
causal expression diﬀ erences between post-mortem samples from patients and controls.
Animal models
Animal models seem to be the perfect way of circumventing the diﬃ  culties encountered 
when using patient material for expression proﬁ ling analyses. Unfortunately, the 
modelling of human psychiatric disorders like schizophrenia in animals meets 
diﬃ  culties, since behavioural symptoms involving human communication and 
language (such as delusions or hallucinations) are diﬃ  cult to simulate in animals. In 
addition, there is concern that especially in rodents some brain areas are not developed 
to the level necessary to express psychotic behaviours. Nonetheless, there are behaviours 
in animals that mimic certain symptoms of schizophrenia, such as locomotor 
hyperactivity, stereotypies, cognitive impairments, disruption of latent inhibition or 
prepulse inhibition, and electrophysiological abnormalities (Gainetdinov et al., 2001; 
Lipska and Weinberger, 2000). Especially the use of animal models in exploring the 
neurodevelopmental hypothesis in schizophrenia will be of vital importance. One of 
the major advantages of the use of animal models in studying schizophrenic symptoms 
is the ability to condition and control their environment. But also embryonic to adult 
studies can be performed much more easily and less expensive in animals compared to 
humans. 
In general, the validity of animal models can be divided into three main categories: 
predictive validity, face validity and construct validity (Cools and Ellenbroek, 2002; 
Ellenbroek and Cools, 1990). In the ﬁ rst category of animal models - predictive validity 
is at the empirical level - the eﬀ ects of substances or treatments on the animals are used 
to predict the situation in human. Th ese models do not necessarily have any resemblance 
to the disease phenotype. Secondly, animal models with face validity, or symptom 
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Figure 2. Comparison of cDNA and oligonucleotide array preparation and analysis
The cDNA microarrays are prepared by amplification of inserts from cDNA collections or libraries and 
subsequent printing of the PCR products on glass slides. The high-density oligonucleotide microarrays 
are prepared by selection of sequences of 16-20 short oligonucleotides (typically 25-mers) from the 
mRNA reference sequence of each gene and these oligonucleotides are synthesised in situ via a light-
directed method, whereby high-density probe arrays containing over 300,000 individual elements 
are generated. The target preparation is also different for both types of microarrays. For the cDNA 
microarray, RNA from two controller and tester is used to synthesise single-stranded cDNA in the 
presence of nucleotides labelled with two different fluorescent dyes (for example, Cy3 and Cy5). Both 
samples are mixed and hybridised to the array surface, resulting in competitive binding of differentially 
labelled cDNAs to the corresponding array elements. Subsequent fluorescence scanning of the array 
provides relative signal intensities and ratios of mRNA abundance for the genes represented on the 
array. The target preparation for the oligonucleotide microarays occurs through polyA+ RNA isolation 
from controller and tester, followed by double-stranded cDNA synthesis and concurrent incorporation 
of the T7 DNA polymerase transcriptional start site. During in vitro transcription, biotin-labelled 
nucleotides are incorporated into the synthesised cRNA molecules, and each target sample is hybridised 
to a separate probe array. After staining with a fluorescent dye coupled to streptavidin and scanning of 
the array, signal intensities of different arrays are used to calculate relative mRNA abundance for the 
genes represented on the array (adapted from Schulze and Downward, 2001).
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validity, have a perceived resemblance with the human disease, but without a similar 
cause (Willner, 1986). Face validity models can be generated by behavioural selection 
of animals, they can be pharmacologically induced, or they can be experimentally 
induced by manipulations such as brain lesions. Examples of such face validity models 
for schizophrenia are given below.
Animal models based on behavioural selection
One test to show the information processing deﬁ cit in the brains of schizophrenic patients 
is the pre-pulse inhibition of the acoustic startle response (PPI). Th e PPI refers to the 
ability of a weak pre-stimulus to transiently inhibit the response to a closely following 
strong sensory stimulus, and is found to be deﬁ cient in schizophrenia (reviewed by 
Braﬀ  et al., 2001). Performing PPI analysis among rat lines and strains have revealed 
marked diﬀ erences (Ellenbroek et al., 1995; Glowa and Hansen, 1994; Markou et al., 
1994). Th e division of rats in groups, based on their diﬀ erences in PPI and subsequent 
analyses of the possible cause for their discrepancies, may also yield useful information 
for understanding certain aspects of schizophrenia.
Pharmacologically induced animal models
As mentioned earlier, the psychotic eﬀ ects of psychomimetric drugs, such as amphetamine 
and phencyclidine (PCP), cause in healthy humans symptoms comparable to the 
positive symptoms in schizophrenia, and PCP also induces negative symptoms. Th e 
pharmacological animal models are based on the observations that such drugs will 
also evoke schizophrenia-like symptoms in animals. In rats, for example, PCP induces 
hyperactivity, stereotypy, ataxia and impaired social behaviour which can be ameliorated 
by clinically eﬀ ective neuroleptic drugs (reviewed by Morris et al., 2005), and it disrupts 
PPI (Geyer et al., 2001). Such animal models may aid especially in testing potential 
novel treatments prior to clinical studies in patients.
Brain lesion animal models
Animal models for schizophrenia using the concept of brain lesions have shown that 
especially neonatal lesions appear to mimic schizophrenic symptoms. Monkeys with a 
neonatally lesioned hippocampus show impairment in relational learning, reduced social 
behaviour and increased locomotor stereotypy (Bachevalier et al., 1999). Additionally, 
neonatal disconnections of the hippocampus or amygdala in rats have also been reported 
to function as models for schizophrenic symptoms (Flores et al., 2005; Lipska, 2004; 
Wolterink et al., 2001). Also chemical lesions such as the injection of 6-OHDA within 
the nucleus accumbens of neonatal rats resulted in an impaired prepulse inhibition and 
were suggested to represent an animal model for schizophrenia as well (Bubser and Koch, 
1994). Unfortunately, neonatal lesioning of brain regions will aid in understanding what 
brain structures are involved in the disease symptoms, but it most likely will not result 
in ﬁ nding causative genetic defects.
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Th e third main category of animal models shows construct validity, and originates from 
the theoretical level. In these models, the actual cause of the human disorder is mimicked. 
As a result, large theoretical and practical similarities in cause, aetiology and symptoms 
can exist between animal model and human disorder (Ellenbroek and Cools, 1990; 
Willner, 1986). As examples for models with construct validity, genetically modiﬁ ed 
animal models and the innovative APO-SUS/-UNSUS rat model are described below.
Genetic animal models
Completion of the genome sequencing of the mouse and rat in 2002 and 2004, 
respectively, has enabled researchers to further exploit these rodents as animal models to 
study (characteristics of) complex disorders at the genetic level. Genetic animal models 
for schizophrenia have been focusing predominantly on knockout or transgenic mice 
with a single genetic mutation. For this approach, the mouse has been a favourite tool of 
geneticists, due to the relatively easy technical procedures for manipulating individual 
genes. One of the major drawbacks of the use of mice in studying complex psychiatric 
traits is that mice have only limited use in complex behavioural research compared to 
rats. Th is would favour rats above mice in the use of studying schizophrenic behaviour. 
Unfortunately, the speciﬁ c manipulation of rat genes has appeared to be much more 
diﬃ  cult. Only via recently described techniques, such as the ENU mutagenesis, random 
mutations can be incorporated in the genome of laboratory rats and via genetic screens 
speciﬁ c mutations could be further analysed (Smits et al., 2004). But this approach still 
has to prove its usefulness. Furthermore, these knockout or mutational approaches in 
mice and rat has provided useful models for Mendelian, but not for complex diseases.
APO-SUS and -UNSUS rat model
For the study of genetic background of complex diseases (i.e. with a presumed multigenic 
cause), a diﬀ erent approach will likely be most eﬀ ective. So-called heuristic (i.e. “serving 
to discover” or innovative) models may help to uncover mechanisms of schizophrenia-like 
phenomena. A good heuristic model will show more schizophrenia-like abnormalities 
besides the feature that is directly manipulated. One example of such a heuristic animal 
model is the APO-SUS/-UNSUS rat model.
In the past, Cools et al. (1990) generated a rat model, not focusing primarily on a 
genetic deﬁ cit, but rather on the behavioural phenotype. Th ey used the approach to 
pharmacogenetically select rats from an outbred Wistar population with either a high 
or a low susceptibility of the dopamine agonist apomorphine (referred to as APO-SUS 
and APO-UNSUS rats, respectively). Th e apomorphine susceptibility of the Wistar 
rats as measured by their gnawing behaviour, revealed a bimodal distribution within 
the population. Both the vigorously gnawing and non-gnawing rats were used to set 
up outbred lines, preventing brother-sister pairing. Both rat lines thus represent two 
extremes of a population of Wistar rats. Extensive phenotyping of the APO-SUS and 
-UNSUS rats has revealed diﬀ erences in many aspects of behaviour, neuroanatomy, 
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and their neurochemical, endocrine and immune systems (Cools and Gingras, 1998; 
Ellenbroek and Cools, 2002). Interestingly, APO-SUS display a variety of features closely 
resembling those observed in patients suﬀ ering from schizophrenia, including increased 
sensitivity to dopamimetic drugs (Ellenbroek et al., 2000; Muller-Spahn et al., 1998), 
increased level of tyrosine hydroxylase mRNA in the substantia nigra (Rots et al., 1996; 
Toru et al., 1984), decrease in prepulse inhibition and latent inhibition (Baruch et al., 
1988; Braﬀ  and Geyer, 1990; Ellenbroek et al., 1995), a retarded development (Degen et 
al., 2005; Wahlbeck et al., 2001), increased hypothalamus-pituitary-adrenal (HPA) axis 
response to stress (Lammers et al., 1995; Rots et al., 1995), relative dominance of TH2 
cells (Kavelaars et al., 1997; Muller et al., 1999), increased occurrence of periodontitis 
(Breivik et al., 2000; Tang et al., 2004), reduced sensitivity to develop arthritis (van de 
Langerijt et al., 1994; Vinogradov et al., 1991) and lower risk of developing (lung) cancer 
(Mortensen, 1994; Teunis et al., 2002) (Table 1).
Table 1. Phenotypic similarities between APO-SUS rats and schizophrenic patients 
(with internal reference list)
Observation
Characteristics APO-SUS schizophrenia
Information processing
prepulse inhibition reduced1 reduced2
latent inhibition reduced1 reduced3
Dopaminergic pathway
TH mRNA in SNPC increased4 increased5
D2-binding in dorsal striatum increased4 increased6
DRD1 mRNA level in lateral caudate putamen increased4 unknown
metabolic activity in globus pallidus increased7 increased8
apomorphine susceptibility increased9,10 increased11
susceptibility to dopamimetric drugs increased9 increased11
Endocrine system
HPA-axis hyper-reactive4,12,13 hyper-reactive14,15
Immune system
TH2/TH1 cell count high16 high17
NK cell activity in spleen reduced18 inconclusive19,20
sensitivity for rheumatoid arthritis reduced21 reduced22
Occurrence of periodontitis increased23 increased24
Lung cancer carcinoma metastasis lower rate25 lower rate26
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In addition, it has been shown that both genetic and environmental factors play an 
important role in the severity of the observed phenotype in the rats. Crossbreeding 
experiments have proven the involvement of genetic factors (Ellenbroek et al., 2000). 
Furthermore, the environmental contribution to the phenotype became apparent 
from the observation that either the application or the lack of stress during early life 
causes diﬀ erences in expression of the apomorphine susceptibility in the adult rats. For 
example, when APO-SUS pups are reared from birth on by APO-UNSUS mothers 
their susceptibility is signiﬁ cantly reduced, whereas such cross-fostering has no eﬀ ect 
on APO-UNSUS rats. Conversely, a 24-h separation of the pups from their mother 
early in life enhances apomorphine susceptibility in APO-UNSUS rats, while this 
maternal deprivation does not aﬀ ect APO-SUS rats (Ellenbroek et al., 2000) (Figure 
3). Interestingly, the APO-SUS and -UNSUS rat lines have been generated twice with a 
ten year interval and many of the phenotypic observations have been found in both the 
original and replicated lines (Cools et al., 1990; Ellenbroek et al., 2000).
Heuristic animal models, like the APO-SUS/-UNSUS rat model, could be valuable in 
the search for the genotype accompanying complex phenotypes. Th e recent completion 
of the sequencing of the human, rat and mouse genomes, and the development of 
powerful genome-wide screening techniques will almost certainly aid in the search for 
causative genes in complex diseases, like schizophrenia.
Scope and outline of this thesis
Th e aim of this study is to identify genes that underlie the phenotypic characteristics of 
the APO-SUS/-UNSUS rat model. Opposed to their phenotypic counterpart, the APO-
UNSUS rats, APO-SUS rats display a complex phenotype reminiscent of schizophrenia. 
Schizophrenia is a chronic, severe, and disabling mental disorder of which the cause is 
still not known. Understanding the molecular mechanism underlying the APO-SUS/
-UNSUS complex phenotype might aid in the ﬁ nding the cause of schizophrenia in 
human.
Chapter 1 lays out the characteristics and aetiology of schizophrenia, and the current 
paths followed to search for the cause of this severe mental disorder. Th e need for heuristic 
animal models is also stressed out in order to further analyse the neurodevelopmental 
hypothesis of schizophrenia. Finally, the phenotypic characteristics of the APO-SUS/
-UNSUS rat model are compared with those of schizophrenic patients.
Chapter 2 describes the quest for gene transcripts whose levels are aﬀ ected in the 
hippocampus of APO-SUS compared to -UNSUS rats. In this search, we analysed 
the gene expression proﬁ les at both the juvenile and adult stage using the microarray 
approach. Th e analysis revealed remarkably few aﬀ ected transcript levels in the rat model. 
Upon validation of the microarray results by quantitative RT-PCR, the transcript with 
the largest diﬀ erence turned out to be the result of a dissection artefact. Part of the 
choroid plexus, an epithelial cell layer directly surrounding the hippocampus, was co-
dissected with hippocampal samples from a number of rats causing some of the observed 
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Figure 3. Effects of cross-breeding, cross-fostering and maternal deprivation 
on the apomorphine susceptibility of APO-SUS and -UNSUS rats
(A) Crossbreeding of APO-SUS (S) and APO-UNSUS (U) rats significantly changes the 
gnawing scores of the offspring (UxS and SxU). (B) Cross-fostering (CF) of APO-SUS 
pups by an APO-UNSUS mother significantly reduced the gnawing scores of these 
APO-SUS rats in adulthood. No significant effects were observed in APO-UNSUS rats 
or upon in-fostering (IF). (C) Maternal deprivation (MD) at PND9 significantly increased 
the gnawing scores of APO-UNSUS rats, whereas this treatment had no significant 
effect on APO-SUS rats. The number between brackets refers to the number of 
animals tested; *: P < 0.05 (adapted from Ellenbroek et al., 2000).
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diﬀ erential expression levels. In fact, after validation only one transcript, Aph-1b, was 
found to be consistently reduced in the APO-SUS compared to -UNSUS rats. Th ese 
diﬀ erences were found in multiple tissues, both in male and female rats, and in both the 
original and the replicated lines of the APO-SUS and -UNSUS rats. Th e possible causes 
for the diﬀ erential expression of Aph-1b mRNA are discussed.
Chapter 3 reports the search for the cause of the reduced expression levels of Aph-1b 
mRNA in APO-SUS compared to -UNSUS rats. Detailed genomic analyses revealed 
diﬀ erences in the genetic locus of Aph-1b. Th e APO-SUS rats harbour only one or two 
copies of Aph-1b (I/I or II/II rats, respectively), whereas APO-UNSUS rats contain three 
gene copies (III/III rats). Th e most likely cause of the alteration in gene-copy numbers 
is presented. Since Aph-1b is part of the γ-secretase enzyme complex that is involved in 
multiple (neuro)developmental signalling pathways, also other γ-secretase components 
have been tested for their expression levels in his rat model, followed by an analysis of 
the activity of the γ-secretase complex towards various substrates. Finally, behavioural 
tests are described testing whether a direct correlation exists between the genotype and 
the phenotypic characteristics.
Chapter 4 deals with a detailed developmental expression analysis of the mRNA levels 
of the Aph-1 family members (Aph-1b, and its paralogues Aph-1aS and -1aL) in the 
rats with one, two or three Aph-1b copies. Also the consequences of the developmental 
dynamics in Aph-1b expression levels on the cleavage activity of the γ-secretase complex 
towards the amyloid-β precursor protein (APP) are presented. Th e eﬀ ects of the altered 
γ-secretase activities during ontogenesis of the APO-SUS rats on the development of the 
complex neurodevelopmental phenotype are discussed.
In chapter 5, the tissue distributions of the Aph-1 family members in both APO-SUS 
and -UNSUS rats are described. Th is analysis shows large diﬀ erences in the mRNA 
levels of Aph-1b relative to Aph-1a between the tissues analysed. In both rat lines, the 
functional consequences of these diﬀ erences are tested towards a number of γ-secretase 
substrates. Our ﬁ ndings are summarised in a model supporting the causative link 
between an aﬀ ected γ-secretase component and the observed complex phenotype in the 
APO-SUS rats.
Chapter 6 describes the use of Xenopus laevis stable transgenesis for the functional analysis 
of the Aph-1 protein. Th e generation of frogs expressing a ﬂ uorescently labelled Aph-1 
fusion protein speciﬁ cally in the neurointermediate lobe of the pituitary is outlined, and 
a rationale for this approach is given. Th e consequences of the overexpression of this 
fusion protein are examined at the protein, cellular, physiological and organismal level.
Chapter 7 discusses the possible causes of the genomic rearrangement in the Aph-1b 
locus, as found in the APO-SUS/-UNSUS rat model. Interesting future experiments 
on rats with diﬀ erent Aph-1b gene copy numbers are suggested to further understand 
the inﬂ uence of the Aph-1b gene-dosage imbalance on the complex phenotype. Th e data 
presented in this thesis, together with earlier observations in the rat lines, are put into a 
general model explaining the observed phenotype. Furthermore, the clinical implications 
of our results in the search for the cause of schizophrenia are discussed and suggestions 
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for translational research are presented, in which our data could be the starting point for 
a new direction in ﬁ nding the cause of and a cure for schizophrenia.
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Abstract
Wistar rats pharmacogenetically selected for a high susceptibility to the dopamine 
agonist apomorphine (APO-SUS rats) display many diﬀ erences with their 
phenotypic counterpart (APO-UNSUS rats). Th ese diﬀ erences encompass a variety of 
pharmacological, biochemical, endocrinological, immunological as well as behavioural 
characteristics that are remarkably similar to those observed in schizophrenic 
patients. In the present study, the mRNA expression proﬁ les were determined in the 
hippocampus and cerebellum of APO-SUS and -UNSUS rats at postnatal days 9 and 
60 with oligonucleotide and cDNA microarrays, respectively. Th e results showed 
that ~0.1% of all genes tested were diﬀ erentially expressed between the two rat lines, 
with the largest diﬀ erences observed for transthyretin and prostaglandin D synthase 
mRNA. However, validation studies revealed that these two diﬀ erences were due to 
a dissection artefact. Th e only reproducible alteration in transcript levels concerned 
the reduced amount in APO-SUS rats of the mRNA encoding Aph-1b, a component 
of the γ-secretase enzyme complex. Th is diﬀ erence was found in all tissues examined, 
in both male and female rats, and in the original as well as the replicated lines of 
the APO-SUS and -UNSUS rats. Together, these results illustrate the importance 
of accurate tissue dissection and data validation of microarray experiments, and the 
complexity of analysing brain tissues. Most importantly, our studies suggest that the 
γ-secretase component Aph-1b is responsible for the phenotypic characteristics of the 
APO-SUS/-UNSUS rat model. 
Introduction
O ver the last decades, it has become more and more clear that the elucidation of the molecular genetic basis of psychiatric diseases is an extremely diﬃ  cult task. Th e 
problem already starts with the heterogeneity in the disease proﬁ les and the subjective 
clinical evaluation of a complex phenotype. A classical example of a complex disorder 
is schizophrenia, which shows a large variety of symptoms partially overlapping with 
diseases such as autism, bipolar disorder and major depression (Bearden et al., 2004; 
Stahlberg et al., 2004). Additional diﬃ  culties in studying human psychiatric disorders 
are factors that can bias the results, such as individual diﬀ erences in environmental 
conditions to which the patients have been exposed (including the way the individuals 
have been raised), their medical history, and possible substance abuse. Th e utilisation of 
animal models could accelerate the pace of genetic research on psychiatric phenotypic 
characteristics, since such models can easily be phenotypically selected, bred, and 
conditioned. Th is is particularly important for studying psychiatric disorders because 
many of these disorders have a neurodevelopmental origin. An example of an animal 
model for a complex neurodevelopmental phenotype is the APO-SUS/-UNSUS rat 
model. Apomorphine-susceptible (APO-SUS) rats are pharmacogenetically selected 
Wistar rats with a vigorous gnawing response upon injection of the dopaminergic receptor 
agonist apomorphine. In contrast, their phenotypic counterpart the apomorphine-
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unsusceptible (APO-UNSUS) rat line shows hardly any response to the drug (Cools et 
al., 1990; Ellenbroek and Cools, 2002). Next to this apomorphine susceptibility, the 
APO-SUS rat line displays many features of a complex neurodevelopmental disorder, 
including a reduced pre-pulse inhibition and latent inhibition, hyperactivity in an open 
ﬁ eld and in the elevated-plus maze, a hyper-reactive dopaminergic pathway, an increased 
stress response, a retarded development, a lower rate of metastasis in lung cancer, and 
enhanced vulnerability to drug abuse and a variety of other behavioural, neurochemical, 
endocrinological and immunological characteristics (Degen et al., 2005; Ellenbroek 
and Cools, 2002; Teunis et al., 2002; van der Kam et al., 2005). Cross-breeding, 
cross-fostering and maternal deprivation experiments have shown that both genetic 
and environmental factors play an important role in the development of the rat model 
(Ellenbroek et al., 2000). Interestingly, the APO-SUS/-UNSUS rat model was created 
twice with a ten-year interval and the replicated line displayed similar features as the 
original one (Ellenbroek et al., 2000). Here, we performed mRNA expression proﬁ ling 
using cDNA and oligonucleotide microarray analyses to search for genes diﬀ erentially 
transcribed in the APO-SUS and -UNSUS rat model.
Materials and methods
Animals
Systemic administration of apomorphine (1.5 mg/kg s.c.) produced Wistar rats with a 
high or low susceptibility to this drug (APO-SUS and APO-UNSUS rats, respectively); 
the behaviour was quantiﬁ ed with the Ungerstedt box and the rats were classiﬁ ed on 
the basis of their gnawing scores (APO-SUS: >500 gnaws in 45 min; APO-UNSUS: 
<10 gnaws in 45 min) to select female and male rats for breeding the two distinct 
lines (Cools et al., 1990). We have avoided brother-sister pairings, and used a speciﬁ c 
procedure that was aimed at selectively breeding for apomorphine susceptibility, while 
otherwise maintaining the genotypic heterogeneity of the initial Wistar strain. Th e 
procedure for the generation of the APO-SUS/-UNSUS rat lines was performed twice 
over time with a ten year interval, resulting in an original APO-SUS and -UNSUS rat 
line and a replicated APO-SUS and -UNSUS rat line (Ellenbroek et al., 2000). For 
the present microarray studies, we used APO-SUS and -UNSUS rats of the 13th to the 
18th generation of the replicated lines. For the validation studies, we also used APO-
SUS and -UNSUS rats of the 28th generation of the original lines. Rats were bred and 
reared in the Central Animal Facility of the Radboud University under approved animal 
protocols and in accordance with institutional guidelines.
cDNA and oligonucleotide microarray experiments
For mRNA expression proﬁ ling, hippocampi and cerebelli were dissected from fresh 
brains of postnatal day (PND) 9 and PND 60 APO-SUS and -UNSUS rats, and 
the tissues were frozen in liquid nitrogen. Furthermore, hippocampi were isolated 
from PND 60 APO-SUS and -UNSUS rats three hours after they were injected with 
apomorphine (1.5 mg/kg, s.c.). Total RNA was prepared with the Trizol reagent (Gibco 
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BRL Life Technologies), and RNAs from 5 individual samples were pooled and used 
in the microarray analyses. For the PND 60 hippocampal samples, we used the Incyte 
high-density cDNA microarrays (Rat NeuroGEM 2.02 containing 8,478 Sprague 
Dawley rat nervous system cDNAs representing 6,746 diﬀ erent genes). Isolation of 
mRNA, conversion to Cy3 or Cy5 ﬂ uorescently labelled cDNA, hybridisation and 
scanning were performed as described previously (Yue et al., 2001) and the data were 
analysed with GEMTools 2.5 software. Th e cDNA microarray experiments were 
performed with biological duplicates. Th e PND 9 hippocampal and cerebellar samples 
were analysed using Aﬀ ymetrix high-density oligonucleotide arrays (Rat Genome Set 
U34A containing ~7,000 full-length sequences and ~1,000 EST clusters randomly 
selected from Rattus norvegicus database sequences) according to the manufacturer’s 
recommendations. Brieﬂ y, total RNA was puriﬁ ed on RNeasy columns (Qiagen) and 
20 µg RNA was reverse transcribed (Superscript II; GibcoBRL Life Technologies) using 
a T7-dT24 primer (GenSet). Following second-strand synthesis, the double-stranded 
cDNA was used in an in vitro transcription reaction to generate biotinylated cRNA. 
Puriﬁ ed, fragmented cRNA (10 µg) was hybridised onto the Aﬀ ymetrix arrays for 16 h 
at 45 °C. Standard post-hybridisation washes and double-stain protocols were performed 
on a GeneChip Fluidics Station 400 (Aﬀ ymetrix). Arrays were scanned on a Hewlett 
Packard Gene Array scanner and analysed using Microarray Suite version 5.0 software. 
Th e internal controls for the reverse transcription and hybridisation processes indicated 
that the array samples were successfully labelled and hybridised to the arrays for both 
cDNA and oligonucleotide arrays.
Rat cDNA and oligonucleotide microarray specifications
Th e spotted NeuroGEM 2.02 cDNA microarray (Incyte Genomics, Inc.) contained 
8,478 sequence-veriﬁ ed cDNAs with an average length of 1,000 bp (500-5,000 bp 
range). Th e cDNAs were derived from 18 diﬀ erent nervous tissues, including spinal cord, 
whole brain and cerebrum of Sprague Dawley rats and chemically bonded to the glass 
surface of the microarray. Th e array contained 6,747 unique elements of which 3,790 
were annotated and 2,957 were not annotated in the Ensemble database of January 
2000. Th e oligonucleotide array U34A or GeneChip (Aﬀ ymetrix, Inc.) contained 
probes interrogating approximately 7,000 mRNA transcripts and approximately 1,000 
EST clusters. Each sequence was represented by 16 perfectly matching probes of 25 
nucleotides, along with 16 probes with a single-nucleotide mismatch for background 
subtraction.  
Quantitative RT-PCR
For quantitative RT-PCR, ﬁ rst-strand cDNA was prepared from 2 µg of total RNA 
(isolated as described above) using Superscript II reverse transcriptase (Invitrogen). PCR 
samples contained 1X SYBR Green buﬀ er, 3 mM MgCl2, 0.4 mM dUTP and 0.2 mM 
each of dATP, dCTP and dGTP, 0.6 U AmpliTaq Gold (all from Applied Biosystems), 
0.6 µM each oligonucleotide primer (Biolegio) and 1/20 synthesised cDNA in a 25-
µl volume. Quantitative PCR was performed in a PE GeneAmp 5700 apparatus with 
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conditions as follows: 10 min at 94 °C, then 40 cycles of 15s at 94 °C, 30s at 60 °C and 1 
min at 72 °C. β-Actin was ampliﬁ ed from all samples to normalise expression. A control 
(no template) was included for each primer set. Data sets were analysed with Sequence 
Detection System 1.3 software. Th e primers used are summarised in Table 1.
Table 1. Primer sequences used for quantitative RT-PCR validation
Included are Genbank numbers, amplicon sizes and positions of 5’-ends of primers relative to the start 
ATG; *): position from start of known sequence given in Appendix 1.
               amplicon
primer name 5’-sequence-3’ position size GenBank
βactin-FW 5’-CGTGAAAAGATGACCCAGATCA-3’ 346
89 V01217 
βactin-RV 5’-AGAGGCATACAGGGACAACACA-3’ 435
TTR-FW 5’-CCTCGCTGGACTGATATTTGC-3’ 30
78 X14876
TTR-RV 5’-ACTTTGACCATCAGAGGACACTTG-3’ 108
PGDS-FW 5’-CGGCCTCAACCTCACCTCTA-3’ 225
162 M94134
PGDS-RV 5’-GCGTACTCATCGTAGTCGGTTTCT-3’ 387
Aph1b-FW 5’-GTGATTCTCCTCAGTTCTTCCTTAATTC-3’ 448
223 XM_217185
Aph1b-RV 5’-GCCCATGAGCACCATGATTATAT-3’ 671
αATLP-FW 5’-ACAAGACTCTAAAGCCAGCAAAGA-3’ 413
263 AY113703
αATLP-RV 5’-GAAGTACCTCATCCTTGTGTGCTT-3’ 676
EST1-FW 5-CCGGTAGGATCTGCCTCCCAAA-3’ 9*)
233 (Appendix 1)
EST1-RV 5’-CACCATGCTGTGGACCTTACTGAG-3’ 242*)
EST2-FW 5’-GCCAAATGAAGAAAGAAGACACTGA-3’ 94*)
125  (Appendix 1)
EST2-RV 5’-AATCCAAAATTCCAGCACAGACTT-3’ 219*)
EST3-FW 5’-AACTCAATGTTTATTCACCTACCCATG-3’ 128*)
85 (Appendix 1)
EST3-RV 5’-AACTTAATTCGTCTGTCTACTCCTCTTACA-3’ 213*)
Aph1a-FW 5’-AGAGGAGACGGTACTGGGCTTT-3’ 547
123  BC087081
Aph1a-RV 5’-ATGGAAACGGTGACTGCATAGA-3’ 670
Vesl2-FW 5’-ACAGTGGAAGCGGCAATTCT-3’ 627
95 NM_053309
Vesl2-RV 5’-TGTTGATCTCACCGCACTGTTC-3’ 722
S100related-FW 5’-GAGTGCTCATGGAAAGGGAGTT-3’ 95
94 J03627
S100related-RV 5’-CGGCACTGGTCCAGGTCTT-3’ 189
Histone H4-FW 5’-TGTCAAGCGTATCTCGGGTCTTAT-3’ 129
142 X13554
Histone H4-RV 5’-CGCGTACACCACGTCCATAG-3’ 271
PI3KP85-FW 5’-TTAATCTCAGCGGAGTGGAGTGA-3’ 877 104 NM_013005
PI3KP55-FW 5’-CAAGACAGATATAAACTGTGGCACAGA-3’ 48 123 D64048
PI3KP50-FW 5’-GGTGGGATACTGGCAGTTCAAA-3’ 59 116 U50412
PI3common-RV 5’-GACATATTGTTGTTCATGCTGTTGTT-3’ 981/171 /175   
CyclinG-FW 5’-ACTACTGCCTTCCAATTTCTGCA-3’ 451
106 X70871
CyclinG-RV 5’-TCAGTTGGGCTTCTAGTCTTTCAA-3’ 557
COMT-FW 5’-CCACTGGAAAGACCGCTACCT-3’ 552
101 BC081850
COMT-RV 5’-CCGGGACGATGACGTTGT-3’ 653
MAP2-FW 5’-CGGATCAACCGACAACATCA-3’ 5025
209 NM_013066
MAP2-RV 5’-GAGCATTGTCAAGTGAGCCAACT-3’ 5234
(continued on next page)
GENE EXPRESSION PROFILING IN APO-SUS/-UNSUS RATS
35
(Table 1 continued)
CAPS-FW 5’-CAGACGTAGCATCAAGCAAGGT-3’  4472
135 NM_013219 
CAPS-RV 5’-ACATTTATAGTCTAGGGTTGTCATTTCG-3’  4607
HERC1-FW 5’-GCTCACCTCTGATTTGATGTTGATAT-3’ 15166
83 XM_236362
HERC1-RV 5’-GGCCACTGCTTATGTCAGCTTAT-3’ 15249
CA12-FW 5’-GACTCCAGCCTCACCAGTACAGA-3’  323
103 XM_343416
CA12-RV 5’-GCAAAGTGCTTCCCACTCACA-3’  426
Rab8B-FW 5’-CAGAACGATAGAACTCGACGGAA-3’ 141
92 U53475
Rab8B-RV 5’-AGTATGCTGTTGTAATTGTTCGGAAT-3’ 233
In situ hybridisation
TTR mRNA. For the synthesis of the TTR mRNA probe, ﬁ rst, RNA from total 
rat brain was isolated and transcribed into cDNA as described above. Th e cDNA 
was then ampliﬁ ed by PCR using the following primers: TTR (84-409) 5’-
CAAGTGTCCTCTGATGGTCA and 5’-TGTAGGAGTACGGGCTGAGCAG. 
Following ligation of the PCR fragment into the pGEM-T Easy Vector (Promega) 
and sequence analysis using the Big Dye Ready Reaction system (Perkin Elmer), the 
construct was linearised with SalI or NcoI for the generation of 11-UTP digoxygenin 
(DIG)-labelled antisense or sense RNA probes as run-oﬀ  transcripts using T7 or Sp6 
RNA polymerase, respectively. For tissue preparation, rats were deeply anaesthetised by 
intraperitoneal administration of sodium pentobarbital (60 mg/kg), and transcardially 
perfused with 50 ml 0.9% NaCl solution, followed by 300 ml Bouin’s ﬁ xative (71% 
picrinic acid, 24% formaldehyde, 5% glacial acetic acid). Brains were removed, postﬁ xed 
in the same ﬁ xative for 24 h at 4°C, dehydrated in a graded series of ethanol and xylene 
and embedded in paraﬃ  n. Coronal sections of 10 µm were mounted on poly-L-lysin 
coated slides and dried for 16 h at 37°C. Sections were deparaﬃ  nated in xylene and 
rehydrated in a graded series of ethanol. Tissue penetration was enhanced by incubation 
in 0.1% pepsin in 0.2 M HCl for 15 min at 37°C, followed by a post-ﬁ xation in 2% 
formaldehyde in PBS for 5 min, and incubation in 1% NH2OH.HCl for 15 min. Sections 
were rinsed in RNase-free water, dehydrated in ethanol and air-dried. Hybridisation was 
performed for 16 h at 50°C in hybridisation buﬀ er (10% sodium dextran sulphate, 50% 
formamide, 4x SSC, 1x Denhardt’s and 200 µg/ml yeast tRNA; 1xSSC: 0.15 M NaCl 
and 15 mM sodium citrate) with 3 ng/ml antisense DIG-labelled TTR mRNA probe. 
After stringency washes in 2x SSC, 1x SSC, 0.5x SSC for 30 min and 0.1x SSC for 30 
min at 37°C, sections were rinsed in buﬀ er 1 (100 mM Tris pH7.5, 150 mM NaCl) 
for 5 min, blocked in 1% BSA and 2% normal goat serum in buﬀ er 1 for 30 min, and 
incubated in alkaline phosphatase-conjugated sheep-anti-DIG Fab fragments (1:500, 
Roche) in blocking solution of 16 h at 4°C. After three washes of 5 min in buﬀ er 1 and 
one wash of 5 min in AP-buﬀ er (100 mM Tris pH9.5, 100 mM NaCl, 50 mM MgCl2), 
sections were stained in 350 µg/ml 4-nitro blue tetrazolium chloride and 175 µg/ml 
5-bromo-4-chloro-3-indolyl-phosphate (Roche) in AP-buﬀ er until colour development 
was suﬃ  cient in case of the anti-sense probe. Signal speciﬁ city was checked by in parallel 
hybridisation of slides with the sense TTR mRNA probe.
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Aph-1b mRNA. For the synthesis of the Aph-1b mRNA probe, ﬁ rst, RNA from total rat 
brain was isolated and transcribed into cDNA as described above. A direct template for 
antisense RNA probe synthesis was then ampliﬁ ed by PCR using the following primers: 
Aph1b-FW: 5’-AGACAGCACCTTCGATGCGA-3’ and T7-Aph1b-RV: 5’-TAATACG
ACTCACTATAGGGAGACACTTATTCTTCTCACAGCCGTCA-3’, with the T7 
promoter sequence underlined. For the sense probe the primers T7-Aph1b-FW: 5’-TAAT
ACGACTCACTATAGGGAGAAGACAGCACCTTCGATGCGA-3’ and Aph1b-RV: 
5’-CACTTATTCTTCTCACAGCCGTCA-3’ were used. Th e PCR products were gel 
puriﬁ ed and 1 µg of template was used to generate 11-UTP digoxygenin (DIG)-labelled 
antisense or sense RNA probes using T7 RNA polymerase. For tissue preparation, rats 
were decapitated, brains were snap-frozen in isopentane on dry-ice and 16 µm cryo-
sections were mounted on poly-L-lysine coated object slides. Sections were ﬁ xed in 4% 
paraformaldehyde in PBS for 10 min, washed and treated with 0.1% pepsin in 0.2 M 
HCl for 5 min at 37°C. After washing in PBS, hybridisation was performed for 16 h at 
50°C in hybridisation buﬀ er (10% sodium dextran sulphate, 50% formamide, 4x SSC, 
1x Denhardt’s and 200 µg/ml yeast tRNA; 1xSSC: 0.15 M NaCl and 15 mM sodium 
citrate) with 160 ng/ml DIG-labelled antisense Aph-1b mRNA probe. After stringency 
washes in 5x SSC for 5 min and 0.2x SSC for 2 hours at 65°C, sections were rinsed 
in buﬀ er 1 (100 mM Tris pH7.5, 150 mM NaCl) for 5 min, blocked in 1% BSA and 
2% normal goat serum in buﬀ er 1 for 30 min, and incubated in alkaline phosphatase-
conjugated sheep-anti-DIG Fab fragments (1:500, Roche) in blocking solution of 16 h 
at 4°C. After three washes of 5 min in buﬀ er 1 and one wash of 5 min in AP-buﬀ er (100 
mM Tris pH9.5, 100 mM NaCl, 50 mM MgCl2), sections were stained in 350 µg/ml 
4-nitro blue tetrazolium chloride and 175 µg/ml 5-bromo-4-chloro-3-indolyl-phosphate 
(Roche) in AP-buﬀ er until colour development was suﬃ  cient in case of the anti-sense 
probe. Signal speciﬁ city was checked by in parallel hybridisation of slides with the sense 
Aph-1b mRNA probe.
Statistics
For the selection of transcripts from the cDNA microarray experiments for follow-up 
analysis, we used an interquartile range (IQR) upper hinge of +3.0 and a lower hinge of 
-3.0 and a balanced diﬀ erential expression (BDE) of  ≤ -1.5 or ≥ +1.5 in at least 3 out 
of 4 cDNA microarray experiments. Selection of transcripts from the oligonucleotide 
microarray experiment was based on a BDE of ≤ -1.4 or ≥ +1.4 in both the hippocampus 
and the cerebellum. Th e quantitative RT-PCR data are presented as means ± s.e.m. 
Statistical evaluation of the RT-PCR data was performed using the Student’s t test. 
Values of P < 0.05 were considered statistically signiﬁ cant.
Results
To examine transcript levels in APO-SUS compared to -UNSUS rats, comprehensive 
gene expression proﬁ les were determined with both oligonucleotide and cDNA 
microarrays. Th e proﬁ les were compared between pooled RNA samples from cerebellum 
and hippocampus of the two rat lines at PND 9 and PND 60. 
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cDNA microarray analysis of APO-SUS and -UNSUS hippocampal mRNA levels at 
PND 60
We ﬁ rst investigated the hippocampus of APO-SUS and -UNSUS rats at PND 60 
with Incyte NeuroGEM 2.02 cDNA microarrays. Th e hippocampus was chosen 
as primary target, because it is one of the brain regions implicated in schizophrenia-
related disturbances, and is involved in emotional regulation and cognitive functions 
suggesting that psychotic symptoms observed in schizophrenia originate from this region 
(Stevens, 1973; Torrey and Peterson, 1974). Furthermore, in schizophrenic patients the 
hippocampus has a reduced size, shape and architecture, and displays alterations in 
metabolic activity and neurochemistry (reviewed by Gothelf et al., 2000; Harrison, 2004). 
Relative to APO-UNSUS rats, the hippocampal mossy ﬁ bers of APO-SUS rats contain 
increased dynorphin B protein levels (Cools et al., 1993) and the mineralocorticoid 
receptors (MR) in the hippocampus have signiﬁ cantly increased binding capacities 
(Sutanto et al., 1992). At the behavioural level, information processing deﬁ cits in 
the brain have been observed in APO-SUS rats, reﬂ ected by a reduction in prepulse 
inhibition of the acoustic startle response (also found to be aﬀ ected in schizophrenic 
patients) (Braﬀ  et al., 2001; Ellenbroek et al., 1995). Th is process is thought to be 
regulated by the hippocampus (Bast and Feldon, 2003; Swerdlow et al., 2001). Finally, 
and most importantly - unlike other brain regions implicated in schizophrenia such as 
the amygdala, prefrontal cortex or accumbal region - the hippocampus is a well-deﬁ ned 
brain region that can be dissected relatively easily from fresh brain tissue. We decided to 
analyse ﬁ rst the rats at PND 60, since at this time point the rats are considered young 
adults. It is not until this adult age that many of the phenotypic characteristics, such as 
the apomorphine susceptibility, become apparent in the rat model. Th e young adult time 
point also mimics the developmental stage at which most schizophrenic patients show 
their ﬁ rst symptoms (Jablensky and Cole, 1997; Sartorius et al., 1986). Th e genome-
wide expression proﬁ les of the hippocampi of male APO-SUS and -UNSUS rats at 
PND 60 were analysed both under basal conditions and three hours after apomorphine 
treatment. For the cDNA microarray analyses under basal conditions, untreated male 
rats were used. For the analysis following apomorphine injection, male rats of the same 
nests were injected with the dopamine agonist and tested for their gnawing behaviour. 
For three hours, the drug was allowed to exert its eﬀ ect on the mRNA transcript levels, 
since this interval between the time of injection and transcript proﬁ le analysis has been 
shown by others to be suﬃ  cient to cause changes in mRNA levels (for example Adams et 
al., 2003; Levant et al., 1992). All APO-SUS and -UNSUS rats that were injected with 
apomorphine and analysed in the gnawing box met the susceptibility criteria, i.e. APO-
SUS and -UNSUS rats gnawed over 500 times and less than 10 times in 45 minutes, 
respectively (Figure 1). 
Th e hippocampi from ten apomorphine-treated and ten non-injected APO-SUS and 
APO-UNSUS rats were dissected and total RNA was isolated. Th e RNA samples 
(following either under basal or apomorphine conditions) were grouped into two pools 
of ﬁ ve isolates per genotype and treatment. Th ese biological duplicate RNA samples 
were used for the generation of ﬂ uorescently labelled targets for the hybridisation to the 
cDNA microarrays. Of the 6,747 unique transcripts represented on the arrays, 82.7% 
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were detectable in duplicate experiments (i.e. a hybridisation signal intensity of at least 
2.5-fold above background), and most signal intensities were highly similar between the 
APO-SUS and -UNSUS samples, both under basal conditions and after apomorphine 
treatment (Figure 2). From the data, genes that showed a balanced diﬀ erential 
expression of ≤ -1.5 or ≥ +1.5 in replicate hybridisation experiments were selected. Of 
these, diﬀ erentially expressed genes that fell outside an inter-quartile range of 3 from the 
upper or lower hinge in 3 out of 4 hybridisation experiments were selected for validation 
experiments. Seven diﬀ erentially expressed genes (~0.1% of the total number of genes on 
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Figure 1. Effect of apomorphine 
injection (1.5 mg/kg) on the 
gnawing behaviour of the APO-
SUS and -UNSUS rats used in the 
microarray experiments
The number of gnaws was measured 
for 45 minutes. ***: P < 0.01; n = 10 
per rat line, with all rats from different 
nests, plus s.e.m.
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Figure 2. Scatter plots of PND 60 APO-UNSUS versus -SUS hippocampal 
hybridisation signal strengths on the cDNA microarrays
Log-log graph of the Cy3 (APO-SUS; x-axis) and Cy5 (APO-UNSUS; y-axis) signal 
values of 6,747 unique transcripts present on the microarray comparing pools of five 
hippocampi per microarray. The abundance of the transcripts was tested both under 
basal conditions (A) and three hours after apomorphine injection (B). The two graphs 
in (A) represent biological duplicates; same for (B). The spots with a name reference 
correspond to genes that were differentially expressed reproducibly (based on a 3-fold 
interquartile range threshold). The numbers between brackets indicate different probe 
sets for the same transcript.
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Table 2. Differential hybridisation intensities of PND 60 hippocampal APO-SUS versus 
-UNSUS rat samples on the cDNA microarrays
(BD: below detection)
fold change
basal conditions after apomorphine
Gene Incyte ZooSeq number array 1 array 2 array 3 array 4
TTR 700491883 28.0 16.9 -15.0 2.7
PGDS 700861868 1.1 1.6 -2.0 1.6
Aph-1b 700251056 -1.6 -1.6 -1.7 -1.4
αATLP 700289556 BD 1.9 2.1 1.4
EST1 700697881 -1.6 -1.3 -1.6 -1.5
EST2 700938990 2.4 2.1 -1.8 1.1
EST3 700253034 -1.5 -1.5 -1.5 -1.6
the array) met these criteria: transthyretin (TTR, also known as prealbumin), prostaglandin 
D synthase (PGDS, also known as β-trace), α-anti trypsin-like protein (αATLP, also 
known as serine proteinase inhibitor HongrES1), the γ-secretase component Aph-1b, and 
three expressed sequence tags encoding unknown proteins (EST1, EST2 and EST3). 
Th e diﬀ erences in hybridisation intensities of each of these transcripts on the cDNA 
microarrays are listed in Table 2 and the corresponding sequences spotted on the 
microarray are listed in Appendix 1.
Oligonucleotide microarray analysis of hippocampal and cerebellar mRNA levels in 
PND 9 APO-SUS and -UNSUS rats
In addition to the cDNA microarray studies, we decided to examine gene expression 
proﬁ les of hippocampal and cerebellar mRNA levels in PND 9 APO-SUS and 
-UNSUS rats with the oligonucleotide microarrays Rn_U34A from Aﬀ ymetrix. Th e 
Incyte NeuroGEM cDNA microarrays used in the expression proﬁ ling at PND 60 
contained genes representing only about one-third of the total number of transcripts. 
In addition, many potentially interesting transcripts were not present on the array (such 
as the dopamine transporter, dopamine receptors 1 to 5, serotonin receptors 1a and 2a, 
NMDA receptor subunits 1, 2A and 2B, brain derived neurotrophic factor, and dynorphin 
B). Th erefore, it was decided to perform these sets of microarray experiments with the 
Aﬀ ymetrix oligonucleotide arrays. Although also this array contained only about one-
third of the complete transcriptome, all 8,478 annotated transcripts were represented 
(annotation based on the Ensemble database, release Oct 2001). Also here, pooled 
RNA samples of ﬁ ve hippocampi or cerebelli from PND 9 APO-SUS and -UNSUS 
rats were used. On the oligonucleotide microarrays, 52.5% of all transcripts analysed 
in the hippocampus gave a signal above background. Similarly, the cerebellum yielded 
53.9% positive hybridisation signals. However, no major diﬀ erences were observed 
between the gene expression proﬁ les of these tissues of the APO-SUS and -UNSUS rats 
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(e.g. linear regression analysis revealed r2 values very close to 1.0, indicative of a close 
correlation to the mean: r2 = 0.9917 and 0.9868, for the hippocampal and cerebellar 
samples, respectively; Figure 3). Th e transcripts with a balanced diﬀ erential expression 
(BDE) of ≤ -1.4 or ≥ +1.4 in both the hippocampus and the cerebellum were selected 
for validation analysis using quantitative RT-PCR. Many of the interesting transcripts 
mentioned above and uniquely present on the Aﬀ ymetrix oligonucleotide microarrays 
either did not reveal any diﬀ erences between the rat lines (e.g. for dopamine receptors 1 
and 3, and NMDA receptor 1), or the expression levels were too low to obtain signals 
above background levels (e.g. for dopamine receptors 2 and 4, serotonin receptor 1A and 
NMDA receptor 2A). Th e seven diﬀ erentially expressed transcripts that did meet the 
selection criteria were: microtubule-associated protein 2 (MAP2), cyclin G, S-100 related 
protein, catechol-O-methyltransferase (COMT ), immediate early gene (IEG) Homer 2 (or 
Vesl-2), histone H4 and phosphatidylinositol 3-kinase regulatory subunit p85 (p85 PI3K; 
Table 3).
Validation of cDNA microarray data
Th e validation experiments for the seven transcripts selected via the cDNA microarray 
experiments were performed by means of real-time quantitative RT-PCR analysis on 
the same RNA samples as used in the microarray experiments. Th e diﬀ erences in TTR, 
PGDS and Aph-1b mRNA levels between the APO-SUS and -UNSUS hippocampal 
samples could be conﬁ rmed by the quantitative RT-PCR analysis (Figure 4). In contrast, 
the validation results of the EST1, EST2 and EST3 mRNA levels showed no diﬀ erences 
between the two rat lines, while the levels of αATLP mRNAs were below detection, 
consistent with the low hybridisation signals of αATLP on the cDNA microarrays 
(Figure 2).
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Figure 3. Scatter plots of PND 9 APO-SUS versus -UNSUS hippocampal and 
cerebellar hybridisation signal strengths on the oligonucleotide microarrays
Log-log graph of the APO-SUS and -UNSUS signal intensities above background levels 
of biotin-labelled cRNA samples of either pooled hippocampi (A) or cerebelli (B). 
Spots with a name reference represent transcripts used in validation and follow-up 
experiments.
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Table 3. Differential hybridisation intensities of PND 9 hippocampal and cerebellar APO-
SUS (AS) and -UNSUS (AU) rat samples on the oligonucleotide microarrays
Included are the gene names, probe set codes, the normalised hybridisation signals, the present (P) 
or absent (A) calls and the fold difference in log(2) ratio as calculated by the Microarray Suite 5.0 
software.
  hippocampus cerebellum
Gene Systematic Name AS AU log(2) ratio AS AU log(2) ratio
MAP2 X17682_s_at 1241.5 P 976 P -0.5 577.3 P 223.3 P -0.8
MAP2 X53455cds_s_at 1884.6 P 1410.7 P -0.4 634.7 P 415.9 P -0.6
cyclin G X70871_at 4743.3 P 2644 P -0.7 2486.1 P 1364 P -0.6
S-100 related J03627_at 2197.2 P 1451.1 P -0.6 662.2 P 424.7 P -0.6
COMT M93257_s_at 1301.7 P 920.4 P -0.3 1358.6 P 917.1 P -0.7
Vesl-2 AB007690_s_at 686.8 P 1139.7 P 0.7 428.9 P 1548.9 P 1.4
histone H4 rc_AA946439_at 182.5 A 564.7 P 1.7 91.1 A 441.8 P 1.7
p85 PI3K D64045_s_at 13.4 A 281.7 P 2.9 46.7 A 278.7 P 2
p85 PI3K U50412_at 75.8 A 694.5 P 2.5 86.9 A 606.3 P 1.7
Th e largest diﬀ erences in mRNA levels between the APO-SUS and -UNSUS rats were 
observed for TTR and PGDS. More detailed analysis of the transcript levels of these genes 
in individual hippocampal samples revealed remarkably large ﬂ uctuations (Figure 5A). 
While in most of the APO-SUS and -UNSUS samples relatively low TTR and PGDS 
mRNA levels were observed, drastically increased TTR and PGDS transcripts levels 
were detected in only a limited number of hippocampal RNA isolates. Subsequent in situ 
hybridisation analysis of TTR mRNA distribution in the rat brain revealed this transcript 
to be exclusively and abundantly expressed in the choroid plexus, an epithelial cell layer 
present in the ventricles and surrounding the hippocampus (Figure 5B). Quantitative 
RT-PCR analysis of isolated choroid plexus tissue showed no signiﬁ cant diﬀ erences in 
the TTR mRNA levels of APO-SUS and -UNSUS rats (Figure 5C). From these results, 
we conclude that the large diﬀ erences in TTR (and presumably also in PGDS) mRNA 
levels between the pools of APO-SUS and of APO-UNSUS hippocampi resulted from 
their expression in contaminating choroid plexus and thus from a dissection artefact 
during the isolation of the hippocampus. Th us, the only reproducible result from the 
cDNA microarray experiments was the observed reduction in Aph-1b mRNA levels in 
APO-SUS compared to -UNSUS rat tissue samples (see below).
Validation of oligonucleotide microarray data
Similar to the cDNA microarray validations, the transcripts selected from the 
oligonucleotide microarrays were subjected to validation using quantitative RT-PCR. 
Now, however, individual RNA samples were used instead of pooled RNA. Th ese 
experiments could not conﬁ rm any of the diﬀ erences indicated from the oligonucleotide 
microarray data (not shown). Th us, the oligonucleotide microarray experiments did not 
reveal any new diﬀ erentially expressed genes.
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Figure 4. Real-time quantitative RT-PCR validation of cDNA microarray 
data
The seven genes that were found on the cDNA microarrays to be differentially 
transcribed were tested for further validation via quantitative RT-PCR. The same 
RNA pools were used as in the expression profiling analysis, under basal conditions 
(A) and after apomorphine administration (B). Results were normalised towards β-
actin and are expressed as arbitrary units (AU). The differences in transcript levels for 
TTR, PGDS and Aph-1b could be confirmed via this technique, while the levels of αATLP 
mRNA were below detection (BD), and the EST1, EST2 and EST3 mRNA levels did not 
appear to differ between the rat lines. Experiments were preformed in triplicate and 
shown as mean plus s.e.m.; *: P < 0.05; ***: P < 0.001.
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Figure 5. TTR and PGDS mRNA levels in the APO-SUS / -UNSUS rats
(A) Real-time quantitative RT-PCR analyses of TTR and PGDS mRNA levels in individual 
hippocampal samples from APO-SUS (AS) and -UNSUS (AU) rats. Results were 
normalised towards β-actin and are expressed as arbitrary units (AU). Note the large 
differences in TTR mRNA levels (and to a lesser extent also for PGDS mRNA levels) 
between some of the individual samples. (B) In situ hybridisation results for TTR in 
Wistar rats. Hybridisation of the TTR DIG-labelled antisense RNA probe was observed 
only in the choroid plexus, an epithelial cell layer surrounding the hippocampus (Hip; 
left panel). No signal for TTR was found within the hippocampus. Hybridisation of a 
TTR DIG-labelled sense control RNA probe revealed no background hybridisation 
(right panel); Ctx: cortex; cc: corpus callosum. (C) Real-time quantitative RT-PCR on 
the choroid plexus TTR mRNA levels in APO-SUS and -UNSUS rats. No significant 
differences for TTR mRNA could be observed; β-actin was used for normalisation.
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Aph-1b mRNA levels in the APO-SUS and APO-UNSUS rats
To further analyse the Aph-1b mRNA levels in the rat model, individual hippocampal 
RNA samples were analysed by quantitative RT-PCR. Relative to APO-UNSUS, in all 
APO-SUS samples the Aph-1b transcript levels were reduced (2.2- and 3.1-fold average 
reduction in basal and apomorphine-treated APO-SUS rats, respectively; P < 0.05) (Figure 
6A). Analysis of the distribution of the Aph-1b transcript in the hippocampus using in 
situ hybridisation revealed strong signals in the dentate gyrus as well as in the pyramidal 
cell layers of the CA1-CA3 regions of the hippocampus, while the choroid plexus gave a 
much lower signal. Th is indicated that the diﬀ erences observed in Aph-1b mRNA levels 
between APO-SUS and -UNSUS hippocampal isolates - in both quantitative RT-PCR 
and microarray experiments - were not caused by contaminating choroid plexus material 
(Figure 6B). Furthermore, semi-quantitative RT-PCR analysis of Aph-1b mRNA in 
various tissues (olfactory bulb, hippocampus, cortex, cerebellum, [hypo]thalamus, 
pituitary, heart, lung, liver, spleen, kidney, adrenal gland, small intestine, thymus, eye, 
tongue, muscle, stomach, testis and epydidimus) revealed expression of the transcript in 
all tissues analysed (data not shown). Th erefore, the reduction of Aph-1b mRNA levels 
in the hippocampus of APO-SUS relative to -UNSUS rats appeared to be the only 
reproducible diﬀ erence found in the gene expression proﬁ les of the two rat lines. 
Further analysis of transcript levels of the Aph-1 family members in APO-SUS and 
-UNSUS rats
From extensive BLAST searches against the rat EST and genome database (via http://
www.ncbi.nlm.nih.gov/BLAST), the complete coding sequence of the rat Aph-1b gene 
was derived. Th e gene consists of 6 exons and is mapped to rat chromosome 8q24 
(LOC503216). A tBLASTn search with the Aph-1b amino acid sequence revealed a 
highly similar (56.2% amino acid identity) paralogue sequence, later termed Aph-1a 
(Figure 7A). Similarities were also found in the build-up of the genes, with highly 
similar exon sizes between the two genes (Figure 7B). Quantitative RT-PCR revealed 
that in the hippocampus of PND 9 APO-SUS and -UNSUS rats the Aph-1a mRNA 
levels were not diﬀ erent, while the Aph-1b mRNA levels were signiﬁ cantly reduced in 
the APO-SUS rats (Figure 7C). Th us, the Aph-1a mRNA levels did not compensate for 
the reduced levels of its paralogue. Furthermore, the diﬀ erences in Aph-1b mRNA were 
observed in both male and female rats, indicating that there are no gender diﬀ erences 
for the Aph-1b mRNA levels. In addition, this experiment showed that the diﬀ erences in 
hippocampal Aph-1b mRNA levels can be observed both at PND 9 and PND 60.
All data presented thus far was generated from the replicated APO-SUS and -UNSUS 
rat lines. Th ese ‘newer’ rat lines are independent phenotypic replications that have been 
generated ten years after developing the original APO-SUS and -UNSUS lines (Cools et 
al., 1990; Ellenbroek et al., 2000). To test whether the original rat lines displayed similar 
diﬀ erences in Aph-1b mRNA levels, quantitative RT-PCR was performed on PND 9 
hippocampal RNA samples from these lines. Th e data showed that the reduction in 
Aph-1b mRNA levels in the APO-SUS relative to the -UNSUS rats was not restricted to 
the replicated rat lines, but was also observed in the original rat lines (Figure 8).
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Analysis of the genetic locus of human, mouse and rat Aph-1b 
A comparison of the rat Aph-1b mRNA sequence with the human genome database 
sequences revealed the human locus for the Aph-1b gene to be 15q22.2. Th e human gene 
consists also of six exons and is surrounded by the Ras-associated small GTPase Rab8b 
(15q22.2) gene at the centromeric side and carbonic anhydrase XII (CA12) (15q22.2) and 
the HECT domain and RCC1 domain 1 (HERC1) gene (15q22.31) at the telomeric side of 
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Figure 6. Aph-1b mRNA levels in the APO-SUS / -UNSUS rats
(A) The Aph-1b mRNA levels in individual PND 60 APO-SUS and -UNSUS rat 
hippocampal samples were determined using real-time quantitative RT-PCR. The 
abundance of the Aph-1b transcripts normalised towards β-actin mRNA levels was 
examined both under basal conditions (left panel) and three hours after apomorphine 
injection (right panel). Results are expressed as arbitrary units (AU). Student t-test 
revealed a significant 2.2- and 3.1-fold reduction in basal and apomorphine-treated 
APO-SUS rats, respectively; P < 0.05. (B) In situ hybridisation results for the Aph-1b 
mRNA distribution in the rat hippocampus (Hip) and choroid plexus (ChP). The Aph-
1b DIG-labelled antisense RNA probe was predominantly detected in the dentate 
gyrus and in the pyramidal cell layers of the CA1-CA3 regions of the hippocampus, 
with much lower signals in the choroid plexus. Other brain regions with strong 
hybridisation signals were the olfactory bulb and cerebellum, while moderate signals 
were observed throughout the rest of the brain (data not shown). Hybridisation of a 
control Aph-1b DIG-labelled sense RNA probe revealed no background signals (right 
panel); Ctx: cortex; cc: corpus callosum; Tha: thalamus.
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A
                  1                                                                             80 
 Rn_Aph-1b    (1) MTAAVFFGCAFIAFGPALSLYVFTIATDPLRVIFLIAGAFFWLVSLLLSSVFWFLVRVITDNRDGPVQNYLLIFGVLLSV
Rn_Aph-1aS    (1) MGAAVFFGCTFVAFGPAFALFLITVAGDPLRVIILVAGAFFWLVSLLLASVVWFILVHVTDRSDARLQYGLLIFGAAVSV
Rn_Aph-1aL    (1) ................................................................................ 
                      **********************      ***********************               ********** 
     TM1          TM2        TM3 
                  81                                                                           160 
 Rn_Aph-1b   (81) CIQELFRLAYYRLLKKANEGLKSINPE-ETAPSMRLLAYVSGLGFGIMSGVFSFVNTLSNALGPGTVGIHGDSPQFFLNS
Rn_Aph-1aS   (81) LLQEVFRFAYYKLLKKADEGLASLSEDGRSPISIRQMAYVSGLSFGIISGVFSVINILADALGPGVVGIHGDSPYYFLTS
Rn_Aph-1aL   (81) ................................................................................ 
                  ***********                         **********************                ****** 
                 TM4 
                  161                                                                          240 
 Rn_Aph-1b  (160) AFMTLVIIMLHVFWGIVFFDGCEKNKWYILLTVFLTHLLVSTQTLLSPHYEVNLVTAYIIMVLMGIWAFCVAGGSRRSLK
Rn_Aph-1aS  (161) AFLTAAIILLHTFWGVVFFDACERRRYWALGLVVGSHLLTSGLTFLNPWYEASLLPIYAVTVSMGLWAFVTAGGSLRSIQ
Rn_Aph-1aL  (161) ................................................................................ 
                  *******************        *********************     *********************** 
     TM5            TM6         TM7 
                  241                   265 
 Rn_Aph-1b  (240) LCLLCQDKDFLLYNQRSR-------
Rn_Aph-1aS  (241) RSLSCKD------------------
Rn_Aph-1aL  (241) ....CRRQEDSRVMVYSALRIPPED
B
 exon 1 intron exon 2 intron exon 3 intron exon 4 intron exon 5 intron exon 6 intron exon 7
Aph-1b 113 1224 171 6087 71 774 123 6190 128 2796 168 - -
Aph-1aS 113 542 171 149 74 228 123 153 128 400 135 - -
Aph-1aL 113 542 171 149 74 228 123 153 128 400 124 331 65
Figure 7. The Aph-1 family
(A) Alignment of the amino acid sequences of the rat Aph-1a and -1b proteins. The Aph-
1a gene can be alternatively spliced into two proteins with distinct carboxy-termini, 
Aph-1aS and -1aL. Predicted transmembrane regions are indicated by an asterix 
(black background: idential amino acids, grey background: conserved amino acids, 
dots: sequence identical to Aph1aS). (B) Comparison of the exon and intron sizes of 
the rat Aph-1a and -1b genes. The base pair counts of the individual exons and introns 
are shown; the base pair count of the first exon does not include the 5’ untranslated 
region (UTR), while for the count of last exon the 3’-UTR is excluded. (C) Real-
time quantitative RT-PCR analysis of Aph-1b and -1a mRNA levels in hippocampal 
samples of PND 9 male and female APO-SUS and -UNSUS rats. The primer sets 
used specifically detected all Aph-1b or -1a-related transcripts. Whereas both male 
and female samples show significant reduction in APO-SUS relative to -UNSUS rats, 
no significant differences were observed in Aph-1a mRNA levels. Results (n = 3, plus 
s.e.m.) were normalised towards β-actin and are expressed as arbitrary units (AU); 
***: P < 0.001.
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the Aph-1b locus. A similar chromosomal distribution of the genes was found on mouse 
chromosome 9d and rat chromosome 8q24. To analyse whether in the genomic locus 
the transcript level of a gene other than Aph-1b was aﬀ ected in the APO-SUS/-UNSUS 
rat model, the mRNA levels of the Rab8b, CA12 and HERC1 genes were determined in 
the APO-SUS and -UNSUS hippocampal samples. Quantitative RT-PCR analysis of 
the expression levels of these genes in the rat model did not reveal any diﬀ erences (Figure 
9), indicating that Aph-1b is the only aﬀ ected gene in this locus.
Discussion
Th e microarray technology is predicted to have a great impact on ﬁ nding causes or 
proper treatments for a variety of diseases (e.g. Archacki and Wang, 2004; Meloni et al., 
2004; Raetz and Moos, 2004). However, for complex neurodevelopmental disorders, 
such as schizophrenia, the variability in sample and patient conditions severely impedes 
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Figure 8. Comparison of Aph-1b 
mRNA levels in male hippocampus 
of the original and replicated PND 9 
APO-SUS and -UNSUS rat lines
Real-time quantitative RT-PCR analysis 
of Aph-1b mRNA revealed significantly 
reduced levels in both the original and 
the replicated rat line samples. Results 
(n = 6, plus s.e.m.) were normalised 
towards β-actin and are expressed as 
arbitrary units (AU); *: P < 0.05; ***: P 
< 0.001.
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Figure 9. Analysis of the transcript levels of genes near the Aph-1b locus 
in the hippocampus of PND 9 APO-SUS and -UNSUS rats by real-time 
quantitative RT-PCR
The primer sets used detected the neighbouring Rab8b, CA12 or HERC1 transcripts. 
Beside the reduced Aph-1b mRNA levels, no significant differences were observed. 
Results (n = 6, plus s.e.m.) were normalised towards β-actin and are expressed as 
arbitrary units (AU); ***: P < 0.001.
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any transcript analysis. In the present study, we analysed the mRNA expression proﬁ les 
of a well-established rat model for schizophrenia-related disturbances, the APO-SUS/
-UNSUS rat model. Our initial cDNA microarray comparison of hippocampal RNA 
samples from APO-SUS and -UNSUS rats at PND 60 revealed only a limited number of 
diﬀ erences, both under basal conditions and after apomorphine administration. Further 
analysis of PND 9 hippocampal and cerebellar mRNA proﬁ les using oligonucleotide 
microarrays showed no major alterations in transcript levels in the rat model. Th e fact 
that only a limited number of diﬀ erences were found could be caused by the cellular 
complexity of the tissues analysed. Both the hippocampus and cerebellum are known to 
consist of many diﬀ erent cell types and the analysis of the whole tissues will thus dilute 
any diﬀ erences that may be present only in a subset of cells or cell types (Mackler et al., 
1992; Zawar et al., 1999). Th e most striking diﬀ erence we observed in the hippocampal 
cDNA microarray analyses was the diﬀ erential mRNA levels of TTR. Detailed validation 
experiments learned that the TTR transcript is present at high levels, but exclusively in 
the choroid plexus, an epithelial cell layer surrounding all ventricles of the brain. Th e 
hippocampus is in direct contact with both the 3rd and the lateral ventricles, and in our 
experiments some of the hippocampal isolates must have been contaminated by partly 
co-dissected choroid plexus material. High TTR mRNA levels have been reported to 
be present in the hippocampus (Long et al., 2003; Puskas et al., 2003; Rho et al., 
2005). However, based on our results, most likely these high levels have been caused also 
by dissection artefacts. Th e observed large diﬀ erences in PGDS mRNA levels among 
individual samples are probably the result of the same artefact. Like TTR, PGDS is one 
of the major protein constituent of cerebrospinal ﬂ uid and in the central nervous system 
it is mainly synthesised in the arachnoid cells and the choroid plexus, but unlike TTR 
also to some extent in oligodendrocytes (Kawashima et al., 2001). Th is may explain 
why the observed ﬂ uctuations in PGDS mRNA levels in the individual hippocampal 
isolates were somewhat smaller than for TTR mRNA. A more accurate dissection may 
be accomplished by the use of laser dissection microscopy on brain sections to isolate 
more speciﬁ c brain regions. Th is technique allows the selection of certain tissue regions 
and even the isolation of only a small subset of cells for expression proﬁ ling studies, 
thereby drastically increasing the chances of ﬁ nding diﬀ erences. Th e major disadvantage 
in using such a small number of cells for microarray expression analysis is that the yield 
of RNA is too low for direct microarray experiments and thus ampliﬁ cation of the RNA 
is necessary. Although after our experiments had been conducted, techniques have been 
greatly improved, per microarray hybridisation several micrograms of total RNA are still 
needed. Since it is extremely diﬃ  cult to amplify all transcripts with the same eﬃ  ciency, 
such an additional step is prone to introduce undesirable diﬀ erences in the expression 
proﬁ les.
Detailed comparisons of results obtained through either cDNA or oligonucleotide 
microarray experiments have shown that data generated from oligonucleotide 
microarrays are more reliable for interrogating changes in gene expression than data 
from long cDNA microarrays (Li et al., 2002; Woo et al., 2004). In our experiments, 
for both types of microarrays we initially observed similar percentages of altered gene 
transcripts (for both microarrays ~0.1%). However, follow-up validation experiments 
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argued against all but one diﬀ erence, namely a 2.6-fold reduction of Aph-1b mRNA 
levels in APO-SUS relative to -UNSUS rats, a diﬀ erence discovered using the cDNA 
microarray. It should be noted that the Aph-1b transcript was not present on the 
oligonucleotide microarrays and therefore not detected in this proﬁ ling study at PND 9. 
However, this does not imply that the aﬀ ected Aph-1b transcript levels represent the only 
transcriptional diﬀ erence between the two rat lines. First, roughly only one third of all 
rat gene transcripts were present on the microarrays used, so diﬀ erences could be hidden 
in the other two thirds of the transcripts. Secondly, expression microarrays have their 
limitations in detection sensitivity. Diﬀ erences have to be of a reasonable order (at least 
~40% increase or decrease) to allow detection above the technical background spreading 
in signal intensities. Nevertheless, only small diﬀ erences can have a great physiological 
impact, especially in in vivo situations. Moreover, for microarray analysis the amount of 
a transcript has to be higher than a certain threshold level to obtain hybridisation signals 
above background. Diﬀ erences in low-abundant transcripts, encoding for example 
pivotal enzymes or receptors of important pathways, may therefore be undetectable.
Detailed PCR-based transcript analysis of the Aph-1b gene conﬁ rmed the reduced levels 
in APO-SUS compared to -UNSUS rats. Diﬀ erences were found in the hippocampus 
at PND 9 and 60, and in both male and female rats, suggesting a general or basic 
cause. Furthermore, since the Aph-1b mRNA levels were reduced in both the original 
and replicated APO-SUS lines the reduced expression levels are likely to be responsible 
for the phenotypic characteristics of the APO-SUS rats. Th e APO-SUS and -UNSUS 
rat lines have been generated independently of each other and with a ten-year interval 
(Ellenbroek et al., 2000).
Th e reduced expression of Aph-1b in the APO-SUS relative to the -UNSUS rats could 
have various origins: the expression of a transcription factor regulating the Aph-1b gene 
may be diﬀ erent, the locus of the Aph-1b gene could be aﬀ ected (for example, by a 
single nucleotide polymorphism [SNP], deletion or mutation), the epigenetic status of 
the locus could vary, the Aph-1b mRNA could have a diﬀ erent stability, or the pathway 
in which the Aph-1b protein is involved could be aﬀ ected (with a feedback on Aph-1b). 
Our analysis of the transcript levels of neighbouring genes of the Aph-1b locus (on rat 
chromosome 8q24) did not reveal any diﬀ erences between APO-SUS and -UNSUS 
rats, indicating that the aﬀ ected transcript levels in this locus are conﬁ ned to the Aph-1b 
gene.
Recently, it has been found that Aph-1b is part of the γ-secretase complex, an enzyme 
responsible for the intramembrane cleavage of many type I transmembrane proteins 
(De Strooper, 2003; Francis et al., 2002; Goutte et al., 2002). Th e complex, consisting 
of presenilin, nicastrin, PEN-2 and Aph-1, is notoriously known for its pathological 
involvement in Alzheimer’s disease (Price et al., 1995; Sherrington et al., 1995). In future 
experiments, we will examine whether in the APO-SUS/-UNSUS rats the diﬀ erences 
observed in Aph-1b mRNA levels are accompanied by alterations in Aph-1b protein levels. 
Furthermore, it will be highly interesting to investigate whether diﬀ erences can be found 
for the other components of the γ-secretase complex as well, or even for the enzymatic 
functionality of the γ-secretase complex. Th us far, we have analysed the mRNA levels for 
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the paralogue of Aph-1b, termed Aph-1a, and found no compensation for the reduction 
of Aph-1b levels in the APO-SUS rats. Future research will thus provide more insight 
into all components and the functioning of γ-secretase in our rat model, and whether 
Aph-1b or γ-secretase is truly causative of the schizophrenia-related phenotype.
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Appendix 1: List of sequences spotted on cDNA microarray
Incyte ZooSeq number 700491883 (TTR):
GCCTGTTCCTCCTCTGCCTCGCTGGACTGATATTTGCGTCTGAAGCTGNCCCTNTAGG
GTGCTGANAAGAATCCAAGTNTCNTCTGATGGTCAAAGTCNTGGANNCNNTCCNAAG
NAGNCCTGNNGTT
Incyte ZooSeq number 700861868 (PGDS):
GTGGAGGCCAAGCCTGGTTCATAAATAGGGTCTCCACGGTGGCCTCTGCTCCATCTGC
CCACAGTCTTCCTTGCTTTGCCCACGTTGCTGGCCTCAGGCTCAGACACCTGCTCTAC
TCCAAGCAAATGGCTGCTCTTCCAATGCTGTGGACCGGGCTGGTCCTCTTGGGTCTCT
TGGGATTTCCACAGACCCCAGCCCAGGGCCATGACACAGTGCAGCCCAACTTTCAACAA
GACAAGTTCCTGGGGCGCTGGTACA
Incyte ZooSeq number 700251056 (Aph-1b):
AAAAAAGCCAGCGAGGGTTTGAAAAGCATAAACCCTGAGGAGACAGCACCTTCGATGC
GACTGTTGGACTATGTTTCTGGCTTGGGCTTTGGAATCATGAGTGGACTGTTTTCCTT
TGTGAACACCCTGTCTAATGCCTTGGGGCTAGTCACAGTGGGCATTCACGGTGATTACC
CTCAGTTCTTCATTAATTCACCTTTCATGACGCTGGTTATCATAATGCTGCACGTGTTC
TGGGGAATCGAGTTTATTAACGGCTGTGAGAAGAATAAGTGG
Incyte ZooSeq number 700289556 (α-ATLP / SPI-1 serine protease inhibitor (AA 1-403)):
GCGGGATCTACACCGGAAGTTTGCTCTTTATAGACAAGACTCTAAAGCCAGCAAAGACT
TTTGTCAAACTAGCCAACAGCTCCTACAACAGCAATGTCGTCCTCATCTCTTTTGGGAA
CTACGGGTTGGCCCAAAAGCAGATAGACTTGGCCATTCGTGCCAGGACCCACGGCAAA
ATTACAAAGCTGCTGAGAATTCTGAAGCCACCAACTAACTTGTTTCTGGCCAATTATAAT
TTCTTTAAAGGGAAGTGGAAATACCCCTTTAACCGGAAGCACACAAGGATGAGGTACTT
CTGGTTAGAAGATG
Incyte ZooSeq number 700697881 (EST1 / MOUSE, CLONE MGC:6948):
GGCGCACGCCGGTAGGATCTGCCTCCCAAATGTTGGGATTAAAAGTGTGAGCTGCCAC
TGCACAGCATCGGAATTCTTTCTATTGCTTCTTCAAAGATTCATTCCCATGGCCACTAT
GATGATGACACGTGATGGGGAGATGGGAAAGACAGAAAACAGTGGTGTATGCAGACATG
GTGGTGGTGACAGGTGAGAGAGGGTTGACCTGCTGTCATTGCTCAGTAAGGTCCACAG
CATGGTGTGTGGC
Incyte ZooSeq number 700938990 (EST2 / CGI-84 protein):
CAAACAATTACATTTTAAAATAAAATTGAGAGTTACCCAAACAGTTACCCAATCTGTCTT
ACAAAGCTTATAAAAGTGAATTGGATATAATTAGCCAAATGAAGAAAGAAGACACTGAAT
TAATAACACTTTACAGTGATGAAAATATACTTGGTCTTTCTTCCAAGAACTGAGATTTTC
TCAGTATGAATTATAAGTCTGTGCTGGAATTTTGGATTGCATTAATATACACATTAAACT
CTGTAAATGAAGCCATTCTT
Incyte ZooSeq number 700253034 (EST3 / Incyte EST):
CAGTAGGTTAGAATACCCAGTGTGGCCTGATAGGGTAGGAGAAAGTTCCTAGATGTGAA
GGTTGACGTTCATTCTTGGAAGTTTGGTGGGTGGTTGGAGGGGTGTTGGGGATCAGG
AAGGGGGCTAAAACTCAATGTTTATTCACCTACCCATGCCAAAAAACTAGTATTTTGTAA
TGGTTTTGTAAGAGGAGTAGACAGACGAATTAAGTTTTAGCCGGTTCCCCCCTAGTCCC
ATCC
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Abstract
A combination of genetic factors and early-life events is thought to determine the 
vulnerability of an individual to develop a complex neurodevelopmental disorder 
like schizophrenia. Pharmacogenetically selected, apomorphine-susceptible Wistar 
rats (APO-SUS) display a number of behavioural and pathophysiological features 
reminiscent of such disorders. Here we report microarray analyses revealing in APO-
SUS rats, relative to their counterpart APO-UNSUS rats, a reduced expression of 
Aph-1b, a component of the γ-secretase enzyme complex that is involved in multiple 
(neuro)developmental signalling pathways. Th e reduced expression is due to a duplicon-
based genomic rearrangement event resulting in an Aph-1b dosage imbalance. Th e 
expression levels of the other γ-secretase components were not diﬀ erent. However, γ-
secretase cleavage activity was aﬀ ected and the APO-SUS/-UNSUS Aph-1b genotypes 
segregated with a number of behavioural phenotypes. Th us, a subtle imbalance in the 
expression of a single, developmentally important protein may be suﬃ  cient to cause 
a complex phenotype.
Introduction
W e used the susceptibility of normal outbred Wistar rats for the dopaminergic agonist apomorphine as a criterion for the selection of two distinct types 
of individuals (Cools et al., 1990; Ellenbroek and Cools, 2002). Th rough systemic 
apomorphine administration and long-term pharmacogenetic selections we produced 
rats with a high or low susceptibility for this drug (referred to as APO-SUS and APO-
UNSUS rats, respectively). Extensive phenotyping of the APO-SUS and -UNSUS rats 
over the last 15 years has revealed diﬀ erences in many aspects of behaviour, neuroanatomy, 
and their neurochemical, endocrine and immune systems (Cools et al., 1990; Ellenbroek 
and Cools, 2002). For example, they diﬀ er in brain information processing (prepulse 
inhibition and latent inhibition; (Ellenbroek et al., 1995)), locomotor activity in response 
to novelty, and ﬂ eeing and problem-solving behaviour (Cools, 1988; Cools et al., 
1990). In addition, APO-SUS and -UNSUS rats show changes in their hypothalamus-
pituitary-adrenal (HPA) axis response to stress (Rots et al., 1995), their sensitivity to 
dopamimetic drugs (Ellenbroek et al., 2000), their neuropeptide, steroid and steroid 
receptor levels (Cools et al., 1993; Rots et al., 1995; Rots et al., 1996), their synaptic 
densities within hypothalamic nuclei (Mulders et al., 1995), their TH2 cell contents and 
their susceptibilities to inﬂ ammatory and infectious diseases, vasorelaxation and stress 
(Kavelaars et al., 1997). Crossbreeding experiments have shown that genetic factors 
play an important role in the development of the rat model (Ellenbroek et al., 2000). 
Furthermore, the propensity of the model to develop the speciﬁ c features in adulthood 
is dependent on the timing and type of stressors to which the rats have been exposed 
during early life (Degen et al., 2004; Ellenbroek et al., 2000). For example, when 
APO-SUS rats are reared from birth on by APO-UNSUS mothers their susceptibility 
to apomorphine is signiﬁ cantly reduced, whereas such crossfostering has no eﬀ ect on 
Chapter 3
56
APO-UNSUS rats. Conversely, a 24-h separation of the pups from their mother early 
in life enhances apomorphine susceptibility in APO-UNSUS rats, while this maternal 
deprivation does not aﬀ ect APO-SUS rats (Ellenbroek et al., 2000). Interestingly, ten 
years after developing the original APO-SUS and -UNSUS lines a separate, independent 
selection and breeding procedure for apomorphine susceptibility of Wistar rats resulted 
in replication of the APO-SUS and -UNSUS lines that displayed similar features as the 
original ones (Ellenbroek et al., 2000). In this study, we examined the molecular basis 
of the diﬀ erences between the APO-SUS and -UNSUS rats.
Materials and methods
Animals
Systemic administration of apomorphine (1.5 mg/kg s.c.) was used to select rats with a 
high or low susceptibility to this drug (APO-SUS and APO-UNSUS rats, respectively); 
the behaviour was quantiﬁ ed with the Ungerstedt box and the rats were classiﬁ ed on 
the basis of their gnawing scores (APO-SUS: >500 gnaws in 45 min; APO-UNSUS: 
<10 gnaws in 45 min) to select female and male rats for breeding the two distinct 
lines (Cools et al., 1990). We have avoided brother-sister pairings, and used a speciﬁ c 
procedure that was aimed at selectively breeding for apomorphine susceptibility, 
while otherwise maintaining the genotypic heterogeneity of the initial Wistar strain. 
For the present study, we used APO-SUS and -UNSUS rats of the 13th to the 20th 
generation; genotyping of the original APO-SUS and -UNSUS lines was on rats of the 
32nd generation. For the behavioural tests, adult male rats (PND 60-70) were used, and 
separate I/I, II/II and III/III lines were generated by PCR-analysis of genomic DNA 
with speciﬁ c primers and intermating each of the genotypes. Th e I/I and II/II sublines 
were produced from the APO-SUS line. Following its creation in 1994, the APO-SUS 
line has been maintained for 19 generations by random breeding. When we recently 
discovered the genomic recombination event reported here, we decided to select APO-
SUS rats homozygous for one or two Aph-1b copies. Th e two rat populations were then 
intermated separately, resulting in the generation of the two APO-SUS sublines (I/I and 
II/II). Since no selection other than for Aph-1b homozygosity was applied, apart from 
the Aph-1b locus these sublines have highly similar general genetic backgrounds. Rats 
were bred and reared in the Central Animal Facility of the Radboud University under 
approved animal protocols and in accordance with institutional guidelines.
Microarray experiments
For mRNA expression proﬁ ling, hippocampi were dissected from fresh brains of 
PND 9 and PND 60 APO-SUS and -UNSUS rats and the tissues were frozen in 
liquid nitrogen. Furthermore, hippocampi were isolated from PND 60 APO-SUS and 
-UNSUS rats three hours after they were injected with apomorphine (1.5 mg/kg, s.c.). 
Total RNA was prepared with the Trizol reagent (Gibco BRL Life Technologies), and 
RNAs from 5 hippocampi were pooled and used in the microarray analyses. Th e PND 
9 hippocampal samples were analysed using Aﬀ ymetrix high-density oligonucleotide 
arrays (Rat Genome Set U34A containing ~7,000 full-length sequences and ~1,000 EST 
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clusters randomly selected from Rattus norvegicus database sequences) according to the 
manufacturer’s recommendations. Brieﬂ y, total RNA was puriﬁ ed on RNeasy columns 
(Qiagen) and 20 µg RNA was reverse transcribed (Superscript II; GibcoBRL Life 
Technologies) using a T7-dT24 primer (GenSet). Following second-strand synthesis, 
the double-stranded cDNA was used in an in vitro transcription reaction to generate 
biotinylated cRNA. Puriﬁ ed, fragmented cRNA (10 µg) was hybridised onto the 
Aﬀ ymetrix arrays for 16 h at 45 °C. Standard post-hybridisation washes and double-stain 
protocols were performed on a GeneChip Fluidics Station 400 (Aﬀ ymetrix). Arrays were 
scanned on a Hewlett Packard Gene Array scanner and analysed using Microarray Suite 
version 5.0 software. For the PND 60 hippocampal samples, we used the Incyte high-
density cDNA microarrays (Rat NeuroGEM 2.02 containing 8,478 Sprague Dawley 
rat nervous system cDNAs representing 6746 diﬀ erent genes). Isolation of mRNA, 
conversion to Cy3 or Cy5 ﬂ uorescently labelled cDNA, hybridisation and scanning 
were performed as described previously (Yue et al., 2001) and the data were analysed 
with GEMTools 2.5 software. With the oligonucleotide microarrays no diﬀ erences were 
found that met the criteria (a diﬀ erence in expression between PND 9 APO-SUS and 
-UNSUS hippocampus of >1.3-fold), while seven cDNAs were found to be diﬀ erentially 
expressed on the cDNA arrays (i.e. >1.5-fold diﬀ erence between PND 60 APO-SUS 
and -UNSUS hippocampus). However, the mRNA expression levels of four of these 
were not signiﬁ cantly diﬀ erent between APO-SUS and -UNSUS rats upon validation 
of the microarray data by quantitative RT-PCR. Th e diﬀ erences in expression of two 
cDNAs (encoding transthyretin and prostaglandin D-synthase) were conﬁ rmed by the 
validation analyses but resulted from their expression in contaminating choroid plexus 
(dissection artefact during the isolation of the hippocampus). Th e Aph-1b transcript met 
the criteria and its ~1.6-fold reduction in hippocampal mRNA expression in basal and 
apomorphine-treated PND 60 APO-SUS relative to APO-UNSUS rats found on the 
cDNA microarrays was conﬁ rmed by quantitative RT-PCR (2.2 ± 0.3- and 3.1 ± 0.8-
fold reduction in basal and apomorphine-treated PND 60 APO-SUS rats, respectively; 
n = 9). Th e Aph-1b transcript was not represented on the oligonucleotide microarrays.
Quantitative RT-PCR
For quantitative RT-PCR, ﬁ rst-strand cDNA was prepared from 2 µg of DNase I 
treated total RNA (isolated as described above) using Superscript II reverse transcriptase 
(Invitrogen). PCR samples contained 1X SYBR Green buﬀ er, 3 mM MgCl2, 0.4 mM 
dUTP and 0.2 mM each of dATP, dCTP and dGTP, 0.6 U AmpliTaq Gold (all 
from Applied Biosystems), 0.6 µM each oligonucleotide primer (Biolegio) and 1/20 
synthesized cDNA in a 25-µl volume. Quantitative PCR was performed in a PE 
GeneAmp 5700 apparatus with conditions as follows: 10 min at 94 °C, then 40 cycles 
of 15 s at 94 °C, 30 s at 60 °C and 1 min at 72 °C. β-Actin was ampliﬁ ed from all 
samples to normalise expression. A control (no template) was included for each primer 
set. Data sets were analysed with Sequence Detection System 1.3 software. Th e following 
primers were used: Aph-1b-related (448-671): 5’-GTGATTCTCCTCAGTTCTTCCT
TAATTC and 5’-GCCCATGAGCACCATGATTATAT; Aph-1a related (547-670): 5’-
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AGAGGAGACGGTACTGGGCTTT and 5’-ATGGAAACGGTGACTGCATAGA; 
presenilin-1 (259-378): 5’-GTTCCTGTGACCCTCTGCATG and 5’-GCCTACAGT-
CTCGGTGTCTTCTG; presenilin-2 (1093-1218): 5’- GGAGACTTCATCTTCTA
CAGCGTTCT and 5’-GAGCAGCAGGAGGGTGAGAC; nicastrin (504-622): 5’-
TGGCTTGGCTTATGACGACTT and 5’-TCGGTGCAGAGCCATTCTG; Pen-2 
(14-162): 5’-GGGTGTCCAATGAGGAGAAGTT and 5’-TTGATTTGGCTCT-
GCTCTGTGTA; β-actin (346-435): 5’-CGTGAAAAGATGACCCAGATCA and 
5’-AGAGGCATACAGGGACAACACA; numbers between brackets are nucleotide 
positions from start ATG). All PCR products were generated over intron-exon 
boundaries.
Genomic DNA analysis
APO-SUS and -UNSUS rats were genotyped by extensive Southern blot analysis and 
PCR screening of genomic tail DNA (primers and conditions available on request). 
Comparative analysis of the nucleotide sequences of rat Aph-1b and -1b’ was performed 
with Vector NTI. Th e nucleotide sequences surrounding exons 5 and 5’ of Aph-1b and 
-1b’, respectively, and of the junction area within chimaeric Aph-1b’/b were determined 
by PCR analysis of genomic DNA from APO-UNSUS, and APO-SUS (II/II) and (I/
I) rats using speciﬁ c primers and subsequent nucleotide sequence analysis of the PCR 
products. 
Northern blotting
Total RNA from hippocampus of PND 9 APO-UNSUS and APO-SUS (II/II), (II/I) 
and (I/I) rats, and from various tissues of PND 9 APO-UNSUS and APO-SUS (I/I) rats 
was isolated as described above, separated on gel (10 µg per lane), blotted and hybridised 
according to standard procedures with a full-length 798-bp rat Aph-1b cDNA probe 
detecting all Aph-1b-related mRNAs (~1,3 kb). 
Western blotting
Protein extractions and immunoblottings were performed as previously described 
(Herreman et al., 2003). To examine Aph-1b protein expression, multiple tissue 
extraction methods and a variety of APO-SUS/-UNSUS and mouse tissues and cell 
lines were used. Th e polyclonal antibodies against presenilin-1 and nicastrin (Herreman 
et al., 2003), against presenilin-2 (Zymed Laboratories Inc.), and against Pen-2 and 
Aph-1a (Nyabi et al., 2003) were raised in rabbits. Th e antibodies against Aph-1b 
were directed against the peptides CLVRVITDNRDGPV and CVAGGSRRSL, and 
generated in rabbits (BioGenes GMBH, Germany). To examine γ-secretase substrate 
cleavage, antibodies were used against the C-terminus of APP (C87, polyclonal antibody 
directed towards the most C-terminal 12 amino acids of APP and generated in rabbits), 
p75NTR (Mahadeo et al., 1994) and ErbB4 (C-18, Santa Cruz Biotechnology, Santa 
Cruz, CA), and against β-tubulin (E7, (Chu and Klymkowsky, 1989) on brain tissue 
samples from three (I/I) rats of diﬀ erent nests and three (III/III) rats of diﬀ erent nests. 
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Sample preparations for the analysis of APP, p75NTR and ErbB4 were performed 
as described by (Herreman et al., 2003), (Jung et al., 2003), and (Ni et al., 2001), 
respectively.
Behavioural analysis
For the apomorphine susceptibility test, rats were injected with 1.5 mg/kg apomorphine 
(s.c.) and their gnawing behaviour was tested in an Ungerstedt box (Cools et al., 1990). 
In the open ﬁ eld test, rats were placed in the centre of an elevated open ﬁ eld of 160 x 160 
cm without walls. Th e open ﬁ eld was artiﬁ cially subdivided into a central part (40 x 40 
cm) and a peripheral area (16 cm in width). Locomotor behaviour was recorded for 30 
min with a computerised automated tracking system, and the habituation time (deﬁ ned 
as the time until the rat stopped locomotor activity for at least 90 s) was measured (Cools 
et al., 1990). Th e elevated plus maze consisted of a plexiglass four-armed maze with two 
open and two closed arms (10 x 50 cm). Each rat was placed in the centre of the plus 
maze facing a closed arm and the rat was allowed to explore the maze for 5 min.
Statistics
Data are presented as mean ± s.e.m. Statistical evaluation was performed using one-way 
analysis of variance (ANOVA) followed by a Bonferroni t-test where three groups were 
compared. For the comparison of two groups, the Student’s t-test was employed. Values 
of P < 0.05 were considered statistically signiﬁ cant.
Results
Gene expression profiling of APO-SUS and -UNSUS hippocampus
In an attempt to understand the diﬀ erence between APO-SUS and -UNSUS rats at the 
molecular level, we decided to determine for both lines the mRNA expression proﬁ les 
of the hippocampus of postnatal day 9 (PND 9) and PND 60 rats using oligonucleotide 
and cDNA microarrays. Th e hippocampus was selected because of its well-established 
physiological role in e.g. behavioural and HPA-axis regulation (McEwen, 2002), 
the neurochemical diﬀ erences observed in APO-SUS and -UNSUS hippocampus 
(Ellenbroek and Cools, 2002), and the relative ease of its dissection. Th e time point PND 
9 was chosen since exposing APO-UNSUS pups to a severe stressor at this stage causes 
the most dramatic eﬀ ect on brain information processing later on in life (Ellenbroek et 
al., 1998). At PND 60 the rats are just past their puberty and considered to be young 
adults, and at this age the clear phenotypic diﬀ erences between APO-SUS and -UNSUS 
rats have been mapped (Cools and Ellenbroek, 2002; Ellenbroek and Cools, 2002; 
Ellenbroek et al., 2000). Th e mRNA expression proﬁ ling experiments revealed only 
one cDNA that met the preset criteria and could be conﬁ rmed by quantitative reverse 
transcription-polymerase chain reaction (RT-PCR) (see Experimental Procedures for 
details). Th is transcript encodes the γ-secretase component Aph-1b, a predicted seven-
transmembrane protein initially identiﬁ ed through genetic screens in worms (Francis et 
al., 2002; Goutte et al., 2002). 
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The Aph-1b gene in APO-SUS and -UNSUS rats
We next considered the possibility that the diﬀ erent Aph-1b mRNA expression levels 
in APO-SUS and -UNSUS were the result of a genomic DNA mutation. Database 
searches revealed that the rat (on chromosome 8q24) and mouse (on chromosome 9c) 
contain in tandem two Aph-1b-related copies (designated here Aph-1b and Aph-1b’ 
with -1b downstream of -1b’ ), each consisting of six exons and spanning ~20 kb, and 
separated by ~24 kb. Th e single human Aph-1b gene (on chromosome 15q21.3) consists 
also of six exons, spans ~28 kb and represents the orthologue of rat/mouse Aph-1b. 
Computational approaches to deﬁ ne potential intron-exon structure, comparative (rat/
mouse) nucleotide sequence analysis and EST database searches gave no indications for 
the presence of a gene in the intergenic region of Aph-1b and -1b’. Southern blot and 
PCR analyses of genomic DNA revealed that all APO-UNSUS tested (n = 93) contained 
three Aph-1b-related copies (here referred to as region III; Figure 1A), namely Aph-1b’, 
chimaeric Aph-1b/b’ (consisting of exons 1-5 of Aph-1b and exon 6’ of Aph-1b’ ) and Aph-
1b. Of 151 APO-SUS genotyped, 26% were homozygous for the duplicated genes (II/
II), 24% were homozygous for chimaeric Aph-1b’/b (consisting of exons 1’-5’ of Aph-1b’ 
and exon 6 of Aph-1b) (I/I), whereas the remaining 50% were heterozygous harbouring 
both the duplicated genes and chimaeric Aph-1b’/b (II/I) (Figure 1A). Interestingly, we 
found that the ﬁ rst-established APO-UNSUS and -SUS lines (Ellenbroek et al., 2000) 
displayed the same genotypes (i.e. all of the original APO-UNSUS tested were III/III, 
while all APO-SUS were II/II, II/I or I/I), indicating that the replication of the original 
APO-SUS/-UNSUS lines had resulted in the same Aph-1b genotypical distribution. 
A comparative nucleotide sequence analysis of rat Aph-1b and -1b’ showed a low degree 
of identity, except for the regions surrounding exons 5 and 5’, and exons 6 and 6’ (Figure 
1B). A region of 1106 nucleotides containing exon 5/5’ and identical between the two 
genes was found to represent the junction area of chimaeric Aph-1b’/b (Figure 1C). Th ese 
results suggest that an unequal crossing-over (non-allelic homologous recombination) 
between the identical regions around exons 5 and 5’ (direct repeats) resulted in three 
in-tandem Aph-1b-related copies (region III) and chimaeric Aph-1b’/b (region I) (Figure 
1D).
Expression of Aph-1b and the other γ-secretase components in APO-SUS and 
-UNSUS rats
Since a longitudinal study on hippocampus of postnatal stages of APO-SUS and -UNSUS 
rats (0, 2, 4, 6, 9, 12, 22, 35, 60 and 100 days of age) showed the largest diﬀ erences in 
Figure 1. Aph-1b in APO-UNSUS and -SUS rats
(A) Schematic of the three Aph-1b-related copies in the APO-UNSUS rat (referred to as region III/III) 
and of the one or two gene copies in the APO-SUS rat (region II/II, II/I or I/I); black box, Aph-1b’; 
white box, Aph-1b; white/black box, chimaeric Aph-1b/b’; black/white box, chimaeric Aph-1b’/b. The 
results are based on Southern blot and PCR analyses of genomic DNA. (B) Schematic of the degree 
of nucleotide sequence identity between rat Aph-1b and -1b’. The locations of exons 1/1’ to 6/6’ of 
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nucleotides in Aph-1b. The region of 1106 nucleotides identical between the two genes (surrounding 
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Schematic of the genomic rearrangement resulting from unequal crossing-over (interchromosomal, 
non-allelic homologous recombination) between the in-tandem Aph-1b’ and -1b (corresponding to 
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shown by the X and dots are used for clarity in the presentation.
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APO-SUS/-UNSUS Aph-1b-related mRNA expression at early post-natal stages (data 
not shown), rats of PND 9 were used for subsequent expression studies. Quantitative 
RT-PCR on hippocampus RNA revealed in PND 9 APO-SUS rats signiﬁ cantly lower 
levels of Aph-1b-related mRNAs than in PND 9 APO-UNSUS rats, namely a 2.3-, 
3.2- and 6.2-fold reduction in APO-SUS (II/II), (II/I) and (I/I), respectively (Figure 
2A). Northern blot analysis conﬁ rmed the quantitative RT-PCR data for hippocampus 
(Figure 2B) and furthermore showed, relative to PND 9 APO-UNSUS rats, clearly 
reduced levels of Aph-1b-related mRNA expression in all other PND 9 APO-SUS (I/I) 
tissues tested (Figure 2C). We were unable to reliably detect the Aph-1b protein, in 
line with the inability of others to detect this seven-transmembrane protein (Gu et al., 
2003) and despite the fact that we generated two additional antibodies against two 
computationally selected and previously not chosen rat Aph-1b peptide regions.
Besides Aph-1b and its paralogue Aph-1a, the γ-secretase complex is presently thought to 
consist of three other physically interacting components, namely the putative enzymatic 
core multipass transmembrane protein presenilin-1 or -2, the type I integral membrane 
presenilin-associated glycoprotein nicastrin, and the small double-membrane-spanning 
protein Pen-2 (Fortini, 2002; Francis et al., 2002; Goutte et al., 2002). Quantitative RT-
PCR revealed that in the hippocampus of PND 9 APO-UNSUS, and APO-SUS (II/II), 
(II/I) and (I/I) the mRNA levels of Aph-1a, presenilin-1 and -2, nicastrin and Pen-2 were 
not signiﬁ cantly diﬀ erent or only slightly aﬀ ected (Figure 3A). Moreover, no signiﬁ cant 
diﬀ erences in the protein levels of these γ-secretase components were observed in the 
hippocampus of PND 9 APO-UNSUS and -SUS rats (Figure 3B). 
Cleavage activity of the γ-secretase enzyme in APO-SUS and -UNSUS rats
To examine the eﬀ ect of the diﬀ erential Aph-1b expression on γ-secretase enzyme activity, 
we performed western blot analysis of the cleavage products of the γ-secretase substrates 
amyloid-β precursor protein APP, p75 neurotrophin receptor (p75NTR) and neuregulin 
receptor ErbB4 in PND 2 APO-SUS (I/I) and APO-UNSUS (III/III) rat brain tissues 
(Figure 4). Since the ratios of the Aph-1b and Aph-1a mRNA levels greatly vary among 
rat tissues (data not shown), we decided to study tissues with a high Aph-1b/-1a mRNA 
ratio (pons/medulla, ratio ~ 3.8; olfactory bulb, ratio ~ 2.9) as well as tissues with a low 
ratio ([hypo]thalamus, ratio ~ 0.9;  cerebellum, ratio ~ 0.7). Th e ﬁ rst substrate examined 
was the C-terminal fragment of APP (APP-CTF, also referred to as C83/C99), a well-
deﬁ ned direct γ-secretase substrate (De Strooper et al., 1998). No diﬀ erences in the 
levels of APP-CTF were observed in the tissues with a low Aph-1b/-1a ratio (cerebellum 
and [hypo]thalamus), while a signiﬁ cant increase was detected in the olfactory bulb 
and pons/medulla (2.1- and 2.7-fold, respectively) of I/I compared to III/III rats. Th is 
ﬁ nding indicates that γ-secretase cleavage activity was reduced in the APO-SUS (I/
I) rats in tissues that normally express relatively high Aph-1b levels (olfactory bulb 
and pons/medulla). Cleavage by γ-secretase of the C-terminal fragment of p75NTR 
(p75NTR-CTF) yields the p75NTR intracellular domain (p75NTR-ICD; (Kanning 
et al., 2003). No major diﬀ erences in the amounts of p75NTR-ICD were found in the 
cerebellum, (hypo)thalamus and pons/medulla, whereas in the I/I rats the levels of this 
APH-1B GENE DOSAGE IMBALANCE
63
product were signiﬁ cantly reduced in the olfactory bulb (1.7-fold). Similarly, the levels of 
the third γ-secretase substrate tested, the C-terminal fragment of ErbB4 (ErbB4-CTF), 
were signiﬁ cantly increased in the olfactory bulb of the I/I compared to the III/III rats 
(3.0-fold) and not in the other three tissues. Th us, the reduced expression of Aph-1b in 
the APO-SUS (I/I) rats has decreased γ-secretase cleavage activity in a tissue-dependent 
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Figure 2. Aph-1b mRNA expression in the hippocampus and other tissues of 
PND 9 APO-UNSUS (U) and APO-SUS (S) rats
(A) Quantitative RT-PCR on RNA extracted from hippocampus of PND 9 APO-
UNSUS and APO-SUS (II/II), (II/I) and (I/I) rats. The primer sets detected all Aph-1b-
related mRNAs. Results (n = 6 plus s.e.m.) were normalized towards β-actin and are 
expressed as arbitrary units (AU). Asterisks denote significant differences (P < 0.02). 
(B) Northern-blot analysis of RNA extracted from hippocampus of PND 9 APO-
UNSUS and APO-SUS (II/II), (II/I) and (I/I) rats. The blot was hybridised with a full-
length rat Aph-1b cDNA probe. As a control for RNA loading and integrity, 18S rRNA 
was used. (C) Northern blot analysis of RNA extracted from various tissues of PND 
9 APO-UNSUS (III/III) and APO-SUS (I/I) rats. Tissues used were cerebellum (cer), 
olfactory bulb (olf), cortex (ctx), hippocampus (hip), striatum (str), (hypo)thalamus 
(thal), pons/medulla (p/m), spinal cord (spin), eye, testis (test), stomach (stom), small 
intestine (s.i.), large intestine (l.i.), lung, liver (liv) and thymus (thym). The blot was 
hybridised with a full-length rat Aph-1b cDNA probe. As a control for RNA loading 
and integrity, 18S rRNA was used. 
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manner, i.e. only in tissues in which normally a high Aph-1b/-1a ratio occurs (pons/
medulla and olfactory bulb) signiﬁ cant changes in activity could be detected.
Behavioural phenotypes of the I/I, II/II and III/III rats 
We next wondered whether the I/I, II/II and III/III genotypes segregated with speciﬁ c 
behavioural phenotypes and therefore performed a set of behavioural studies with 
adult rats of the three sublines. We ﬁ rst tested the susceptibility of the three lines for 
apomorphine by scoring their gnawing responses, and found that the III/III rats (32 
± 20 gnaws per 45 min) were signiﬁ cantly less susceptible for the drug than the II/II 
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Figure 3. mRNA and protein expression of gamma-secretase components in 
the hippocampus of PND 9 APO-UNSUS (U) and -SUS (S) rats
(A) Quantitative RT-PCR analysis of Aph-1a, presenilin-1 (PS1) and -2 (PS2), nicastrin 
(Nct) and Pen-2 mRNAs in the hippocampus of PND 9 APO-UNSUS and APO-SUS 
(II/II), (II/I) and (I/I) rats. Results (n = 7 plus s.e.m.) were normalised towards β-actin 
and are expressed as arbitrary units (AU). Asterisks denote significant differences (P 
< 0.02). (B) Western blot analysis of the Aph-1a, PS1, PS2, Nct and Pen-2 proteins 
in the hippocampus of PND 9 APO-UNSUS and APO-SUS (II/II), (II/I) and (I/I) rats. 
Results (n = 6 plus s.e.m.) were normalised towards β-actin and are expressed as 
arbitrary units (AU).
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and I/I rats (1141 ± 189 and 1370 ± 99 gnaws per 45 min, respectively; Figure 5A). We 
then examined the explorative behaviour of the three sublines on a large open ﬁ eld. 
III/III rats habituated signiﬁ cantly faster (605 ± 76 s) than II/II and I/I rats, which were 
found to hardly habituate (1548 ± 98 s and 1536 ± 123 s, respectively; the maximum 
score was 1800 s) (Figure 5B, upper panel). For the III/III, II/II and I/I lines, a gradual 
increase in locomotor activity in the centre of the open ﬁ eld was found, with the I/I rats 
being signiﬁ cantly more active than the III/III rats (Figure 5B, lower panel), indicating 
a high explorative activity of the I/I rats in a cue-less environment. Finally, to assess 
novelty seeking in a stressful environment, the behaviours of the three sublines in the 
open versus the closed arms of the elevated plus maze were compared. Th e time spent 
on the open relative to the closed arms gradually increased for the III/III, II/II and 
I/I lines, with a signiﬁ cant diﬀ erence between the III/III rats (8.0 ± 3.5) and the II/II 
and I/I rat lines (22.6 ± 5.0 and 30.5 ± 3.9, respectively) (Figure 5C, upper panel). Th e 
III/III rats travelled signiﬁ cantly shorter distances on the open relative to the closed 
arms than the II/II or I/I rats (Figure 5C, middle panel). Furthermore, the number 
of entries into the open versus the closed arms gradually increased for the III/III, II/II 
and I/I rats, and was signiﬁ cantly diﬀ erent between the III/III and I/I rats (Figure 5C, 
lower panel). Th e results of the elevated plus maze therefore suggest that the I/I and 
II/II rats are less anxious and more active than the III/III rats. Together, the results of 
the apomorphine susceptibility, open ﬁ eld and elevated plus maze tests indicate that a 
number of behavioural phenotypes of the III/III, II/II and I/I rats segregated with the 
genotypes of the three sublines.
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Figure 4. Western blot analysis of the cleavage products of gamma-secretase 
substrates in PND 2 APO-UNSUS (U, III/III) and APO-SUS (S, I/I) rat 
tissues
The cleavages of three direct γ-secretase substrates were investigated by analysing 
the levels of C-terminal fragments of amyloid-β precursor protein (APP-CTF), p75 
neurotrophin receptor (p75NTR-CTF) and neuregulin receptor ErbB4 (ErbB4-CTF) 
in the olfactory bulb (olf), pons/medulla (p/m), cerebellum (cer), and (hypo)thalamus 
(thal) of APO-UNSUS (U,  III/III) and APO-SUS (S, I/I) rats. Included for p75NTR is 
the analysis of its intracellular domain (p75NTR-ICD), a (-secretase cleavage product. 
Tubulin was used for normalisation. Levels were significantly different between the I/I 
and III/III rats for APP-CTF, p75NTR-ICD and ErbB4-CTF in the olfactory bulb and 
for APP-CTF in the pons/medulla (P < 0.05; n = 3, with the three rats from different 
nests).
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Figure 5. Behavioural phenotypic analysis of adult rats with I/I, II/II and III/III 
genotypes
(A) Apomorphine susceptibility test for gnawing behaviour. Following 1.5 mg/kg 
apomorphine (s.c.) injection, the gnawing scores of III/III, II/II and I/I rats were 
recorded for 45 min (n = 12, 10 and 11, respectively; plus s.e.m.). (B) Open field test 
for explorative behaviour. III/III, II/II and I/I rats were analysed on a large open field 
for 30 min. Upper panel: the time period the rats have used to habituate (i.e. cease 
their locomotor activity for 90 s); lower panel: the locomotor activity in the centre of 
the open field (n = 11, 10 and 10, respectively; plus s.e.m.). (C) Elevated plus maze 
test for novelty seeking in a stressful environment. The walking patterns of III/III, II/II 
and I/I rats in the open and closed arms of the elevated plus maze were analysed for 
10 min. Upper panel: the time spent in the open relative to the closed arms; middle 
panel: the relative distance travelled in the open relative to the closed arms; lower 
panel: the number of entries into the open relative to the closed arms (n = 11, 16 and 
10 respectively; plus s.e.m.). Asterisks denote significant differences (*: P < 0.05; **: 
P < 0.01; ***: P < 0.001).
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Discussion
In this study, we explored the molecular genetic basis of APO-SUS rats that have a complex 
phenotype displaying a number of behavioural, neurochemical, endocrinological and 
immunological disturbances. Microarray analyses revealed the diﬀ erential expression 
of only one gene (Aph-1b) that was found to be due to a gene-dosage eﬀ ect with one 
or two Aph-1b copies in APO-SUS and three copies in APO-UNSUS rats. Th e dosage 
imbalance was caused by an unequal crossing-over event and the site of recombination 
was established, namely between direct repeats (a segmental duplication) within the 
Aph-1b locus in the rat genome. Th is recombination event is reminiscent of recently 
described human chromosomal rearrangements that involve segmental duplications, 
cause dosage imbalance of genetic material and result in so-called genomic disorders; 
segmental duplications comprise at least 5% of the human genome and duplicon-based 
genomic rearrangements appear to occur de novo at a frequency of 0.7-1 in every 1000 
births (Ji et al., 2000). However, in contrast to the situation in rodents, the human 
genome harbours only a single Aph-1b.
In addition to the ﬁ nding of its diﬀ erential expression, a direct link between Aph-1b 
and the observed characteristics of the APO-SUS and -UNSUS rat lines is suggested by 
the fact that the replicated APO-SUS and -UNSUS lines displayed similar diﬀ erences 
in behaviour and Aph-1b copy numbers as the original lines. Furthermore, the results 
of our behavioural tests indicated that the Aph-1b genotypes segregate with a number 
of behavioural APO-SUS and -UNSUS phenotypes. Aph-1b and its paralogue Aph-
1a represent components of the γ-secretase enzyme complex and, together with Pen-2, 
are thought to be involved in the regulation of γ-secretase activity by modulating the 
biogenesis of presenilin-nicastrin complexes (De Strooper, 2003). We have indeed found 
that in the APO-SUS rats the lower Aph-1b levels had changed γ-secretase cleavage 
activity. Th e γ-secretase enzymatic machinery mediates intramembranous proteolytic 
cleavage of at least 14 type I transmembrane proteins that are thought to be involved 
in a complicated network of signalling pathways aﬀ ecting many biological processes 
with a variety of physiological eﬀ ects, especially during early (neuro)development (De 
Strooper, 2003; Fortini, 2002). Taken altogether, the results show that the reduced 
expression of Aph-1b underlies the APO-SUS phenotype. Th us, a subtle imbalance in 
the expression of a single gene product that is involved in a wide variety of developmental 
signalling pathways may well constitute the molecular basis of a complex phenotype that 
is generally believed to have a multifactorial background.
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Abstract
Selectively bred apomorphine susceptible (APO-SUS) rats display a complex behavioural 
phenotype remarkably similar to that of human neurodevelopmental disorders, such 
as schizophrenia. We recently found that the APO-SUS rats have only one or two Aph-
1b gene copies (I/I and II/II rats, respectively), whereas their phenotypic counterpart 
has three copies (III/III). Aph-1b is a component of the γ-secretase enzyme complex 
that is involved in multiple (neuro)developmental signalling pathways. Nevertheless, 
surprisingly little is known about γ-secretase expression during development. Here, we 
performed a longitudinal quantitative PCR study in embryos and the hippocampus 
of I/I, II/II and III/III rats, and found gene-dosage dependent diﬀ erences in Aph-
1b, but not Aph-1a, mRNA expression throughout pre- and post-natal development. 
On the basis of the developmental mRNA proﬁ les, we assigned relative activities to 
the various Aph-1a and -1b gene promoters. Furthermore, in the three rat lines we 
observed both tissue-speciﬁ c and temporal alterations in γ-secretase cleavage activity 
towards one of its best-known substrates, the amyloid-β precursor protein APP. We 
conclude that the low levels of Aph-1b mRNA and γ-secretase activity observed in 
the I/I and II/II rats during the entire developmental period may well underlie their 
complex phenotype.
Introduction
S elective breeding of Wistar rats that diﬀ er in their susceptibility to the dopamine receptor agonist apomorphine has resulted in the generation of two rat lines 
with either a high or a low susceptibility for this drug, the so-called APO-SUS and 
-UNSUS lines, respectively (Cools et al., 1990; Ellenbroek and Cools, 2002). Extensive 
phenotypic analysis of these lines revealed for the APO-SUS rats not only a strong, 
stereotyped gnawing response, but in addition many features that are also found in 
patients suﬀ ering from developmental psychiatric illnesses, such as schizophrenia. Th ese 
features include information processing deﬁ cits in the brain (measured by a reduced 
prepulse inhibition and latent inhibition), a hyper-reactive dopaminergic pathway, an 
increased stress response, and a variety of behavioural, neurochemical, endocrinological 
and immunological features (Ellenbroek and Cools, 2002). While many of the 
diﬀ erences between the APO-SUS and -UNSUS rat lines become apparent later in life, 
some features have been found at earlier developmental stages. For example, APO-SUS 
rats display a retarded development in comparison to APO-UNSUS rats (Degen et al., 
2005), such as the development and maturation of the thymus and spleen (Cools et 
al., 1993). Retarded development (e.g. low birth weight and slower gestation) is also a 
hallmark of schizophrenia (Kunugi et al., 2001; Wahlbeck et al., 2001). As the molecular 
basis of the diﬀ erences between the APO-SUS and -UNSUS rats, we recently identiﬁ ed 
a gene-dosage imbalance of Aph-1b (Coolen et al., 2005). APO-SUS rats have only one 
or two Aph-1b gene copies, whereas APO-UNSUS rats have three in tandem gene copies, 
resulting in reduced Aph-1b mRNA levels in the APO-SUS rats. Th e Aph-1b protein 
is a component of γ-secretase, an enzyme complex that regulates the intramembrane 
proteolysis of a number of type I membrane proteins, including Notch, neuregulin and 
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the Alzheimer’s disease-linked amyloid-β precursor protein APP (Kopan and Ilagan, 
2004). Th ese substrates play diverse physiological roles in multiple cell types and tissues, 
especially during early development. Th e minimal molecular subunit composition of 
an enzymatically active γ-secretase complex consists of presenilin (either PS-1 or PS-2), 
nicastrin (Nct), presenilin enhancer 2 (PEN-2) and the anterior pharynx defective 1 
protein Aph-1, in mammals Aph-1aS, -1aL or -1b (Kimberly and Wolfe, 2003). We 
further established that the three Aph-1b rat genotypes segregated with a number of 
behavioural phenotypes (Coolen et al., 2005). We now generated by crossbreeding, 
genetic reselection and phenotyping (susceptibility for apomorphine) three lines with 
one, two or three copies of the Aph-1b gene against an otherwise highly similar general 
genetic background (I/I, II/II and III/III lines, respectively). In this study, we performed 
an embryonic to adult longitudinal study on the mRNA expression levels of the three 
Aph-1 family members in the I/I, II/II and III/III rat lines, and analysed the γ-secretase 
cleavage activity towards APP at a number of developmental stages.
Materials and methods
Animals
Th e generation of the APO-SUS and APO-UNSUS lines from Wistar rats with a high 
or low susceptibility to apomorphine, respectively, has been described previously (Cools 
et al., 1990). When we recently discovered the Aph-1b genotypes in the APO-SUS and 
-UNSUS rat lines (Coolen et al., 2005), we decided to set up a crossbreeding scheme. 
Four male and four female I/I rats of the APO-SUS line were crossed with four female 
and four male III/III rats of the APO-UNSUS line, respectively. Th e oﬀ spring (either 
I/III or III/I) was intercrossed preventing brother-sister pairing and the resulting F2 
generation was genotyped for the Aph-1b locus by PCR analysis of genomic DNAs. Th e 
rats homozygous for either one or three Aph-1b gene copies were used to generate the 
I/I and III/III lines, respectively; apart from the Aph-1b locus, these lines have highly 
similar general genetic backgrounds. Th e crossbred I/I rats showed a signiﬁ cantly higher 
apomorphine susceptibility than the crossbred III/III rats. For the present studies, we 
used I/I and III/III rats of the F3 generation of the crossbred lines. Similarly, the II/
II rat line was generated by crossbreeding II/II rats of the APO-SUS line and III/III 
rats of the APO-UNSUS line. Th e presence of a vaginal plug was used to determine 
embryonic day 0 (ED 0). Rats were bred and reared in the Central Animal Facility 
of the Radboud University under approved animal protocols and in accordance with 
institutional guidelines.
Quantitative RT-PCR
Quantitative RT-PCR was performed as described previously (Coolen et al., 2005). Th e 
following primers were used: Aph-1b (448-671): 5'-GTGATTCTCCTCAGTTCTTC
CTTAATTC and 5'-GCCCATGAGCACCATGATTATAT; Aph-1aL (572-779):5'-
CCTGGTAGTTGGGAGTCACCTT and 5'-CGCAGGGCAGAGTACACCAT; 
Aph-1aS (572-761): 5'-CCTGGTAGTTGGGAGTCACCTT and 5'-CGGTGCAG-
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TCCAGGTAGTCAGT; β-actin (346-435): 5'-CGTGAAAAGATGACCCAGATCA 
and 5'-AGAGGCATACAGGGACAACACA; numbers between brackets are nucleotide 
positions from start ATG. All PCR products were generated over intron-exon boundaries. 
PCR product analysis on a 2% agarose gel revealed a single band for each primer pair 
used. A control (no template) was included for each primer set. Data sets were analysed 
with Sequence Detection System 1.3 software.
Western blotting
Protein extractions and immunoblottings were performed as described (Herreman 
et al., 2003). Th e polyclonal antibody C87 directed towards the most C-terminal 12 
amino acids of APP was used at a dilution of 1:3000, and detected both the APP full-
length protein and the C-terminal fragment of APP (APP-CTF) (Coolen et al., 2005). 
For quantiﬁ cation, the signals were analysed using the Labworks 4.0 program (UVP 
BioImaging systems, Cambridge, United Kingdom). Western blot analysis of Aph-1b 
protein expression was not successful.
Statistics
Statistical evaluation of the quantitative RT-PCR data for the three Aph-1 family 
members was performed by means of a univariate analysis of variance (ANOVA) with 
as dependent variable the normalised transcript levels and as ﬁ xed factors the genotypes 
(I/I, II/II and III/III) and the developmental time points (either ED or PND). For 
every time point, data were further analysed for signiﬁ cant diﬀ erences between the 
three genotypes using a one-way ANOVA and where appropriate a post hoc Bonferroni 
test. Per genotype, the statistical analysis for diﬀ erences in transcript levels during 
development was performed by means of an independent samples T-test to compare 
the two embryonic time points, or using a one-way ANOVA and a post hoc Bonferroni 
test for the postnatal time points. A probability of P < 0.05 was considered statistically 
signiﬁ cant. For the longitudinal Western blot analyses, the data sets were statistically 
analysed by means of a univariate ANOVA with as dependent variable the APP-CTF/
APP-FL levels and as ﬁ xed factors the genotypes and the developmental time points. 
Subsequent analysis using an independent samples T-test at every time point revealed 
signiﬁ cant diﬀ erences between I/I and III/III rat tissues. Per rat line, a one-way ANOVA 
and where appropriate a post hoc Bonferroni analysis was used to identify diﬀ erences 
between developmental time points. All statistical analyses were performed with the 
SPSS 12.0.1 software program (SPSS Inc., Chicago, Illinois, USA).
Results
Aph-1 mRNA levels in developing I/I, II/II and III/III rats
Real-time quantitative RT-PCR analysis of RNA from whole embryos (prenatal) and 
hippocampal tissue (postnatal) revealed similar overall Aph-1b mRNA expression 
proﬁ les for the I/I, II/II and III/III rats with relatively low pre- and early postnatal 
expression that gradually increased over time until at ~PND 22 a plateau was reached 
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(Figure 1A). Statistical analysis of the Aph-1b mRNA levels by means of a univariate 
ANOVA revealed signiﬁ cant diﬀ erences between the genotypes, as well as between the 
time points analysed (see supplemental tables 1-3 for statistical details). Subsequent 
one-way ANOVA per time point and post hoc Bonferroni analysis showed that the 
Aph-1b mRNA levels were signiﬁ cantly increased in the III/III hippocampal samples 
compared to the II/II or I/I samples at all pre- and postnatal time points tested, with 
the largest diﬀ erences in the pre- and early postnatal samples (up to 16-fold reduction 
in ED13 embryos of I/I compared to III/III rats). Furthermore, in the postnatal II/II 
hippocampal samples the Aph-1b mRNA levels were higher than in the I/I samples and 
reached signiﬁ cant diﬀ erences from PND 35 onwards (up to a two-fold increase). Th e 
mRNA expression patterns of Aph-1aL in the three rat lines were reminiscent of those of 
Aph-1b with signiﬁ cant increases from PND 35 onwards. In contrast, the developmental 
Aph-1aS mRNA expression levels were similar at all stages tested until PND 100, when 
a signiﬁ cant ~three-fold increase was observed (Figure 1C and D). For Aph-1aL as well 
as Aph-1aS, statistical analyses revealed no signiﬁ cant diﬀ erences in mRNA expression 
levels between the three genotypes at any pre- or postnatal time point. 
γ-Secretase cleavage activity in developing I/I, II/II and III/III rats
Next, we were interested in the eﬀ ects of the diﬀ erential expression of Aph-1b mRNA 
in the I/I, II/II and III/III rats on γ-secretase cleavage activity. One of the best-known 
substrates of γ-secretase is the APP protein. Th e proteolytic processing of APP starts with 
shedding of its extracellular domain by α- or β-secretase, leaving a C-terminal fragment 
(CTF) that is subsequently cleaved by γ-secretase. Western blot analysis showed similar 
amounts of the APP holoprotein (APP-FL) in the olfactory bulb of PND 13 I/I, II/II 
and III/III rats, whereas the levels of the direct γ-secretase substrate APP-CTF were 
relatively high in the I/I, moderate in the II/II, and low in the III/III rats (Figure 2A). 
An increased level of APP-CTF implies reduced γ-secretase activity. Statistical analysis 
by means of a one-way ANOVA and post hoc Bonferroni revealed between the three 
genotypes a signiﬁ cant diﬀ erence in the amounts of APP-CTF relative to APP-FL 
(F[2,8] = 13.5 P < 0.05), namely an ~1.4-fold and an ~1.8-fold higher ratio in the I/I 
rats relative to the II/II and III/III rats, respectively. Th us, the degree of proteolytic 
processing of APP by the γ-secretase complex correlated with the Aph-1b gene dosage in 
the I/I, II/II and III/III rats.
Since the Aph-1b mRNA expression levels signiﬁ cantly diﬀ ered during development 
(Figure 1), we wondered whether the APP cleavage activity of γ-secretase would also 
show ontogenic dynamics. For this purpose, we ﬁ rst determined the γ-secretase cleavage 
activity (i.e. APP-CTF levels) in a number of tissues of I/I and III/III rats at PND 13 
to identify appropriate tissues for a more detailed longitudinal analysis. Western blot 
analysis revealed variations in APP-CTF levels between the various tissues (Figure 2B). 
An accumulation of the APP-CTF levels was observed in the olfactory bulb, testis, spinal 
cord and lung of I/I compared to III/III rats and the latter two tissues were used for the 
more detailed study. In the spinal cord, the levels of APP-FL gradually decreased over 
time for both I/I and III/III rats from PND 9 onwards, whereas the APP-CTF levels 
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Figure 1. Longitudinal study on Aph-1aL, -1aS and -1b mRNA expression 
levels in the I/I, II/II and III/III rats
Quantitative RT-PCR analysis of the mRNA levels of Aph-1b (A), Aph-1aL (B) and 
Aph-1aS (C) in total ED13 and ED17 embryos (left halves of the graphs) and in the 
hippocampus of PND 0, 4, 9, 12, 22, 35, 60 and 100 rats (right halves of the graphs). 
The Aph-1b primer set detected all Aph-1b gene transcripts; the Aph-1aL or Aph-
1aS primer sets detected the long or short transcripts, respectively. Results were 
normalised towards β-actin mRNA levels and are expressed as arbitrary units (AU) 
with the level in the PND 0 III/III hippocampus set to 1 (per time point n = 3, plus 
s.e.m.). (A) Throughout development significant differences between the III/III and 
II/II rats as well as the III/III and I/I rats were observed for the Aph-1b mRNA levels 
(P < 0.05). From PND 35 onwards, Aph-1b mRNA levels also differed significantly 
between the II/II and I/I rats (P < 0.05). (B, C) No significant differences between the 
three genotypes were observed for the Aph-1aL or -1aS mRNA levels.
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increased. In contrast, lung tissue showed similar expression levels of the holoprotein 
throughout postnatal development, while the APP-CTF levels were markedly increased 
in both I/I and III/III rats from PND 13 onwards (Figure 2C and D). Statistical analysis 
of the APP-CTF/APP-FL ratio per time point revealed a signiﬁ cant increase of APP-
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Figure 2. Ontogenic analysis of gamma-secretase cleavage activity towards 
APP in the I/I, II/II and III/III rats
(A) APP processing by γ-secretase is dependent on the number of Aph-1b gene copies. 
Western blot analysis of the levels of the APP holoprotein (APP-FL) and C-terminal 
fragment (APP-CTF) was performed in the olfactory bulb of I/I (1), II/II (2) and III/
III (3) rats at PND 13. Quantification of the APP-CTF relative to the APP-FL levels 
revealed significant differences between the I/I and II/II, and between the I/I and 
III/III rats (*: P < 0.05; **: P < 0.02; n = 3, with the three rats from different nests, 
plus s.e.m.). (B) Western blot analysis of the APP-CTF levels in a number of tissues 
of PND 13 I/I (1) and III/III (3) rats. Tissues analysed were olfactory bulb (olf), pons/
medulla (p/m), hippocampus (hip), spinal cord (spc), cortex (ctx), (hypo)thalamus 
(tha), cerebellum (cer), lung (lng), liver (liv), spleen (spl), muscle (msc), testis (tes), 
pancreas (pan) and tongue (tng). The additional product observed in cortex and 
(hypo)thalamus corresponds to the β-secretase cleavage product CTFβ(C99). (C, D) 
Western blot analysis of the levels of APP-FL and -CTF in the spinal cord (C) and lung 
(D) of I/I (1) and III/III (3) rats at PND 2, 9, 13, 35 and 60. Significantly elevated APP-
CTF/-FL ratios in I/I compared to III/III rats were found in the spinal cord at PND 2, 
13 and 35 and in the lung from PND 13 onwards. (*: P < 0.05; **: P < 0.02; n = 3, with 
the three rats per genotype from different nests, plus s.e.m.).
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CTF levels in the spinal cord of I/I compared to III/III rats already at PND 2 and also 
at PND 13 and 35, whereas in the lung signiﬁ cant accumulations were found from 
PND 13 onwards (see also supplemental table 4 for statistical details). Th us, during 
development of the I/I, II/II and III/III rats the diﬀ erential Aph-1b expression levels 
have spatio-temporal eﬀ ects on γ-secretase cleavage activity towards APP.
Discussion
Th e γ-secretase enzyme is involved in a large variety of developmental signalling pathways 
(Artavanis-Tsakonas et al., 1999; Huang et al., 2000; Kopan and Ilagan, 2004; Turner 
et al., 2003). It is therefore surprising that little is known about the developmental 
expression patterns of PS, Nct, PEN-2 and Aph-1, the components of the γ-secretase 
complex. In the present study, we examined the mRNA expression levels of the three 
Aph-1 family members (Aph-1b, -1aS and -1aL) and the γ-secretase cleavage activity 
towards APP during the development of rats with one, two or three Aph-1b gene copies 
(I/I, II/II and III/III rats, respectively). Relatively low levels of Aph-1b mRNA were 
detected during the pre- and early postnatal developmental stages, whereas from PND 
35 onwards we found increased levels that remained high during further development. 
Th is developmental Aph-1b mRNA expression proﬁ le thus suggests that in the rat the 
demand for Aph-1b is higher postnatally than during early development. Th e availability 
of the three Aph-1b mRNA expression proﬁ les together with the knowledge of the genetic 
make-up of the Aph-1b loci in the I/I, II/II and III/III rat lines allows us to speculate 
about the developmental activity of the various Aph-1b gene promoters; the diﬀ erent 
sets of Aph-1b genes and gene promoters in the three rat lines are schematically depicted 
in Figure 3. Despite the extra gene copy in the II/II rats, the Aph-1b mRNA expression 
levels were not diﬀ erent during early development of the I/I and II/II rats, indicating 
that prenatally either the Aph-1b gene promoter displays a relatively low activity or the 
Aph-1b’/b hybrid gene promoter has a relative high activity. Conversely, in the III/III 
rats we found higher Aph-1b mRNA expression levels than one would expect on the 
basis of three gene copies and the promoter of the Aph-1b/b’ hybrid gene thus appears to 
display a relatively high activity throughout development. Th e observed Aph-1b mRNA 
expression levels are therefore not always in full accordance with the number of Aph-1b 
gene copies. 
Neither pre- nor postnatally the levels of Aph-1aS and -1aL mRNA diﬀ ered between the 
three rat lines, indicating that these paralogues did not compensate for the altered Aph-
1b mRNA levels. Th is is in line with the results of recent RNA interference and knockout 
studies on the Aph-1 family members in the mouse showing that the expression levels 
of the other γ-secretase components were aﬀ ected only when Aph-1a expression was 
silenced and not with abolished Aph-1b expression (Saito and Araki, 2005; Serneels 
et al., 2005; Shirotani et al., 2004). Similar to the results obtained with reduced Aph-
1a expression, knock down or knock out of either of the γ-secretase components PS1, 
Nct or PEN-2 in the mouse led to aﬀ ected levels of most of the nonsilenced γ-secretase 
subunits (Chen et al., 2003; Gu et al., 2003; Hasegawa et al., 2004; Li et al., 2003). 
In contrast, ablation of mouse PS2 expression had little eﬀ ect on the expression levels 
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of the other γ-secretase components (Chen et al., 2003; Herreman et al., 1999; Zhang 
et al., 2005), comparable to what we have observed in the I/I, II/II and III/III rat lines 
concerning the eﬀ ect of reduced Aph-1b expression (Coolen et al., 2005). Th ese ﬁ ndings 
suggest that PS2 and Aph-1b are somehow related. 
Th e reduced ontogenic Aph-1b mRNA levels observed in the hippocampus may well 
underlie the large diﬀ erences in stress susceptibility of the rats with one, two or three 
Aph-1b gene copies , as the hippocampus is known to modulate the stress axis (Jacobson 
and Sapolsky, 1991; Knigge, 1961). In addition, the marked hippocampal diﬀ erences 
may be related to the dopaminergic hyperreactivity of the rats, since one of the most 
important projections of the hippocampus runs to the ventral striatum (Groenewegen 
et al., 1999). In psychiatric disorders, such as schizophrenia, stress susceptibility and 
dopaminergic hyperreactivity have also been observed (Lammers et al., 1995; Muller-
Spahn et al., 1998). According to the developmental hypothesis of schizophrenia, the 
pathophysiology and aetiology of the disorder are related to an aﬀ ected development 
or maturation of the brain. Epidemiological studies have provided a solid basis for 
this hypothesis, e.g. during early life schizophrenic individuals have shown a retarded 
motor and cognitive development (Cannon et al., 2002; Isohanni et al., 2000; Jones, 
1997). Furthermore, disturbances in the cytoarchitecture of the hippocampal formation 
(Kovelman and Scheibel, 1984) and entorhinal cortex (Bernstein et al., 1998) can only 
be adequately explained by aberrant brain development. Unfortunately, schizophrenia 
has an adult onset and it has turned out to be diﬃ  cult to elucidate its molecular basis 
II
Aph-1b' Aph-1b
III
Aph-1b' Aph-1bAph-1b/b'
I
Aph-1b'/b
5 kb
prenatal
postnatal
Figure 3. Schematic representation of the Aph-1b genes in the I/I, II/II and 
III/III rat lines
The I/I rats have only one Aph-1b gene (the Aph-1b’/-1b hybrid gene consisting of 
exons 1-5 of Aph-1b’ and exons 5-6 of Aph-1b), the II/II rats contain the Aph-1b’ and 
Aph-1b genes, and the III/III rats harbor, besides the Aph-1b’ and Aph-1b genes, an 
additional Aph-1b/-1b’ hybrid gene (Coolen et al., 2005). The activities of the various 
promoters, as deduced from the developmental mRNA expression profiles (Figure 
1), are indicated by the black arrows with their thickness corresponding to the level 
of activity (lower arrows: prenatal activity; upper arrows: postnatal activity). Open 
arrows indicate the promoters of the various genes.
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(Andreasen, 2000). Perhaps the results of our longitudinal developmental study on the 
I/I, II/II and III/III rat lines may help in the understanding of the molecular background 
of such neurodevelopmental disorders. 
We have found that in the three rat lines the Aph-1b mRNA expression levels correlated 
with the degree of APP processing by γ-secretase. Similarly, complete silencing of the 
expression of PS1, Nct, PEN-2 or Aph-1a in the mouse resulted in reduced γ-secretase 
activity (also indicated by elevated APP-CTF levels) (Zhang et al., 2005). Conversely, 
preventing mouse PS2 or Aph-1b expression did not aﬀ ect or only slightly decreased 
γ-secretase activity, respectively, and gave only a mild phenotype, whereas removal of 
PS1, Nct or Aph-1a is lethal (Herreman et al., 1999; Serneels et al., 2005). We therefore 
hypothesize that the functioning of the PS2- and Aph-1b-containing γ-secretase complex 
is diﬀ erent from that of the complexes with other subunit compositions. 
Th e reduction in APP processing that we observed may be related to the hyperactive 
behaviour displayed by rats with one or two Aph-1b gene copies (Coolen et al., 2005). 
Interestingly, in mice the reverse situation, namely overexpressed APP (or APP-CTF), 
results in general hypoactive behaviour (D'Hooge et al., 1996; Lalonde et al., 2002). We 
further found that the eﬀ ects on γ-secretase activity were tissue speciﬁ c. In general, in a 
tissue with a high level of Aph-1b mRNA compared to the Aph-1a mRNA level (a high 
Aph-1b/-1a mRNA ratio) relatively large diﬀ erences in the APP-CTF levels were found 
between the I/I and III/III rats. In the hippocampus, a tissue with a relatively low Aph-
1b/-1a ratio, we did not observe signiﬁ cant diﬀ erences in γ-secretase cleavage activity 
between the three rat lines, while large alterations in hippocampal Aph-1b mRNA levels 
were detected (~8-fold at PND 13). It thus appears that a reduced Aph-1b expression 
causes a more severe eﬀ ect on γ-secretase activity in tissues with a high Aph-1b/-1a ratio 
than in tissues with a low ratio. Furthermore, suﬃ  cient amounts of the direct γ-secretase 
substrate APP-CTF had to be present in a tissue to allow detection of any signiﬁ cant 
diﬀ erence in γ-secretase cleavage activity. For instance, the lung has a high Aph-1b/-1a 
ratio, but we did not observe an aﬀ ected γ-secretase activity in early postnatal lung, 
presumably due to the low levels of APP-CTF in this tissue. 
Th e γ-secretase complex is able to cleave an ever-growing list of now at least 15 substrates 
and it is likely that in the I/I rats the eﬀ ect of the reduced Aph-1b mRNA expression 
was not restricted to the decreases in APP cleavage, but that the cleavages of other 
(developmentally important) γ-secretase substrates, like Notch, neuregulin, ErbB4 and 
N-cadherin, were also aﬀ ected. Such a broad ontogenic eﬀ ect presumably resulted in 
not only retarded development (Cools et al., 1993; Degen et al., 2005), but also in the 
complex phenotype of the SUS rats in adulthood (Coolen et al., 2005; Ellenbroek and 
Cools, 2002). 
In conclusion, a subtle ontogenic imbalance in the expression of a single γ-secretase 
component causes spatio-temporal diﬀ erences in γ-secretase enzymatic activity. Because 
γ-secretase complexes with diﬀ erent subunit compositions are not functionally redundant 
and each complex is involved in the preferential cleavage of a subset of γ-secretase 
substrates (Hebert et al., 2004; Shirotani et al., 2004), a complex (neuro)developmental 
phenotype may arise in an organism with altered expression of a γ-secretase component. 
Chapter 4
82
Th us, aﬀ ecting the ontogenic expression of a single developmentally important protein 
may ultimately result in a complex phenotype later in life.
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Supplemental tables
Supplemental table 1. Statistical support for Figure 1 by means of a univariate ANOVA on 
longitudinal mRNA expression levels of Aph-1 family members in the hippocampus of I/I, II/II and 
III/III rats (significant if P < 0.05; NS: no significant differences).
Aph-1b Aph-1aS Aph-1aL
ED
geno: F(2,19) = 57.6 geno: NS geno: NS
ED: F(1,19) = 9.8 ED: F(1,21) = 12.6 ED: F(1,22) = 18.9
geno*ED: F(2,19) = 4.5 geno*ED: NS geno*ED: NS
PND
geno: F(2,81) = 242.3 geno: NS geno: NS
PND: F(1,81) = 26.8 PND: F(1,86) = 64.1 PND: F(1,86) = 20.0
geno*PND F(1,81) = 3.2 geno*PND: NS geno*PND: NS
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Supplemental table 2. Since the univariate ANOVA for Figure 1 yielded statistical significance, we 
performed for the I/I, II/II and III/III rats over the embryonic time points an independent samples 
T-test and over the postnatal time points a one-way ANOVA and where appropriate a post hoc 
Bonferroni analysis. Significant differences between time frames are indicated (significant if P < 0.05; 
NS: no significant differences).
ED PND
independent 
samples T-test
one-way ANOVA Bonferroni
Aph-1b
I/I NS PND: F(7,27) = 17.7
PND(0-4) < PND(22-100) 
PND(9-12) < PND(35-60)
II/II NS PND: F(7,25) = 5.5 PND(0) < PND(22)
III/III ED13 < ED17 PND: F(7,26) = 17.2
PND(0-4) < PND(22-
100) PND(0-4) < PND(9) 
PND(12) < PND(22-35)
Aph-1aS
I/I NS PND: F(7,27) = 19.1 PND0-60) < PND(100)
II/II NS PND: F(7,27) = 17.9 PND(0-60) < PND(100)
III/III NS PND: F(7,29) = 29.8 PND(0-60) < PND(100)
Aph-1aL
I/I NS PND: F(7,27) = 11.6 PND(0-9) < PND(35-60)
II/II NS PND: F(7,27) = 3.2 NS
III/III NS PND: F(7,29) = 11.4 PND(0-12) < PND(35-100)
Supplemental Table 3. Since the univariate ANOVA for Figure 1 yielded statistical significance, we 
performed for every developmental time point a comparison of the transcript levels of the I/I, II/II 
and III/III rats by means of a one-way ANOVA and where appropriate a post hoc Bonferroni analysis. 
Significant differences between genotypes are indicated (significant if P < 0.05; NS: no significant 
differences).
Aph-1b Aph-1aS Aph-1aL
ED
13
one-way ANOVA geno: F(2,8) = 34.1 NS NS
Bonferroni (I/I or II/II) < III/III - -
17
one-way ANOVA geno: F(2,9) = 34.0 NS NS
Bonferroni (I/I or II/II) < III/III - -
PND
0
one-way ANOVA geno: F(2,8) = 129.5 NS NS
Bonferroni (I/I or II/II) < III/III - -
4
one-way ANOVA geno: F(2,8) = 52.0 NS NS
Bonferroni (I/I or II/II) < III/III - -
9
one-way ANOVA geno: F(2,8) = 148.2 NS NS
Bonferroni (I/I or II/II) < III/III - -
12
one-way ANOVA geno: F(2,8) = 90.9 NS NS
Bonferroni (I/I or II/II) < III/III - -
22
one-way ANOVA geno: F(2,10) = 10.7 NS NS
Bonferroni (I/I or II/II) < III/III - -
35
one-way ANOVA geno: F(2,8) = 135.5 NS NS
Bonferroni I/I < II/II < III/III - -
60
one-way ANOVA geno: F(2,15) = 51.9 NS NS
Bonferroni I/I < II/II < III/III - -
100
one-way ANOVA geno: F(2,8) = 295.3 NS geno: F(2,8) = 5.2
Bonferroni I/I < II/II < III/III - NS
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Supplemental table 4. Statistical support for Figure 2 by means of a univariate ANOVA on longitudinal 
APP-CTF levels in the spinal cord and lung of I/I and III/III rats. Since the univariate ANOVA yielded 
statistical significance, we performed an independent samples T-test over the APP-CTF levels for 
every developmental time point, and for both I/I and III/III rats a one-way ANOVA and post hoc a 
Bonferroni analysis. Significant differences between genotypes or time frames are indicated (significant 
P < 0.05; NS: no significant differences).
      
     
spinal cord 
univariate ANOVA  PND independent samples T-test 
 geno: NS  2 NS  
 PND: F(4,30) = 15.6  9 NS  
 geno*PND: NS  13 I/I > III/III  
   35 I/I > III/III  
   60 NS  
      
geno one-way ANOVA Bonferroni 
  I/I F(4,14) = 4.4 PND(2) < PND(35)  
  III/III F(4,14) = 46.2 PND(2-13) < PND35-60)  
      
      
     
lung
univariate ANOVA  PND independent samples T-test 
 geno: F(1,30) = 13.1  2 NS  
 PND: F(4,30) = 22.7  9 NS  
 geno*PND: F(4,30) = 3.4  13 NS  
   35 I/I > III/III  
   60 I/I > III/III  
      
geno one-way ANOVA Bonferroni 
  I/I F(4,14) = 21.3 PND(2-9) < PND(13-60)  
  III/III F(4,14) = 4.4 NS  
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Abstract
Th e γ-secretase enzyme complex displays intramembrane catalytic activity towards 
many type I transmembrane proteins, including the Alzheimer-linked amyloid-β 
protein precursor (APP) and the neuregulin receptor ErbB4. Active γ-secretase is 
a tetrameric protein complex consisting of presenilin-1 (or -2), nicastrin, PEN-2, 
and Aph-1a (or -1b). We have recently discovered that pharmacogenetically bred 
apomorphine-susceptible Wistar rats (APO-SUS) have only one or two copies of 
the Aph-1b gene (termed I/I and II/II rats, respectively), whereas their phenotypic 
counterparts (APO-UNSUS) have three copies (III/III). As a result, APO-SUS 
rats display reduced Aph-1b expression and a complex phenotype reminiscent of 
neurodevelopmental disorders. Here we determined in the I/I and III/III rats the 
γ-secretase cleavage activity towards the three APP superfamily members, p75 
neurotrophin receptor, ErbB4 and neuregulin-2, and found that the cleavage of 
only a subset of the substrates was changed. Furthermore, the observed diﬀ erences 
were restricted to tissues that normally express relatively high Aph-1b compared to 
Aph-1a levels. Th us, we provide in vivo evidence that subtle alterations in γ-secretase 
subunit composition may lead to a variety of aﬀ ected (neuro)developmental signalling 
pathways and, consequently, a complex phenotype.
Introduction
T he γ-secretase complex belongs to the family of aspartyl proteases and cleaves many type I transmembrane proteins within their membrane domain, after removal of 
the ectodomain (Kopan and Ilagan, 2004). Th e complex is notoriously known because 
of its role in the pathological production of amyloid-β in Alzheimer’s disease (reviewed 
in Fortini, 2002; Sisodia and St George-Hyslop, 2002; Tanzi and Bertram, 2005). 
Under normal physiological conditions, γ-secretase causes the release of the intracellular 
domain (ICD) of a growing list of proteins, such as the amyloid-β precursor protein 
(APP), its relatives the APP-like proteins APLP1 and APLP2, Notch, neuregulin, the 
neuregulin receptor ErbB4, p75 neurotrophin receptor, N-cadherin and ApoER2. Th ese 
type I transmembrane proteins are part of multiple (neuro)developmental signalling 
pathways (reviewed in Koo and Kopan, 2004; Kopan and Ilagan, 2004). Recently, the 
minimal molecular subunit composition of the γ-secretase complex has been solved, 
namely presenilin (either PS-1 or PS-2), nicastrin (Nct), presenilin enhancer 2 (PEN-2) 
and the anterior pharynx defective 1 protein Aph-1, in mammals Aph-1aS, -1aL or -1b 
(De Strooper et al., 1998; Edbauer et al., 2003; Francis et al., 2002; Yu et al., 2000). 
In total six complexes with diﬀ erent subunit compositions can be formed because of 
the two presenilin proteins and the three Aph-1 proteins (Shirotani et al., 2004). It 
has been widely accepted that PS is the catalytic core protein of the complex, but the 
speciﬁ c functions of the other γ-secretase components are less clear. Nct may have a role 
in stabilizing the complex or create a substrate docking site of the complex (Berezovska 
et al., 2003; Zhang et al., 2005), while Aph-1 has been suggested to stabilize both the 
maturing and ﬁ nal γ-secretase complex (Lee et al., 2004), and PEN-2 may assist in the 
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endoproteolysis of the presenilin holoprotein during ﬁ nal maturation of the complex 
(reviewed in Periz and Fortini, 2004).
In a previous gene expression proﬁ ling study, we discovered a reduced expression 
of Aph-1b mRNA as the only diﬀ erence between a pharmacogenetically selected 
apomorphine-susceptible (APO-SUS) rat line displaying many features of a complex 
neurodevelopmental disorder and its phenotypic counterpart, the apomorphine-
unsusceptible (APO-UNSUS) line (Coolen et al., 2005). Th e APO-SUS and -UNSUS 
rats diﬀ er not only in information processing deﬁ cits in the brain (measured by pre-
pulse inhibition and latent inhibition), but also show hyperactivity in an open ﬁ eld 
and in the elevated-plus maze, a hyper-reactive dopaminergic pathway, an increased 
stress response, and a variety of behavioural, neurochemical, endocrinological and 
immunological features (Ellenbroek and Cools, 2002). A detailed genomic analysis of 
the rat lines revealed an imbalance in Aph-1b gene copy numbers; APO-SUS rats have 
only one or two copies of the gene, whereas the APO-UNSUS genome contains three 
in-tandem gene copies (Coolen et al., 2005). We now generated via cross-breeding and 
genetic re-selection two new rat lines; one homozygous for the allele with a single Aph-1b 
gene (the I/I rat line) and one homozygous for the allele with three gene copies (the III/
III rat line). Here, we analysed in various tissues of the I/I and III/III rats the γ-secretase 
cleavage activity by determining the endogenous levels of protein fragments derived 
from a number of γ-secretase substrates, namely the three APP superfamily members, 
p75, ErbB4 and neuregulin-2 (NRG2).
Materials and methods
Animals
Initially, systemic administration of apomorphine (1.5 mg/kg s.c.) was used to select 
Wistar rats with a high or low susceptibility to this drug (APO-SUS and APO-UNSUS 
rats, respectively). Th e evoked stereotyped gnawing behaviour (APO-SUS: >500 gnaws 
in 45 min; APO-UNSUS: <10 gnaws in 45 min) was used to select female and male 
rats for breeding the two distinct lines (Cools et al., 1990). Phenotyping of the rat lines 
was reviewed elsewhere (Ellenbroek and Cools, 2002). When we recently discovered the 
diﬀ erent Aph-1b genotypes in the rat lines (Coolen et al., 2005), we decided to use rats 
of the 21st generation to set up a crossbreeding scheme. Four male and four female I/I 
rats of the APO-SUS line were crossed with four female and four male III/III rats of the 
APO-UNSUS line, respectively. Th e oﬀ spring (either I/III or III/I) was inter-crossed 
preventing brother-sister pairing and the resulting F2 generation was genotyped for the 
Aph-1b locus by PCR analysis of genomic DNAs. Th e rats homozygous for either one or 
three Aph-1b gene copies were used to generate I/I and III/III lines, respectively; apart 
from the Aph-1b locus, these lines have highly similar general genetic backgrounds. Th e 
crossbred I/I rats showed a signiﬁ cantly higher apomorphine susceptibility than the 
crossbred III/III rats. For the present γ-secretase cleavage activity studies, we used I/I 
and III/III rats of the F3 generation of the crossbred lines. Rats were bred and reared in 
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the Central Animal Facility of the Radboud University under approved animal protocols 
and in accordance with institutional guidelines.
Northern blot analysis
Total RNA from various tissues of PND 9 I/I and III/III rats was isolated with the Trizol 
reagent (Gibco BRL Life Technologies), separated on gel (10 µg per lane), blotted and 
hybridised according to standard procedures with a full-length 798-bp rat Aph-1b cDNA 
probe detecting one product of ~1.3 kb. After stripping, the blot was rehybridised with a 
full-length 741-bp rat Aph-1aS cDNA probe detecting both the short and long isoform 
of Aph-1a (Aph-1aS of ~2.2 kb and Aph-1aL of ~1.8 kb, respectively). For quantiﬁ cation, 
hybridisation signals were analysed using the Labworks 4.0 program (UVP BioImaging 
systems, Cambridge, United Kingdom).
Quantitative RT-PCR
For quantitative RT-PCR, ﬁ rst-strand cDNA was prepared from 2 µg of DNase I 
treated total RNA (isolated as described above) using Superscript II reverse transcriptase 
(Invitrogen). PCR samples contained 1X SYBR Green buﬀ er, 3 mM MgCl2, 0.4 
mM dUTP and 0.2 mM each of dATP, dCTP and dGTP, 0.6 U AmpliTaq Gold 
(all from Applied Biosystems), 0.6 µM each oligonucleotide primer (Biolegio) and 
1/20 synthesised cDNA in a 25-µl volume. Quantitative PCR was performed in a 
PE GeneAmp 5700 apparatus with conditions as follows: 10 min at 94 °C, then 40 
cycles of 15 s at 94 °C, 30 s at 60 °C and 1 min at 72 °C. β-Actin was ampliﬁ ed from 
all samples to normalize expression. A control (no template) was included for each 
primer set. Data sets were analysed with Sequence Detection System 1.3 software. Th e 
following primers were used: Aph-1b (448-671): 5’-GTGATTCTCCTCAGTTCTT
CCTTAATTC and 5’-GCCCATGAGCACCATGATTATAT; Aph-1a (547-670): 5’-
AGAGGAGACGGTACTGGGCTTT and 5’-ATGGAAACGGTGACTGCATAGA; 
β-actin (346-435): 5’-CGTGAAAAGATGACCCAGATCA and 5’-AGAGGCATACA-
GGGACAACACA; numbers between brackets are nucleotide positions from start 
ATG). Th e Aph-1b primers detected all transcripts from the Aph-1b genes and the Aph-
1a primers detected both Aph-1aS and -1aL mRNA. All PCR products were generated 
over intron-exon boundaries.
Western blot analysis
Protein extractions and immunoblottings were performed as previously described 
(Herreman et al., 2003). Brieﬂ y, selected brain regions and tissues were dissected from 
pups at PND 13 and homogenised in 50 mM Tris (pH8.0), 150 mM NaCl and 0.5% 
NP-40 and postnuclear fractions were isolated by centrifugation at 10,000 x g for one 
hour at 4°C. Proteins in the supernatant were quantiﬁ ed using a standard Bradford 
assay (Pierce) and 20 µg protein was loaded per lane on Tris-Tricine SDS-PAGE gels 
(in case of APP, APLP1 and APLP2) or on Tris-Glycine SDS-PAGE gels (for NRG2, 
ErbB4, p75 and tubulin) and transferred to nitrocellulose or PVDF membranes for 
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Western blot detection. Th is Western blotting procedure allowed the detection of 
the C-terminal fragments (CTFs) of APP (using the C-terminally directed antibody 
C87, 1:3000) (Coolen et al., 2005), APLP1 (antibody CT-11, 1:2000) (Th inakaran et 
al., 1995) , APLP2 (antibody AP-tail, 1:2000) (Sester et al., 2000) and NRG2 (anti-
proNRG, 1:2000) (Montero et al., 2002), the intracellular domain (ICD) of ErbB4 
(antibody C-18, 1:3000; Santa Cruz Biotechnology, Santa Cruz, CA) and both the 
CTF and ICD of p75 (anti-p75-ICD, 1:3000) (Mahadeo et al., 1994). Th e antibody 
against β-tubulin (antibody E7, 1:3000) (Chu and Klymkowsky, 1989) was used as an 
internal loading control. All antibodies were tested on tissue samples from ﬁ ve I/I rats 
of diﬀ erent nests and ﬁ ve III/III rats of diﬀ erent nests. Identical tissue lysates were used 
to test the diﬀ erent γ-secretase substrate levels. For quantiﬁ cation, hybridisation signals 
were analysed using the Labworks 4.0 program (UVP BioImaging systems, Cambridge, 
United Kingdom).
Statistics
Data obtained by quantitative RT-PCR were analysed per tissue by means of an 
independent samples T-test. Data from the Western blot analyses were analysed per 
substrate by means of a univariate analysis of variance (ANOVA) with the dependent 
variable density (values normalised against tubulin) and the ﬁ xed factors genotype (I/I 
and III/III) and tissue (e.g. olfactory bulb, spinal cord, or cortex). Where appropriate, 
data were further analysed per tissue by means of a one-way ANOVA on genotype. A 
probability of P < 0.05 was considered statistically signiﬁ cant. All statistical analyses 
were performed with the SPSS 12.0.1 software program (SPSS Inc., Chicago, Illinois).
Results
Aph-1a and Aph-1b mRNA levels in I/I and III/III rat tissues
Northern blot analysis revealed high levels of Aph-1b mRNA in most III/III rat tissues 
analysed, whereas in the same tissues of I/I rats the levels were not or hardly above 
background (Figure 1A). In contrast, the mRNA levels of Aph-1aS and -1aL did not 
diﬀ er between I/I and III/III rat tissues, also not in the tissues with large diﬀ erences 
Figure 1. Analysis of Aph-1a and -1b mRNA expression in various tissues of I/I and III/III 
rats
(A) Northern blot analysis of total RNA from the respective tissues of I/I and III/III rats. The blot was 
hybridised with a full-length rat Aph-1b cDNA probe and subsequently, following stripping, rehybridised 
with a full-length rat Aph-1a cDNA probe; the Aph-1a probe detected both the short and long isoform 
(Aph-1aS and -1aL, respectively). The 18S rRNA signal was used as a control for RNA loading and 
integrity. The Aph-1b/-1a intensity ratio was determined for every III/III rat tissue and categorised 
as high (Aph-1b/-1a > 2.0; +++), moderate (1.0 < Aph-1b/-1a ≤ 2.0; ++) or low (Aph-1b/-1a ≤ 
1.0; +). Tissues used were cerebellum (cer), olfactory bulb (olf), cortex (ctx), hippocampus (hip), 
striatum (str), (hypo)thalamus (tha), pons/medulla (p/m), spinal cord (spc), eye, testis (tes), heart, 
(hrt), muscle (msc), stomach (sto), small intestine (s.i.), large intestine (l.i.), lung (lng), spleen (spl), 
liver (liv), thymus (thy) and pancreas (pan) of PND 9 III/III (3) or I/I (1) rats. (B) Real-time quantitative 
RT-PCR on total RNA from a number of I/I and III/III rat tissues. Tissues examined were cerebellum 
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(cer), olfactory bulb (olf), cortex (ctx) and lung (lng). The Aph-1b mRNA levels of I/I 
compared to III/III rats were significantly reduced in the four tissues analysed (P < 
0.05), whereas Aph-1a mRNA levels did not differ between the rat lines. The Aph-
1b/-1a ratios calculated from the quantitative RT-PCR data were categorised as high 
(Aph-1b/-1a > 2.0; +++), moderate (1.0 < Aph-1b/-1a ≤ 2.0; ++) or low (Aph-1b/-1a 
≤ 1.0; +). The Aph-1a primer set detected both Aph-1aS and -1aL mRNA. Results (n 
= 3; plus s.e.m.) were normalised towards β-actin and are expressed as arbitrary 
units (AU).
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in Aph-1b expression. Furthermore, the ratios between the Aph-1b and Aph-1a mRNA 
levels greatly varied among the III/III rat tissues. Tissues such as the olfactory bulb, 
pons/medulla, testis and lung showed high Aph-1b/-1a ratios, while the cortex, 
hippocampus, spinal cord, stomach, large intestine and thymus had moderate ratios, 
and the cerebellum, striatum, (hypo)thalamus, eye, heart, muscle, small intestine, 
spleen, liver and pancreas showed low ratios (Figure 1A). Real-time quantitative RT-
PCR analysis of Aph-1b mRNA expression in cerebellum, olfactory bulb, cortex and 
lung revealed signiﬁ cant reductions in these tissues of I/I compared to III/III rats (P 
< 0.05), with the largest diﬀ erence observed in the olfactory bulb (~8-fold reduction) 
(Figure 1B). Th e four tissues did not diﬀ er in Aph-1a mRNA levels between the two 
rat lines; the cerebellum showed the highest Aph-1a mRNA expression levels (one-way 
ANOVA followed by a post-hoc Bonferroni test: P < 0.05). Th e quantitative RT-PCR 
data conﬁ rmed the Aph-1b/-1a ratios obtained through Northern blot analysis (olfactory 
bulb and lung displayed high ratios, cortex showed moderate ratios, and cerebellum had 
low ratios) (Figure 1B).
γ-Secretase cleavage activity towards the APP superfamily members in I/I and III/III 
rat tissues
Since the Aph-1 protein is an essential component of the γ-secretase complex, we were 
interested in the eﬀ ect of the diﬀ erential mRNA expression of Aph-1b on the proteolytic 
cleavage activity of the complex in I/I and III/III rat tissues. To this end, the levels 
of cleavage products of various γ-secretase substrates were examined by Western blot 
analysis using antibodies directed against the C-terminal regions of the substrates. In 
general, the proteolytic processing of a γ-secretase substrate starts with shedding of 
its extracellular domain, leaving a C-terminal fragment (CTF) that is subsequently 
cleaved by γ-secretase to its ICD. One of the best-known substrates of γ-secretase is 
the Alzheimer’s disease-linked APP protein. APP is part of the APP superfamily that 
in mammals includes the two APP-like proteins APLP1 and APLP2. We compared 
the γ-secretase cleavage activities towards the APP superfamily members in tissues of 
III/III rats having diﬀ erent Aph-1b/-1a ratios (high: olfactory bulb and lung; moderate: 
spinal cord and cortex; low: [hypo]thalamus, cerebellum and spleen) with the activities 
in the corresponding I/I rat tissues. Statistical analysis of the levels of direct γ-secretase 
substrates (CTFs) using a univariate analysis of variance (ANOVA) revealed a genotype 
eﬀ ect for all three APP superfamily members (APP-CTF: F(1,62) = 15.9 P < 0.05; APLP1-
CTF: F(1,13) = 22.4 P < 0.05; APLP2-CTF: F(1,46) = 17.6 P < 0.05). Subsequent 
one-way ANOVA analysis showed that the CTF levels were signiﬁ cantly increased in 
the olfactory bulb (APP: 1.6-fold [P < 0.01]; APLP1: 2.0-fold [P < 0.05]; APLP2: 2.1-
fold [P < 0.05]), the lung (APP: 2.2-fold [P < 0.05]; APLP2: 1.3-fold [P < 0.05]), the 
Figure 2. Western blot analysis of the gamma-secretase cleavage products derived from the 
APP, APLP1 and APLP2 proteins in various tissues of I/I and III/III rats
(A) The levels of the C-terminal fragments (CTFs) of amyloid-β precursor protein (APP), and the APP-
like proteins APLP1 and APLP2 (sizes of all three CTFs ~10 kDa) were analysed in neuronal tissues of 
PND 13 I/I (1) and III/III (3) rats using specific antibodies. Tissues used were the olfactory bulb (high 
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Aph-1b/-1a ratio), spinal cord and cortex (moderate ratio), and (hypo)thalamus and 
cerebellum (low ratio). (B) Levels of APP-, APLP1- and APLP2-CTF were analysed 
in the lung (high Aph-1b/-1a ratio) and spleen (low ratio) of PND 13 I/I and III/III 
rats. In each case, tubulin (~55-kDa) was used for normalisation. Bars represent 
quantifications in arbitrary units of normalised CTF signals of five tissue samples with 
the average level in III/III rat tissues set to 1. The levels of the APP, APLP1 and APLP2 
holoproteins were similar in the I/I and III/III rat tissues. Significant differences in CTF 
levels between the I/I and III/III rats for the three APP superfamily members were 
found in the olfactory bulb and spinal cord, and for APP and APLP2 in the cortex, 
(hypo)thalamus and lung. *:P < 0.05; **:P < 0.02; ***: P < 0.01; n = 5, with the five rats 
per genotype from different nests; plus s.e.m.; BD: below detection.
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spinal cord (APP: 1.6-fold [P < 0.02]; APLP1: 1.6-fold [P < 0.05]; APLP2: 1.8-fold [P 
< 0.05]) and the cortex (APP: 1.3-fold [P < 0.05]; APLP2: 2.2-fold [P < 0.02]) of I/I 
compared to III/III rats. No signiﬁ cant diﬀ erences in the CTF levels were observed in 
the (hypo)thalamus, cerebellum and spleen of I/I and III/III rats, that is in tissues with 
a low Aph-1b/-1a ratio (Figure 2).
γ-Secretase cleavage activity towards p75, ErbB4 and NRG2 in I/I and III/III rat 
tissues
To examine whether substrates other than the APP superfamily members showed aﬀ ected 
levels of their γ-secretase cleavage products in I/I compared to III/III rats, we next 
analysed the cleavages of p75, ErbB4 and NRG2. Although no signiﬁ cant diﬀ erences 
were found in the univariate ANOVA for the cleavage products of p75, ErbB4, or NRG2, 
visual inspection of the data prompted us to perform a one-way ANOVA per tissue. Th e 
levels of p75-CTF were similar in all I/I and III/III rat tissues tested, whereas p75-ICD 
showed signiﬁ cantly reduced levels only in the olfactory bulb of the I/I rats (1.8-fold [P 
< 0.05]). Th e olfactory bulb was also the only tissue with signiﬁ cantly reduced ErbB4-
ICD levels when comparing I/I and III/III rat tissues (1.3-fold [P < 0.05]). Th e CTF 
levels of NRG2 were similar in all tissues examined (Figure 3).
Discussion
Over- and under-expression studies with transfected cells as well as analyses of knockout 
mice have shown that the γ-secretase complex requires at least four protein components 
to display cleavage activity, namely presenilin (PS-1 or -2), nicastrin, PEN-2 and Aph-1 
(Aph-1aS, -1aL or -1b) (De Strooper et al., 1998; Edbauer et al., 2003; Francis et al., 
2002; Kim et al., 2003; Lai et al., 2003; Serneels et al., 2005; Yu et al., 2000). In the 
present study, we examined the mRNA expression levels of Aph-1aS, -1aL and Aph-
1b, and the eﬀ ects of the diﬀ erential Aph-1b expression on the cleavage activity of the 
γ-secretase complex in rats with one or three Aph-1b gene copies (I/I and III/III rats, 
respectively). Since a clear reduction of the Aph-1b mRNA levels in I/I compared to 
III/III rats was found, while the Aph-1aS and -1aL mRNA levels were similar between 
Figure 3. Western blot analysis of the gamma-secretase cleavage products derived from 
p75, ErbB4 and NRG2 in various tissues of I/I and III/III rats
(A) The levels of the C-terminal fragments (CTFs) of p75 neurotrophin receptor (~30-kDa, p75-CTF) 
and neuregulin-2 (~20/25-kDa, NRG2-CTF) were analysed in neuronal tissues of PND 13 I/I (1) and 
III/III (3) rats. For p75 and neuregulin receptor ErbB4, levels of a γ-secretase cleavage end product, 
namely the intracellular domains (~25-kDa, p75-ICD and ~80-kDa, ErbB4-ICD, respectively), are 
included. Tissues used were the olfactory bulb (high Aph-1b/-1a ratio), spinal cord and cortex (moderate 
ratio), and (hypo)thalamus and cerebellum (low ratio). (B) Levels of p75-CTF, p75-ICD, ErbB4-ICD 
and NRG2-CTF were analysed in lung (high Aph-1b/-1a ratio) and spleen (low ratio) of PND 13 I/I and 
III/III rats. Tubulin (~55-kDa) was used for normalisation. Bars represent quantifications in arbitrary 
units of normalised signals of five tissue samples with the average level in III/III rat tissues set to 1. 
While the levels of the holoproteins of p75 and ErbB4 were similar in all I/I and III/III rat tissues tested, 
the levels of intact NRG2 were significantly increased in the (hypo)thalamus and spleen of the I/I rats 
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(2.7-fold [P < 0.01], and 2.3-fold [P < 0.05], respectively. The levels of p75-ICD and 
ErbB4-ICD were significantly different only in the olfactory bulb of I/I and III/III rats 
(1.8-fold [P < 0.05], and 1.3-fold [P < 0.05], respectively). Although the NRG2-CTF 
levels were different in the spleen of the I/I and III/III rats, dividing the CTF levels by 
the NRG2 holoprotein levels showed no affected γ-secretase cleavage activity. *: P < 
0.05; **: P < 0.02; ***: P < 0.01; n = 5, whereby the five rats per genotype were taken 
from different nests; plus s.e.m.;  : non specific product; BD: below detection.
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the two rat lines, the Aph-1a paralogues do not compensate for the reduced expression 
of Aph-1b. Th e ratios between the Aph-1b and -1a mRNA levels greatly varied among 
the III/III rat tissues. Tissues that normally have a high Aph-1b/-1a ratio displayed clear 
diﬀ erences in γ-secretase cleavage activity when comparing I/I and III/III rats, whereas 
the activity in tissues with a low ratio was not or hardly aﬀ ected. Furthermore, within 
a particular tissue the processing of the various substrates tested was not aﬀ ected to the 
same extent. Th is suggests that in vivo Aph-1a and -1b are not functionally redundant 
but are each involved in the preferential cleavage of a subset of γ-secretase substrates 
(Figure 4).
We have previously found that the Aph-1b rat genotypes segregated with a number of 
behavioural phenotypes (Coolen et al., 2005), and that rats with the natural Aph-1b 
knockdown (APO-SUS) display alterations in brain information processing (prepulse 
inhibition and latent inhibition), locomotor activity in response to novelty, ﬂ eeing 
and problem-solving behaviour, and hypothalamus-pituitary-adrenal axis response 
to stress (Coenders et al., 1992; Cools et al., 1990; Ellenbroek et al., 1995; Rots et 
al., 1995). It would have been of great interest to compare this complex behavioural 
phenotype with the phenotype of mice generated by partial gene inactivation and thus 
reduced expression of the other γ-secretase components (heterozygous knockout mice), 
but behavioural studies on such models have not yet been performed. Unfortunately, 
complete knockouts of PS1, nicastrin and Aph-1a are lethal (Li et al., 2003; Ma et al., 
2005; Serneels et al., 2005; Shen et al., 1997), and although PS2 as well as Aph-1b null 
mutations are viable and healthy, they have not been analysed for the features observed 
in APO-SUS rats (Donoviel et al., 1999; Herreman et al., 1999; Serneels et al., 2005) 
and a PEN-2 knockout mouse has not yet been generated. However, the behavioural 
phenotypes of a number of mice with altered expression of a substrate of γ-secretase 
have been examined and some of these show an interesting overlap with the APO-SUS 
phenotype. For example, heterozygous ErbB4 or NRG1 knockout mice (with an overall 
~50% reduction of mRNA expression) are also hyperactive in an open ﬁ eld test and 
show an impaired prepulse inhibition (Gerlai et al., 2000; Stefansson et al., 2002), 
whereas reduced expression of Notch had no eﬀ ect on the open ﬁ eld behaviour (Costa et 
al., 2003). Conversely, overexpression of human APP751 or APP-CTF caused a general 
hypoactivity in mice (D’Hooge et al., 1996; Lalonde et al., 2002). Behavioural studies 
on APLP1, APLP2, p75 or NRG2 heterozygous knockout or transgenic mice have not 
yet been described.
In our studies, we further found that of the brain tissues examined, the olfactory bulb of 
the I/I rats displayed the most severely aﬀ ected γ-secretase cleavage activity. Th is tissue 
showed signiﬁ cantly changed levels of the γ-secretase cleavage products of the three APP 
superfamily members, as well as of ErbB4 and p75. Th e olfactory bulb not only contains 
relatively high expression levels of PS1 and PS2, and of the γ-secretase substrates APP, 
APLP2 and p75 (Lee et al., 1996; Page et al., 1996; Th inakaran et al., 1995; Tisay 
et al., 2000), but also shows high binding aﬃ  nity for γ-secretase ligands (Yan et al., 
2004). Removal of the olfactory bulb from normal rats has been accepted as a model 
for agitated depression (reviewed in Harkin et al., 2003; Kelly et al., 1997). Th ese so-
called OBX rats show a number of behavioural changes, such as hyperactivity in an open 
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Figure 4. Schematic representation of the tissue- and substrate-specific 
changes in gamma-secretase activity upon reduced expression of Aph-1b, 
affecting a great variety of signalling pathways and resulting in a complex 
phenotype
Reduction of Aph-1b levels (in I/I compared to III/III rats) causes changes in γ-secretase 
complex compositions; complexes containing Aph-1b (termed 1b) become less 
available (smaller hexagonal sizes), whereas Aph-1a containing complexes remain 
unaffected (1a; same hexagonal sizes). These changes affect γ-secretase cleavage 
activity (indicated by changes in arrow thickness), but only towards a limited number 
of substrates and only in certain tissues. The sizes of the circles reflect the different 
substrate levels in the various tissues and the thickness of the arrows corresponds 
to the activity towards a specific substrate. For clarity, only two types of γ-secretase 
complexes (1a and 1b) and six substrates (A through F) are shown; in mammals, six 
γ-secretase complexes with different subunit compositions can be formed and over 
15 substrates are known thus far. Since the various substrates are part of diverse 
(neuro-)developmental signalling pathways, the reduced expression of a single gene 
(Aph-1b) eventually results in a complex phenotype, which is generally thought to 
have a multigenic origin.
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ﬁ eld test, increased open arm entries in the elevated plus-maze, impairment in passive-
avoidance learning as well as impaired acquisition in aversive learning, which can be 
reversed by chronic treatment with antidepressant drugs. Furthermore, OBX rats display 
alterations in the functioning of the HPA-axis, the immune system, thymus and spleen 
weight, and self-administration of drugs. Intriguingly, all of these phenotypic features 
are also observed in APO-SUS rats (Coolen et al., 2005; Ellenbroek and Cools, 2002). 
Of further interest is that human neurological disorders, such as Alzheimer’s disease and 
schizophrenia, are characterised by olfactory dysfunction (reviewed in Hawkes, 2003; 
Moberg and Turetsky, 2003). Still, at present it is not clear to what extent the diﬀ erences 
in γ-secretase cleavage activity found in tissues other than the olfactory bulb, such as 
the cortex, spinal cord and lung, have also contributed to the complex phenotype of the 
APO-SUS rats. 
In conclusion, the diﬀ erential expression of Aph-1b in the I/I and III/III rats caused 
substrate-speciﬁ c alterations in γ-secretase cleavage activity, particularly in tissues with 
relatively high Aph-1b levels. We conclude from our studies on a natural Aph-1b knock-
down in the rat that a subtle imbalance in the expression of a γ-secretase component gives 
rise to subtle changes in the proteolytic processing of a number of γ-secretase substrates 
that occur in multiple tissues (Figure 4). Th us, a single gene defect may aﬀ ect a great 
variety of (neuro)developmental signalling pathways, resulting in a complex phenotype 
that is generally thought to have a multigenic origin. Furthermore, the γ-secretase 
complex, generally known because it is linked to Alzheimer’s disease (a neurodegenerative 
and ageing disorder), may also be associated with (neuro)developmental disorders that 
become apparent much earlier in life.
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Abstract
Aph-1 is an essential subunit of the γ-secretase enzyme complex that displays 
intramembrane catalytic activity towards various type I transmembrane proteins. 
However, the exact function of Aph-1 remains elusive. Here we investigated in vivo 
the role of one of the Aph-1 family members, Aph-1a, by using the neuroendocrine 
intermediate pituitary melanotrope cells of the South-African claw-toed frog Xenopus 
laevis as a model system. Th ese cells produce large amounts of the prohormone 
proopiomelanocortin (POMC) when the animal is placed on a black background, 
whereby a POMC-derived hormone causes the dispersion of skin melanophores. On 
a white background the melanotrope cells are inactive because of directly innervating 
inhibitory neurons of hypothalamic origin, including dopaminergic neurons. Here we 
employed the technique of stable Xenopus transgenesis in combination with a cell-speciﬁ c 
POMC gene promoter fragment as a tool to express Aph-1a carboxy-terminally tagged 
with the green ﬂ uorescent protein (Aph1a-GFP) speciﬁ cally in the melanotrope cells. 
Th e Aph1a-GFP fusion protein was synthesised as a ~45-kDa protein and expressed 
from stage-25 tadpoles onwards, and the expression persisted after metamorphosis. Th e 
fusion protein was capable of forming a complex with endogenous presenilin-1. Pulse-
chase metabolic cell labelling studies revealed that, despite the high levels of transgene 
expression, POMC synthesis and processing, and the secretion of POMC-derived 
products remained unaﬀ ected in the transgenic melanotrope cells. Intriguingly, the 
transgenic melanotrope cells appeared to be more sensitive to the dopamine receptor 
agonist apomorphine, i.e. their regulated secretion of newly synthesised POMC-derived 
products was more inhibited than secretion from wild-type cells. Furthermore, the 
transgenic frogs adapted more rapidly to a white background than wild-type animals. 
Together, the results of our preliminary functional analysis suggest that transgene 
expression of Aph-1 in Xenopus melanotrope cells leads to a modiﬁ ed sensitivity of the 
dopaminergic system, in line with the diﬀ erential expression of Aph-1b in the APO-
SUS and -UNSUS rats that display diﬀ erent susceptibilities to apomorphine.
Introduction
T he γ-secretase enzyme complex is notoriously known for its pathological involvement in Alzheimer’s disease. Under physiological conditions the γ-
secretase complex is responsible for the intramembrane cleavage of a variety of type 
I transmembrane proteins, including amyloid-β precursor protein APP, Notch and 
neuregulin. Active γ-secretase is a tetrameric protein complex consisting of presenilin-
1 (or -2), nicastrin, PEN-2, and Aph-1. In mammals, three homologues of Aph-1 are 
found, termed Aph-1aS, -1aL and -1b. Th e γ-secretase complex is found throughout 
the vertebrates and invertebrate kingdom, from human to silk worm and plant (for a 
review, see Kimberly and Wolfe, 2003). Recently, we identiﬁ ed a gene-dosage eﬀ ect of 
Aph-1b in a rat model with a complex phenotype, whereby the reduced expression of 
the gene caused many features of a neurodevelopmental disorder such as schizophrenia 
(Coolen et al., 2005). An alignment of the Rattus norvegicus Aph-1aS, -1aL and -1b 
amino acid sequences, and the Aph-1 sequence of the South-African claw-toed frog 
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Xenopus laevis revealed a high degree of conservation of the Aph-1 family members, 
with the rat Aph-1aS sequence being the closest relative of the frog sequence (see Figure 
2 of general discussion). To gain more insight into the function of Aph-1, we here used 
stable Xenopus transgenesis for in vivo overexpression in the intermediate pituitary 
melanotrope cells. Since at the time of the generation of the transgenic frogs, the full-
length Xenopus laevis Aph-1 coding sequence was not known, we decided to use the rat 
Aph-1aS sequence carboxy-terminally tagged with the green ﬂ uorescent protein GFP for 
transgene expression.
Th e Xenopus melanotrope cells constitute a homogeneous population of strictly 
regulated neuroendocrine secretory cells. In the melanotrope cells, the prohormone 
proopiomelanocortin (POMC) is processed to a number of bioactive peptides, including 
α-melanophore stimulating hormone (α-MSH), a peptide that stimulates pigment 
dispersion in dermal melanophores, thus causing skin darkening (Jenks et al., 1977). 
Xenopus has thus the unique capability of adapting its skin colour to the background 
(dark or light). Adaptation to a black background involves a stimulation of α-MSH 
release, while in animals on a white background the release of α-MSH is inhibited, 
and consequently, the skin colour becomes lighter. Th e regulation of α-MSH release is 
conducted from various brain regions by neuropeptides and neurotransmitters, including 
dopamine (Kolk et al., 2002; Roubos et al., 2005). POMC is the major cargo protein 
in the melanotrope cells and during adaptation to a black background the amount of 
POMC mRNA is induced 30-fold, and cell activity and cell size increase enormously (for 
a review, see Roubos, 1997). Placing the amphibian on a white or a black background 
thus allows physiological manipulation of the biosynthetic and secretory activity of the 
melanotrope cell.
In this study, we combined the unique properties of the melanotrope cell with the 
technique of stable Xenopus transgenesis (Kroll and Amaya, 1996; Sparrow et al., 2000) 
to drive transgene expression of Aph-1aS in a cell-speciﬁ c manner. A DNA construct was 
made that encodes Rattus norvegicus Aph-1aS fused to the amino-terminus of GFP and 
under the control of a Xenopus POMC gene A promoter fragment that directs expression 
of the fusion protein speciﬁ cally to the Xenopus melanotrope cells, leaving the integrity 
of the regulation by the hypothalamic neurons intact. Th e results indicate that in the 
generated Xenopus transgenic for Aph-1aS-GFP the melanotrope cells overexpress the 
fusion protein and have a more sensitive dopaminergic system than wild-type cells.
Materials and Methods
Animals
South-African claw-toed frogs Xenopus laevis were bred and reared at the Central Animal 
Facility of the Radboud University of Nijmegen. For the transgenesis experiments, 
female Xenopi were directly obtained from South Africa (Xenopus Express, Cape Town, 
South-Africa). Animals were adapted to a black or white background under constant 
illumination at 28°C for at least three weeks. All animal experiments were carried out in 
accordance with the European Communities Council Directive 86/609/EEC for animal 
welfare, and permit TRC 99/15072 to generate and house transgenic Xenopus.
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Quantitative RT-PCR
For quantitative RT-PCR, neurointermediate lobes (NILs) and anterior lobes (ALs) of 
black- and white-adapted Xenopus pituitaries were dissected and total RNA was isolated 
using the Trizol method. First-strand cDNA was prepared from 2 µg of DNase I treated 
total RNA using Superscript II reverse transcriptase (Invitrogen). PCR samples contained 
1x SYBR Green buﬀ er, 3 mM MgCl2, 0.4 mM dUTP and 0.2 mM each of dATP, dCTP and 
dGTP, 0.6 U AmpliTaq Gold (all from Applied Biosystems), 0.6 µM each oligonucleotide 
primer (Biolegio) and 1/20 synthesised cDNA in a 25-µl volume. Quantitative PCR was 
performed in a PE GeneAmp 5700 apparatus with conditions as follows: 10 min at 94°C, 
then 40 cycles of 15 s at 94°C, 30 s at 60°C and 1 min at 72°C. GAPDH was ampliﬁ ed from 
all samples to normalise expression. A control (no template) was included for each primer 
set. Data sets were analysed with Sequence Detection System 1.3 software. Th e following 
primers were used: X-APH1-RQ-FW: 5’-CAGTACGGGCTCTGGATATTTGG-3’, 
X-APH1-RQ-RV: 5’-CGGTCCTCACTGATCGTAGCA-3’, X-GAPDH-RQ-FW: 5’-
GCCGTGTATGTGGTGGAATCT-3’ and X-GAPDH-RQ-RV: 5’- AAGTTGTCGTT-
GATGACCTTTGC-3’.
Antibodies
Polyclonal antibody ST62 directed against the precursor form of Xenopus POMC (Berghs 
et al., 1997), polyclonal antibody C87 raised against the carboxy-terminal 12 amino 
acids of Xenopus APP (Collin et al., 2005), polyclonal antibody PS1 against the carboxy-
terminal fragment of Xenopus PS1 (Tsujimura et al., 1997), polyclonal antibody anti-
PC2 against recombinant mature human PC2 (Van Horssen et al., 1998), polyclonal 
antibody anti-1262CH against the carboxy-terminal region of Xenopus p24δ1/2 (Kuiper 
et al., 2001) and monoclonal anti-tubulin antibody E7 (Chu and Klymkowsky, 1989) 
have been described previously. A polyclonal antiserum against GFP was kindly provided 
by Dr. B. Wieringa (Cuppen et al., 1999). Antibodies against Nct (Herreman et al., 
2003), PEN-2 and Aph-1a (Nyabi et al., 2003) were tested on lysates from Xenopus 
tissues via western blotting, but did not yield any speciﬁ c results.
Generation of the DNA constructs encoding Aph-1aS fused to the amino-terminus 
of GFP (Aph1aS-GFP)
To generate the Aph1aS-GFP DNA construct, Aph-1aS cDNA was prepared by RT-PCR 
on RNA from Wistar rat brain using primers based on the Rattus norvegicus Aph-1aS 
coding sequence. Th e coding sequence of Aph-1aS lacking the stop codon was ampliﬁ ed 
using primers containing EcoRI and SalI restriction sites at their 5’ ends (RnAph-1aS-
EcoRI-FW: 5’-GGTTGAATTCCCCAGCTGTCCAGTCATG-3’ and RnAph-1aS-SalI-
RV: 5’-GGTTGTCGACGTCCTTACACGAAAGGCTGCG-3’, respectively, with the 
restriction sites underlined) resulting in an 820-bp PCR product. Inserting the EcoRI×SalI-
digested PCR fragments into the pEGFP-N3delAUG vector (Clontech, Mountain View, 
CA, USA) generated the pEGFP-N3delAUG-Aph-1aS construct with the GFP fusion 
construct under the control of the CMV promoter. Th e construct was veriﬁ ed by cycle 
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DNA sequencing using the Big Dye Ready Reaction system (Applied Biosystems, Foster 
City, CA) and the primers CMV-IE-FW (5’- GCCTAATGGGAGGTCTATATAAGC-
3’) and GFP-RV (5’-TTTACGTCGCCGTCCAGCTC-3’) that allowed sequence 
analysis into the Aph-1aS DNA sequence from the CMV promoter sequence and the 
GFP sequence, respectively. Th is construct was used for transfection studies in COS-1 
(African green monkey kidney) and Neuro2A (mouse neuroblastoma) cells (see below). 
Th e Aph1aS-GFP fragment of pEGFP-N3delAUG-Aph-1aS was subcloned into the 
pPOMC(A)2+ vector (Jansen et al., 2002). To this end, pEGFP-N3delAUG-Aph-1aS 
was digested with NotI, blunted and digested with EcoRI, and the 1579-bp Aph1aS-GFP 
fragment was inserted into the EcoRI×StuI-digested pPOMC(A)2+ vector, giving rise to 
the pPOMC-Aph1aS-GFP construct.
Transfection studies
COS-1 or Neuro 2A cells were transfected with the pEGFP-N3delAUG-Aph-1aS 
construct using Fugene 6 transfection reagent (Roche, Basel, Switzerland) and after 24 
hours, cells were ﬁ xed with 4% paraformaldehyde in phosphate-buﬀ ered saline, enclosed 
with Mowiol (200 µg/µl), and localisation of the GFP signal was analysed under a 
Leica DMRA ﬂ uorescent microscope and photographs were taken with a Cohu high-
performance charge-coupled device camera using the Leica Q Fluoro software.
Preparation of Xenopus unfertilised eggs
To harvest unfertilised eggs, mature female Xenopus laevis were injected with 375 IU 
human gonadotropic hormone (Pregnyl; Organon, Oss, Th e Netherlands) into their 
dorsal lymphatic cavities. Eggs were collected from the females 18 hr following injection, 
de-jellied in 2% cysteine/1x MMR (100 mM NaCl, 1 mM KCl, 0.5 mM MgCl2, 
1.5 mM CaCl2, and 5 mM Hepes; pH 8.2), extensively washed with 1×MMR, put 
in 0.4x MMR/6% Ficoll-400 with 50 µg/ml gentamycin, and immediately used for 
transgenesis.
Generation of Xenopus transgenic for Aph1aS-GFP
For the generation of transgenic Xenopus, a BssHII/NotI fragment of about 2600 bp, 
containing the pPOMC-Aph1aS-GFP construct followed by the SV40 polyA signal, 
was puriﬁ ed using a Qiaex II Gel Extraction Kit (Qiagen, Hilden, Germany). Th e DNA 
fragment (~150 ng/µl) was mixed with sperm nuclei (2.5*105 in 2.5 µl), incubated for 
15 min at room temperature, and diluted to 500 µl. About 10 nl was injected per egg. 
Sperm nuclei were prepared as described previously (Jansen et al., 2002; Sparrow et al., 
2000). Normally cleaving embryos were selected at the four-cell stage and cultured in 
0.1x MMR/6% Ficoll-400 with 50 µg/ml gentamycin at 18°C until gastrulation (stage 
12) was reached. At that time point, embryo culturing was continued in 0.1× MMR with 
50 µg/µl gentamycin at 22°C. From stage 45 onwards, tadpoles were raised in tap water 
at 22°C. Th e presence of GFP ﬂ uorescence was examined in living embryos anaesthetised 
with 0.25 mg/ml MS222 (3-aminobenzoic acid ethyl ester; Sigma, St. Louis, MO) using 
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a Leica MZ FLIII ﬂ uorescent stereomicroscope and photographs were taken with a Leica 
DC200 colour camera using the Leica DC viewer software. Staging of Xenopus embryos 
was carried out according to Nieuwkoop and Faber (1967).
In vitro fertilisation of wild-type Xenopus eggs with transgenic sperm cells
For in vitro fertilisation, the testis of a male transgenic Xenopus frog was isolated and gently 
pulled apart prior to use. Pieces of testes were rubbed against unfertilised eggs harvested 
from wild-type Xenopus females. After 10 min, the eggs were incubated in 0.1× MMR. 
Th e fertilised eggs were selected in their 4-cell stage and screened for speciﬁ c pituitary 
ﬂ uorescence during early development (stage 45). Remaining pieces of testes were used 
to isolate sperm nuclei that were stored at -80°C for future injection experiments to 
obtain additional transgenic animals.
Background adaptation
For black-to-white background adaptation, wild-type and transgenic animals fully 
adapted to a black background (at least two months) were placed individually on a 
white background under constant illumination and the dermal melanophores of the 
webs were analysed for their dispersion state at ﬁ xed time points. Th e dispersion state 
was indexed from completely aggregated around the nucleus (melanophore index 1) to 
maximal dispersed throughout the cytoplasm (index 5; Figure 6A). Wild-type (wt) and 
transgenic (tr) animals were transferred individually to white buckets by an independent 
person, who labelled the buckets either ‘wt’ or ‘tr’ on the bottom side, invisible to the 
experimenter (a blinded test set-up). Th e melanophore index was determined by the 
experimenter at the set time intervals and following index scoring, the ‘wt’ and ‘tr’ labels 
were combined with the measurements. For white-to-black background adaptation, 
animals that were adapted to a white background for at least two months were placed 
on a black background and indexed as in the black-to-white background adaptation 
experiment.
Western blot analysis
For western blot analysis, NILs were homogenised in TTD buﬀ er (50 mM Hepes, 140 
mM NaCl, 0.1% Triton X-100, 1% Tween-20, 0.1% deoxycholate, 1 mM EDTA, 
1 mM PMSF, and 0.1 mg/ml soybean trypsin inhibitor; pH 7.3). After the lysates 
were cleared by centrifugation at 13,000 x g at 4°C, they were denatured in Laemmli 
sample buﬀ er at 100°C for 5 min, separated on 12.5% SDS-PAGE, and transferred to 
nitrocellulose (for GFP, APP, POMC, PC2 and p24δ) or PVDF (for PS1) membranes. 
For extraction under native conditions, NILs were ﬁ rst homogenised in CHAPS buﬀ er 
(1% CHAPS, 5 mM EDTA, 1 mM PMSF, and 0.1 mg/ml soybean trypsin inhibitor 
in 1x PBS) followed by centrifugation at 1000 x g for 10 min at 4°C yielding a post-
nuclear supernatant. Following blocking in 5% skimmed milk/1% Tween-20/PBS for 
one hr, blots were incubated with anti-GFP (1:5000), anti-PS1 (αPS1; 1:2000), anti-
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APP (C87; 1:3000), anti-POMC (ST62; 1:20,000), anti-PC2 (hPC2; 1:5000) and anti-
p24δ1/2 (anti-1262CH; 1:5000) and anti-tubulin (E7; 1:500) overnight at 4°C. After 
extensively washing with 1% skimmed milk/1% Tween-20/PBS for 30 min at RT, blots 
were incubated with a peroxidase conjugated secondary antibody (1:5000) for 45 min 
at RT, and subsequently thoroughly washed with 1% skimmed milk/1% Tween-20/PBS 
for 30 min at RT. Proteins on western blots were immunodetected using Lumi-Light 
substrate (Roche Diagnostics, Mannheim, Germany) and subsequently exposed to X-ray 
ﬁ lm (Kodak, Rochester, NY). Quantiﬁ cation was performed using a BioChemi imaging 
system and signals were analysed using Labworks 4.0 software (UVP BioImaging systems, 
Cambridge, UK).
Co-immunoprecipitation analysis
For co-immunoprecipitation analysis, NILs were lysed in CHAPS buﬀ er (1% CHAPS, 
5 mM EDTA, 1 mM PMSF, and 0.1 mg/ml soybean trypsin inhibitor in 1x PBS) and 
the extract was diluted with TTD buﬀ er to 1 ml, and supplemented with SDS (ﬁ nal 
concentration of 0.08%) and an α-GFP antibody (1:500). Precipitation was performed 
O/N at 4°C while rotating the samples. Immune complexes were precipitated with 
protein A-sepharose (Amersham Biosciences) for 6 hr at 4°C while rotating the samples 
and resolved by SDS-PAGE. After transfer to PVDF membrane, the blot was incubated 
with anti-PS1 as described under western blot analysis.
Metabolic cell labelling
For metabolic cell labelling, NILs of black-adapted wild-type and transgenic Xenopus were 
rapidly dissected and preincubated in Ringer’s medium for 15 min at 22°C. Radioactive 
labelling of newly synthesised proteins was performed by incubating the NILs in Ringer’s 
medium containing 5 mCi/ml Tran35S-label for 30 min at 22°C, rinsed, and chased 
with 0.5 mM L-methionine in Ringer’s medium for three hours. After the chase, NILs 
were homogenised on ice in TTD buﬀ er and the lysates were cleared by centrifugation 
at 13,000 x g for 7 min at 4°C. Parts of the lysates and incubation media were analysed 
directly on SDS-PAGE, while the remainder was used for western blot.
Apomorphine treatment
For the analysis of the inﬂ uence of apomorphine on POMC processing and release of the 
POMC-derived peptides, dissected wild-type or transgenic NILs were pulsed and chased 
as described above, whereby apomorphine was added during the chase period to a ﬁ nal 
concentration of 2.0*10-8 M or 6.7*10-9 M.
Statistics
Data from the quantitative RT-PCR and background adaptation experiments are 
presented as means ± s.e.m. (n = 3 and n = 8 per group, respectively). Statistical 
evaluation of the RT-PCR data was performed using an unpaired Student’s t-test, while 
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the background adaptation experimental data were analysed a univariate ANOVA on the 
melanophore index of the webs of wild-type and transgenic frogs. Since the univariate 
ANOVA yielded statistical signiﬁ cance, we performed an independent samples T-test 
over the melanophore index for every time point, and for both wild-type and transgenic 
frogs a one-way ANOVA and post hoc a Bonferroni analysis. Diﬀ erences are signiﬁ cant 
if P < 0.05.
Results
Endogenous Aph-1 mRNA is not differentially expressed in the pituitary of black- 
and white- adapted Xenopus laevis
In Xenopus, the Aph-1 gene family consists of only one gene, while mammals have two 
Aph-1 genes (Aph-1a and Aph-1b). To determine the levels of endogenous Xenopus Aph-
1 transcripts in the NIL and AL of the pituitary of animals adapted to a black or white 
background, we performed real-time quantitative RT-PCR analysis. Th e melanotrope 
cells in the NIL regulate the process of background adaptation. Depending on the colour 
of the background of the frog, these cells are either highly activated or inhibited by 
neurons of hypothalamic origin. In contrast, the anterior pituitary cells are not involved 
in background adaptation (Martens et al., 1987). In both NIL and AL, Aph-1 mRNA was 
detected, but no signiﬁ cant diﬀ erences were observed between the levels in the NILs of 
black- and white-adapted animals, nor between the levels in the ALs (Figure 1). Despite 
many attempts to study the expression levels of Xenopus Aph-1 at the protein level, none 
of the available antibodies recognised a speciﬁ c product in the NIL or AL.
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Figure 1. Real-time quantitative RT-PCR analysis of endogenous Aph-1 mRNA 
levels in the neurointermediate lobe (NIL) and anterior lobe (AL) of the 
pituitary of black- (B) and white- (W) adapted Xenopus
The level of Aph-1 mRNA in the NIL of black-adapted animals was set to 100%. No 
differences in Aph-1 mRNA levels were observed in the NILs or ALs of black- and 
white-adapted animals. In each case, the values shown are relative to the amounts of 
GAPDH mRNAs and represent the mean plus SEM from 3 different animals. 
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Generation of Xenopus transgenic for the Aph1aS-GFP fusion protein
Th e Xenopus Aph-1 sequence is most highly related to the mammalian Aph-1a sequence 
(see Figure 2 of the General Discussion). To study functional aspects of Aph-1, we used 
the short form of rat Aph-1a (Aph-1aS) to produce a transgenesis DNA construct and 
then generated Xenopus transgenic for Aph-1aS fused to the amino-terminus of GFP 
(Aph1aS-GFP). Th e DNA construct containing the sequence encoding Aph1aS-GFP 
downstream of the CMV promoter (pEGFP-N3delAUG-Aph-1aS; Figure 2A) was ﬁ rst 
used for transfection studies in COS-1 and Neuro2A cells. Twenty-four hours after 
transfection the Aph1aS-GFP cells revealed ﬂ uorescence in a network-like structure 
throughout the cytoplasm, but predominantly at one side of the nucleus (Figure 2B). 
Western blot analysis of transfected COS1 cell lysates showed that the Aph1a-GFP 
fusion protein migrated as a ~45-kDa protein, whereas an additional product of ~85 
kDa and high-molecular weight products of >110 kDa were observed as well (Figure 
2C). Similar results were obtained when lysates of transfected Neuro2A cells were 
analysed (data not shown). In these analyses, a denaturing lysis buﬀ er was used and the 
samples were heated to 100°C prior to loading, which is known to cause co-aggulation of 
multi-transmembrane proteins (Hansson et al., 2005; Shirotani et al., 2004), eventually 
resulting in the observed high-molecular weight products.
Subcloning of the Aph-1aS insert from the pEGFP-N3delAUG-Aph-1aS construct into 
the pPOMC(A)2+ vector generated a construct with the insert downstream of a 529-
bp Xenopus POMC gene A promoter fragment (pPOMC-Aph-1aS-GFP), which directs 
transgene expression speciﬁ cally to the melanotrope cells of the Xenopus intermediate 
pituitary (Jansen et al., 2002). Th e linearised pPOMC-Aph-1aS-GFP DNA (Figure 
3A) was mixed with Xenopus sperm nuclei from a male wild-type animal, the mixture 
was microinjected into unfertilised Xenopus eggs from a female wild-type animal and 
a number of ﬂ uorescent tadpoles were generated (Figure 3B). Th e diﬀ erent levels of 
Aph1aS-GFP expression among the various F0 transgenic animals could be readily 
and directly established by visual inspection of the living Xenopus tadpoles under a 
ﬂ uorescence microscope. Th e expression of the Aph1aS-GFP fusion protein was restricted 
to the intermediate lobe (IL; neuroendocrine melanotrope cells) of the pituitary, while 
the pituitary AL, in which the POMC producing corticotrope cells are located, and 
other brain structures did not show any ﬂ uorescence (Figure 3C). An F1 oﬀ spring was 
generated by in vitro fertilisation of eggs harvested from wild-type Xenopus females with 
sperm isolated from the testis of a male Xenopus frog transgenic for pPOMC-Aph1aS-
GFP. We selected a transgenic F1 line (#2) of which all oﬀ spring showed relatively high 
Aph1aS-GFP transgene expression and raised these embryos for further analysis.
Steady-state levels of the Aph1aS-GFP fusion protein, POMC, PC2 and p24δ1/2 in 
the pituitary of Xenopus transgenic for Aph1aS-GFP 
From the adult Xenopus pituitary (consisting of the pars nervosa, IL and AL), the AL can 
be dissected, but the pars nervosa (containing nerve terminals of hypothalamic origin) 
is intimately associated with the IL. To examine the steady-state levels of Aph1aS-GFP 
protein expression, the NIL was dissected from black-adapted frogs transgenic for 
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Figure 2. Expression of the Aph1aS-GFP fusion protein in transfected COS1 
and Neuro2A cells
(A) Schematic representation of the circular construct pEGFP-N3delAUG-Aph-1aS 
containing the Rattus norvegicus Aph-1aS coding sequence fused to the amino-terminus 
of GFP. The fusion construct was under the control of the CMV promoter and the 
selection marker gene kanamycin was under the control of the SV40 promoter; SV40 
poly A and HSV TK poly A, polyadenylation signals; /ori (upstream of pSV40), SV40 
origin for replication in mammalian cells expressing the SV40 T-antigen; F1 origin, 
origin for single-stranded DNA production; pUC ori, origin for replication in E. coli. (B) 
Fluorescence microscopy on COS1 cells (left panel) and Neuro2A cells (right panel) 
transfected with pEGFP-N3delAUG-Aph-1aS. Direct GFP fluorescence was observed 
in a network-like structure throughout the cytoplasm, but most prominent near the 
nucleus. Bars equal 25 µm. (C) Western blot analysis of proteins extracted from COS1 
cells transfected with pEGFP-N3delAUG-Aph-1aS (Aph1aS-GFP) or mock transfected. 
In addition to a number of higher molecular weight products ({: ≥119 kDa; *: ~85 kDa 
in size), the anti-GFP antibody staining revealed a product of ~45 kDa (indicated by 
the arrow) in the Aph1aS-GFP-transfected cell lysate. No product was detected in the 
lysate of the mock-transfected cells.
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Figure 3. Intermediate pituitary-specific fluorescence in Xenopus embryos 
transgenic for Aph1aS-GFP
(A) Schematic representation of the linear injection fragment pPOMC-Aph1aS-GFP 
containing the Xenopus POMC gene A promoter fragment (pPOMC) and the Aph1aS-
GFP fusion protein-coding sequence that was used to generate transgenic Xenopus. 
(B) Intermediate-pituitary-specific fluorescence in living Xenopus embryos (stage ~40) 
transgenic for the Aph1aS-GFP fusion protein. Arrows indicate the localisation of the 
fluorescent intermediate pituitary expressing the fusion product. Bars equal 0.5 mm. 
(C) Ventrocaudal view on the brain of a black-adapted 6 month-old frog transgenic for 
Aph1aS-GFP. The brain (br) was lifted to reveal intense fluorescence in the intermediate 
lobe (IL), but not in the anterior lobe (AL) of the pituitary; sb, skull base. Bar equals 1 
mm.
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Aph1aS-GFP and wild-type animals, and homogenised in CHAPS buﬀ er. Western blot 
analysis of the NIL lysates from the transgenic animals revealed that the majority of 
the Aph1aS-GFP fusion protein migrated as a ~45-kDa protein, whereas an additional 
higher molecular weight band of ~90 kDa was observed. No GFP signal was observed 
in lysates of the NILs of wild-type animals, or in the ALs of wild-type and transgenic 
animals (Figure 4A and data not shown). Th e steady-state protein levels of POMC, 
the POMC cleavage enzyme PC2 and the putative ER-to-Golgi cargo receptor proteins 
p24δ1/2 were similar in the NILs and ALs of transgenic and wild-type animals (Figure 
4B). In conclusion, expression of the Aph1aS-GFP fusion protein was restricted to the 
intermediate pituitary melanotrope cells and its level does not appear to aﬀ ect the steady-
state levels of POMC, PC2 or p24δ1/2.
Analysis of the γ-secretase component presenilin-1 and γ-secretase cleavage 
activity towards APP in the intermediate pituitary cells of Xenopus transgenic for 
Aph1aS-GFP
Next, we were interested in the eﬀ ects of the overexpression of the Aph1aS-GFP fusion 
protein on the expression of the other γ-secretase components in the NILs of the transgenic 
animals. Th e γ-secretase complex is ubiquitously expressed and consists of one of the 
presenilin proteins (PS1 or PS2), Nct, Aph1 and PEN-2. Unfortunately, except for PS1 
(Tsujimura et al., 1997), no suitable antibodies were available to detect the endogenous 
levels of any of these proteins in Xenopus. Western blot analysis using the anti-Xenopus 
PS1 antibody revealed no diﬀ erences between PS1 levels in transgenic and wild-type 
NIL lysates (Figure 4C, upper panel). To test whether the Aph1aS-GFP fusion protein 
was associated with endogenous γ-secretase components, we immunoprecipitated NIL 
proteins with an anti-GFP antibody and subsequently performed western blot analysis of 
the immunoprecipitate using the anti-PS1 antibody. Th is co-immunoprecipitation (co-
IP) analysis revealed that in the transgenic NIL lysates the carboxy-terminal fragment of 
PS1 was pulled down with the fusion protein, while no PS1 was detected in NIL lysates 
from wild-type animals (Figure 4D).
We then decided to determine the eﬀ ects of the overexpression of Aph1aS-GFP on γ-
secretase cleavage activity by analysing one of the best-known substrates of γ-secretase, 
namely the amyloid-β precursor protein APP. Th e proteolytic processing of APP starts 
with shedding of its extracellular domain by α- or β-secretase, leaving a carboxy-terminal 
fragment (CTF) that is subsequently cleaved by γ-secretase. Western blot analysis showed 
similar amounts of both the APP holoprotein (APP-FL) and the APP-CTF, indicating 
no direct eﬀ ect of the overexpression of Aph1aS-GFP on the proteolytic processing of 
APP by the γ-secretase complex (Figure 4E).
Biosynthesis and processing of newly synthesised POMC in Xenopus melanotrope 
cells transgenic for Aph1aS-GFP
We next examined the eﬀ ect of the overexpressed Aph1aS-GFP fusion protein on the 
biosynthesis and processing of POMC as well as the secretion of the POMC-derived 
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Figure 4. Steady-state levels of the Aph1aS-GFP fusion protein and a number 
of Xenopus intermediate pituitary proteins in the NILs of frogs transgenic for 
Aph1aS-GFP and wild-type animals
(A) Western blot analysis of native tissue lysates of neurointermediate lobes (NILs) 
derived from wild-type animals (wt) and frogs transgenic for the Aph1aS-GFP fusion 
protein (tr) using an anti-GFP antibody (α-GFP). In the transgenic NIL, a prominent 
product of ~45 kDa and an additional product (*)of ~90 kDa was observed. (B) Western 
blot analysis of lysates of NILs from wild-type animals (wt) and animals transgenic for 
Aph1aS-GFP (tr) using anti-POMC, anti-PC2, anti-p24δ1/2, and anti-tubulin antibodies. 
Tubulin was used as a control for protein loading. (C) Western blot analysis of the γ-
secretase component PS1 in transgenic Xenopus NILs. Similar amounts of PS1 were 
detected in the wild-type and transgenic NILs. (D) Co-immunoprecipitation (co-IP) 
analysis of NIL lysates from wild-type animals (wt) and frogs transgenic for the Aph1aS-
GFP fusion protein (tr) using an anti-GFP antibody for immunoprecipitation and an anti-
PS1 antibody for western blot analysis. Products of ~18 and ~21 kDa were detected 
in the transgenic NIL samples and suggested to represent different post-translational 
modifications of the CTF of PS1. The amounts of PS1-CTF in the input lanes of wild-
type and transgenic NILs showed that equal amounts of tissue lysates were used. (E) 
Western blot analysis of the γ-secretase cleavage activity towards APP in transgenic 
Xenopus NILs. Similar amounts of APP holoprotein (APP-FL) as well as APP C-terminal 
fragment (APP-CTF) were detected in the wild-type and transgenic NILs, indicating 
no affected γ-secretase cleavage activity. Tubulin was used as a control for protein 
loading.
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products. To this end, we performed pulse-chase analyses of newly synthesised proteins 
produced in the tissue and secreted into the incubation medium by NILs of Xenopus 
transgenic for Aph1aS-GFP and wild-type animals. Because besides the melanotrope 
cells, the Xenopus NIL consists of nerve terminals of hypothalamic origin that are 
biosynthetically inactive (the pars nervosa), the radiolabelled proteins are synthesised 
by the melanotropes. Following a 30-min pulse labelling and a subsequent three-hour 
chase, in both wild-type and transgenic NILs most of the 37-kDa POMC precursor 
protein was processed to an 18-kDa POMC cleavage product, which was subsequently 
secreted into the incubation medium (Figure 5). Th e 18-kDa product represents the 
N-terminal portion of 37-kDa POMC and is generated by the ﬁ rst endoproteolytic 
cleavage step during POMC processing, while the 14-18-kDa products resemble the 
small POMC-derived products (Martens, 1986). Aside from a limited reduction in the 
levels of the secretory products 14-18-kDa POMC and 69-kDa PC2 in the medium, no 
clear diﬀ erences were found in the newly synthesised protein levels of transgenic NILs 
in comparison to wild-type NILs. Together, these results indicate that the transgene 
expression of the Aph1aS-GFP fusion protein in the intermediate pituitary melanotrope 
cells had no eﬀ ect on POMC and PC2 biosynthesis and processing, or on the release of 
the POMC-derived products.
18-kDa POMC
37-kDa POMC
actin
69 kDa PC2
75-kDa proPC2
lysate medium
wt wttr tr
Figure 5. Biosynthesis and processing 
of newly synthesised POMC in 
intermediate pituitary cells of 
Xenopus transgenic for Aph1aS-GFP 
and wild-type animals
Neurointermediate lobes (NILs) of black-
adapted wild-type animals (wt) and animals 
transgenic for Aph1aS-GFP (tr) were 
pulse labelled for 30 min and subsequently 
chased for 3 hr. Newly synthesised proteins 
extracted from the lobes (5%) or secreted 
into the incubation medium (20%) were 
resolved by SDS-PAGE on 15% gels 
and visualised by autoradiography. The 
experiments were performed in triplicate 
and a representative example is shown.
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Background adaptation of Xenopus transgenic for Aph1aS-GFP
Th e Xenopus intermediate pituitary melanotrope cells are involved in the process 
of background adaptation (Jenks et al., 1977). We therefore decided to examine the 
physiological consequence of the expression of the Aph1aS-GFP transgene speciﬁ cally in 
the melanotrope cells for background adaptation of the transgenic animal. Upon placing 
a completely white-adapted Xenopus on a black background, the melanotrope cells 
regulate the dispersion of the melanin in the skin melanophores by releasing α-MSH 
into the bloodstream resulting in a darkening of the animals skin (Jenks et al., 1977). 
Simultaneously scoring the melanophore state in the webs of the adapting frogs according 
to the melanophore index (Figure 6A) allowed real-time analysis of this physiological 
adaptation process. A white-to black adaptation experiment studying wild-type frogs and 
frogs transgenic for Aph1aS-GFP did not reveal any signiﬁ cant diﬀ erences in adaptation 
speed to a black background (Figure 6B). Surprisingly, in the reverse experiment, fully 
black-adapted transgenic frogs adapted more rapidly to a white background than wild-
type animals, which was signiﬁ cant from t = 0.5 hours onward (Figure 6C; P < 0.05). 
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Figure 6. The rate of background adaptation is affected in transgenic Xenopus 
overexpressing Aph1aS-GFP specifically in the intermediate pituitary
(A) Skin melanophore index after Hogben and Slome (1931). The dispersion state of 
melanin pigment granules in skin melanophores, responsible for the darkening of the 
skin, was indexed from completely aggregated around the nucleus (melanophore index 
1) to maximally dispersed throughout the cytoplasm (index 5). (B) Fully white-adapted 
wild-type (wt) or transgenic (tr) frogs placed on a black background show similar 
adaptation rates, based on their melanophore index. Shown are means plus s.e.m. (n 
= 5). (C) Fully black-adapted transgenic (tr) frogs placed on a white background show 
a more rapid background adaptation than black-adapted wild-type (wt) animals, based 
on their melanophore index. Shown are means plus s.e.m. (n = 5).
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Effects of apomorphine on the biosynthesis and processing of newly synthesised 
proteins in Xenopus melanotrope cells transgenic for Aph1aS-GFP
As mentioned above, background adaptation of Xenopus laevis is regulated by the 
amount of α-MSH secreted by the neurointermediate lobe into the blood stream of the 
frog. Upon placing the animal on a lighter background, α-MSH secretion is reduced, 
which can be regulated at multiple levels (Roubos et al., 2005). One of these levels is 
the dopaminergic input from neurons originating in the suprachiasmatic nucleus of the 
hypothalamus (Tuinhof et al., 1994). Since in the rat a reduced level of Aph-1b aﬀ ects 
the dopaminergic system (Coolen et al., 2005), we examined the dopaminergic system 
in the NILs of wild-type and transgenic animals. To this end, we performed pulse-chase 
analyses in the presence or absence of various concentrations of the dopaminergic agonist 
apomorphine. It has previously been found that in the wild-type situation 1*10-7 M 
apomorphine caused complete inhibition of secretion of the POMC-derived products 
into the medium, whereas 2*10-8 M resulted in ~70% blockage (Eric Jansen, personal 
communication). We now determined the signal intensities of the 18-kDa POMC in the 
medium relative to the 37-kDa POMC in the lysate to analyse the level of (inhibition 
of ) regulated secretion in the wild-type and transgenic NILs (Figure 7). Again, in the 
absence of apomorphine a small reduction in the secretion rate was observed in the 
transgenic compared to the wild-type NILs, indicated by slightly decreased levels of 18-
kDa POMC in the medium relative to 37-kDa POMC in the lysate (compare Figures 
5 and 7). Low levels of apomorphine (7*10-9 M) clearly decreased the secretion in the 
transgenic NIL (to ~73%), while the wild-type NIL did not show a diﬀ erence with 
the situation in the absence of apomorphine. At levels of 2*10-8 M apomorphine, both 
the transgenic and wild-type NILs displayed a clear reduction of secretion of 18-kDa 
POMC relative to of the presence of 7*10-9 M apomorphine (Figure 7). Since this 
experiment has been performed only once, no error bars are presented. However, all 
three individual NILs of frogs transgenic for Aph1aS-GFP showed a reduced regulated 
secretion compared to their respective wild-type controls. Th erefore, these data indicate 
that the Xenopus melanotrope cells transgenic for Aph1aS-GFP appear to be more 
sensitive to apomorphine in blocking secretion than wild-type cells.
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Figure 7. Effect of apomorphine on the biosynthesis and processing of newly 
synthesised POMC in Xenopus intermediate pituitary cells transgenic for 
Aph1aS-GFP and wild-type cells
(A) Neurointermediate lobes (NILs) of black-adapted wild-type animals (wt) and animals 
transgenic for Aph1aS-GFP (tr) were pulse labelled for 30 min and subsequently chased 
for 3 hr in the presence or absence of 2*10-8 or 7*10-9 M apomorphine or in chase 
medium lacking apomorphine (-). Newly synthesised proteins extracted from the lobes 
(5%) or secreted into the incubation medium (20%) were resolved by SDS-PAGE on 
15% gels and visualised by autoradiography. (B) Quantification of the amounts of the 
18-kDa POMC product in the medium relative to the levels of the 37-kDa POMC 
product in the lysates. Similar results were obtained when the levels of 18-kDa POMC 
product in the medium were normalised to the levels of newly synthesised actin in the 
lysates (data not shown).
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Discussion
Th e aim of the present study was to study in vivo the role of Aph-1, one of the γ-secretase 
components, by examining the eﬀ ect of the transgene expression of Aph-1aS in Xenopus 
intermediate pituitary melanotrope cells on prohormone biosynthesis and processing, the 
secretion of the prohormone-derived peptides, γ-secretase functioning and background 
adaptation of the animal. For a number of reasons, the Xenopus melanotrope cells 
represent an attractive cell model system. First, this homogeneous cells population of 
strictly regulated neuroendocrine secretory cells and their biosynthetic and secretory 
activity can be physiologically manipulated in vivo by simply placing the amphibian on 
a black or white background. Second, on a black background these cells produce large 
amounts of a single cargo molecule, the prohormone proopiomelanocortin (POMC), 
that is transported via the regulated secretory pathway and processed to a number of 
bioactive peptides including α-melanophore stimulating hormone (α-MSH), which is 
responsible for darkening of the skin (Jenks et al., 1977). Th e Xenopus melanotrope 
cells also produce Aph-1, but its mRNA expression is not altered in black- compared 
to white-adapted animals. Th ird, all γ-secretase components as well as many γ-secretase 
substrates are highly conserved between Xenopus and mammals, making Xenopus a good 
animal model to study the function of Aph-1. In contrast to the two genes existing in 
mammals (Aph-1a and -1b), Xenopus has only one ancestral Aph-1 gene (i.e. a single 
ancestral gene that is duplicated due to a duplication of the whole genome in the genus 
Xenopus laevis that occurred some 50 million years ago, Evans et al., 2004). Since at the 
time of the generation of the frogs transgenic for Aph1aS-GFP, the full-length Xenopus 
laevis Aph-1 coding sequence was not yet known, we decided to use for our studies the 
highly similar Rattus norvegicus the Aph-1aS sequence fused to the amino-terminus of 
GFP. Substituting a mammalian component of γ-secretase by its Drosophila counterpart 
has been shown to be successful in reconstituting active γ-secretase, emphasizing the 
evolutionary conservation of γ-secretase assembly and function (Takasugi et al., 2003). 
Th e fact that we were successful in generating Aph1aS-GFP-transgenic frogs indicates 
that overexpression of the fusion protein in the intermediate pituitary is not lethal. Th e 
transgene expression was under the control of a POMC gene promoter fragment to 
generate frogs overexpressing the fusion protein speciﬁ cally in the intermediate pituitary 
melanotrope cells.
Th e transfection experiments with COS1 and Neuro2A cells revealed an intracellular 
distribution of the Aph1aS-GFP protein in membrane structures, predominantly close 
to the nucleus and resembling most likely the endoplasmic reticulum (ER) or the Golgi 
apparatus. Th ese observations are in line with previous reports on transfected 293T and 
HEK293 cells overexpressing HA-tagged Aph-1b and -1aL, respectively, showing that 
the protein localises to the ER and cis-Golgi (Gu et al., 2003; Hansson et al., 2005). 
Th e size observed for the major Aph1aS-GFP fusion product in the western blot analysis 
(~45 kDa, of which ~27 kDa is accounted for by the GFP tail and ~18 kDa by Aph-1aS; 
resembles that found by others (Gu et al., 2003; Hebert et al., 2004; Ormo et al., 1996). 
Th e additional product of roughly twice the size of the monomeric protein has been 
reported previously to represent aggregated forms of Aph-1 due to overexpression of the 
multi-pass transmembrane protein (Hansson et al., 2005; Shirotani et al., 2004).
Chapter 6
124
Th e temporal and spatial expression pattern in Xenopus transgenic for Aph1aS-GFP 
observed during early embryonic development (from stage 25 onwards and gradually 
speciﬁ c to the intermediate pituitary) resembles that found in Xenopus transgenic for 
POMC-promoter-driven expression of GFP itself (Jansen et al., 2002). In addition, the 
pattern is in line with the expression pattern of the endogenous POMC-derived α-MSH-
peptide in developing Xenopus (Kramer et al. 2003). While our co-IP analyses revealed 
that in the transgenic melanotrope cells the Aph1aS-GFP fusion protein was capable of 
forming a complex with endogenous PS1-CTF, no direct eﬀ ects were observed on the 
steady-state levels of PS1-CTF, nor for the major cargo protein POMC, or other secretory 
pathway components, such as the POMC cleavage enzyme PC2 and the p24δ1/2 proteins. 
Similarly, studies in HEK293 and Chinese hamster ovary cells have shown (endogenous) 
multimerisation of Aph-1aL with PS1, and no increase of PS1 levels upon overexpression 
of Aph-1aL (Gu et al., 2003; Luo et al., 2003). At the functional level, the γ-secretase 
cleavage activity towards APP appeared not to be aﬀ ected in the transgenic compared 
to the wild-type melanotrope cells. It should here be noted that, to date, γ-secretase is 
known to cleave a long list of over 15 substrates (Coolen et al., 2006). Th erefore, it may 
very well be that the cleavage activity towards other substrates is aﬀ ected in the transgenic 
melanotrope cells. Since in the pulse-chase metabolic cell labelling studies on the Xenopus 
intermediate pituitary no large diﬀ erences in the amounts of 37-kDa POMC and the 
18-kDa POMC-derived product in the cells and incubation media were observed for the 
wild-type and transgenic melanotrope cells, the introduction of the Aph1aS-GFP fusion 
protein did not greatly aﬀ ect prohormone biosynthesis and processing, and the secretion 
of the prohormone-derived proteins. 
We found that fully black-adapted transgenic animals showed a signiﬁ cantly more rapid 
adaptation to a white background compared to wild-type animals, which could indicate 
that the melanotrope cells are more prone to inhibition and thus give a more rapid 
reduction of α-MSH levels in the blood than the wild-type cells. Future superfusion 
experiments with NILs of animals adapted to a white background for a relatively short 
time may shed light on this matter.
Inhibition of α-MSH secretion by the NIL can be regulated at multiple levels (Roubos 
et al., 2005). Our apomorphine pulse-chase experiment indicated that the transgenic 
melanotrope cells are more sensitive to apomorphine and more eﬃ  ciently block secretion 
compared to wild-type cells. Superfusion experiments with dopamine or apomorphine as 
secretagogues could be informative and support these preliminary data. Also, other known 
inhibitors of melanotrope secretion, such as neuropepide Y (NPY) and γ-aminobutyric 
acid (GABA) (de Rijk et al., 1990; de Rijk et al., 1992) could be tested in such an assay 
to examine whether the overexpression of the Aph1aS-GFP fusion protein only aﬀ ects 
dopamine sensitivity or also inﬂ uences other neurotransmitter systems.
Th us far, only one Xenopus F1 line transgenic for Aph-1 has been analysed. It will be essential 
to study multiple lines to draw more deﬁ nite conclusions from these experiments. In any 
case, the increased sensitivity to apomorphine is not a general eﬀ ect in transgenesis; for 
example overexpression of the V-ATPase accessory subunit Ac45 fused to the animo-
terminus of GFP in the NIL results in a reduction of the eﬀ ect of apomorphine compared 
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to wild-type animals (Eric Jansen, unpublished results). Interestingly, we have previously 
shown in the APO-SUS/-UNSUS rat model a link between the mammalian Aph-1 family 
member Aph-1b and the dopamine receptor agonist apomorphine. Rats with reduced 
Aph-1b levels appeared to be more sensitive to the drug, as measured by an increased 
gnawing response (Coolen et al., 2005). Surprisingly, we now ﬁ nd that increased Aph-
1a expression causes also a more sensitive dopamine system. At present, it is not clear 
whether this increase in sensitivity is due to a displacement of the endogenous Xenopus 
Aph-1 protein, causing reduced levels of this protein, by the high levels of the Aph-
1a transgene product. Alternatively, the GFP tag of the Aph-1aS-GFP fusion protein 
may have had a dominant-negative eﬀ ect on the functioning of the Aph-1aS/γ-secretase 
complex. Th e generation and analysis of transgenic Xenopus overexpressing Aph-1aS 
without a tag may clarify whether the latter explanation is correct.
Altogether, we have successfully targeted Aph1aS-GFP to the Xenopus melanotrope 
cells of the intermediate pituitary. Our preliminary results indicated a possible novel 
link between the Aph-1-containing γ-secretase complex and the dopaminergic 
neurotransmitter system. Further analyses will be necessary to shed more light on this 
remarkable observation.
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N eurodevelopmental disorders, such as schizophrenia, autism and attention-deﬁ cit hyperactivity disorder (ADHD), are characterized by complex 
phenotypes with a variety of symptoms that are not just restricted to neural tissues, 
and multiple genes are thought to be responsible for each of these disorders. Th e aim 
of the research described in this thesis was to gain insight into the molecular cause of 
complex neurodevelopmental phenotypes, using the APO-SUS and -UNSUS rats as an 
experimental model. Th e APO-SUS and -UNSUS rat lines have been pharmacogenetically 
selected from an outbred Wistar population. Extensive phenotyping revealed a complex 
phenotype for the APO-SUS rats with a range of characteristics, both neuronal and 
non-neuronal, and remarkably similar to that observed in schizophrenic patients 
(Chapter 1).
The molecular basis of the APO-SUS/-UNSUS rat model: genomic 
rearrangement in the Aph-1b locus
We performed expression microarray analyses of the APO-SUS/-UNSUS rat model 
and found as the only reproducible diﬀ erence a reduced level of Aph-1b mRNA in 
APO-SUS compared to -UNSUS rats (Chapters 2 and 3). Detailed genomic analyses 
revealed that a genomic rearrangement between segmental duplications had occurred 
in the Aph-1b locus of these rats, resulting in one (I) or two (II) in-tandem copies of 
the Aph-1b gene in APO-SUS rats and three (III) copies in -UNSUS rats. Segmental 
duplications are quite common in the rodent and human genomes; ~2.92% of the rat 
genome, ~1.2% of the mouse genome and ~5% of the human genome consists of such 
direct-repeat elements (≥1kb in size and ≥90% sequence identity), all widely distributed 
across the chromosomes (Tuzun et al., 2004). Th e duplication of a gene and subsequent 
mutation of the descendent copy is widely regarded as a mechanism by which genes 
with new functions are created. In addition, segmental duplications are hot spots for 
non-allelic homologous recombination and unequal crossing over, leading to genomic 
deletions, duplications, inversions and translocations. Many disorders (generally referred 
to as genomic disorders) show an involvement of segmental duplications, such as the 
Williams-Beuren syndrome and the Charcot-Marie-Tooth syndrome (Samonte and 
Eichler, 2002).
Recently, the genome of the Brown Norway laboratory rat strain has been sequenced (Gibbs 
et al., 2004) and a search through the database shows that the Aph-1b locus contains two 
Aph-1b gene copies; Aph-1b and -1b’. Surprisingly, Southern blotting and PCR analyses 
revealed that various rat strains (including the Wistar, Lewis, Fischer as well as the Brown 
Norway strain) have three Aph-1b gene copies (i.e. also harbouring the chimaeric Aph-
1b/b’ gene). Only the wild brown rat (sample collection through various pest control 
companies) displayed an Aph-1b locus similar to the genome database and the II/II rats 
(data not shown). Th is suggests that the ancestral wild rat harboured two Aph-1b genes 
that shifted to three genes when laboratory rat strains were generated. Perhaps, during 
the generation and maintenance of these standard laboratory rat strains, an unintentional 
selection has occurred toward more manageable (i.e. less stress susceptible) rats within 
the strains, in favour of the III/III genotype. Th e discrepancy in the Aph-1b gene copy 
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number of the Brown Norway rat sequence described in the rat genome database and 
found in our genotyping experiments may be caused by a heterogeneity in the Brown 
Norway strains, or - perhaps more likely - the segmental duplication in this region 
was problematic for sequencing and computer assembly of the rat genome (the mouse 
genome database sequence has also two Aph-1b gene copies). Furthermore, all Wistar 
rats tested contained the III/III genotype, implicating that a genomic rearrangement in 
the Aph-1b locus has occurred only in the APO-SUS rats, while this locus has remained 
unchanged in the APO-UNSUS rats. Th us, a diﬀ erence in recombination susceptibility 
may exist between the two rat lines. Such a diﬀ erence could have been caused by for 
example a diﬀ erential epigenetic status of the Aph-1b locus. Epigenetic factors, such as 
nucleosome reorganisation, histone modiﬁ cations and DNA methylation, are generally 
known to inﬂ uence the phenotype without changing the genotype. In addition, a 
number of studies have demonstrated that histone/chromatin modiﬁ cations not only 
inﬂ uence DNA expression, but also DNA replication, recombination, and repair (Hassa 
and Hottiger, 2005; Khorasanizadeh, 2004). It would therefore be very interesting to 
analyse in these rats the epigenetic status of the Aph-1b locus in more detail. Also, the 
recombination event resulting in the APO-SUS rats could have been driven by external 
factors, such as the injection of the dopamine receptor agonist apomorphine that was used 
for the generation of the rat lines. Previous research has revealed the mutagenic capacity 
of apomorphine and especially of its oxidation derivative (Picada et al., 2005). Other 
external factors, like pre-, peri- or early post-natal stress or maternal care, may aﬀ ect the 
methylation or recombination events as well (Weaver et al., 2004). It would therefore be 
interesting to identify the trigger leading to the recombination event in the rats (e.g. by 
the injection of Wistar rats with oxidized apomorphine or by applying severe stress and 
subsequent DNA [methylation] and chromatin analysis). In addition, examining direct 
repeat sequences in the APO-SUS genome would be of interest. Perhaps other regions 
also show a recombination event.
Th e observation that all Wistar rats are of the III/III genotype is not in line with the 
observed link between the Aph-1b copy number and apomorphine susceptibility 
described in Chapters 3 and 5. In an apomorphine susceptibility test, the Wistar rat 
population showed a bimodal distribution; some rats hardly responded whereas others 
gnawed vigorously (Cools et al., 1990; Ellenbroek and Cools, 2002, and personal 
observation). In addition, the Aph-1b mRNA levels did not diﬀ er signiﬁ cantly between 
these Wistar rats (data not shown). On the other hand, our backcross experiments 
(Chapter 5) showed that in a highly similar general genetic background, rats with one 
Aph-1b gene were signiﬁ cantly more susceptible to apomorphine than rats with three 
gene copies. Apparently, next to the Aph-1b copy number also other factors can inﬂ uence 
apomorphine susceptibility. Nevertheless, our functional studies on the paralogue of 
Aph-1b, termed Aph-1a, by transgene expression in the neuroendocrine intermediate 
pituitary melanotrope cells of the South-African claw-toed frog Xenopus laevis, revealed 
in the transgenic cells an increased sensitivity to inhibition of regulated secretion by 
apomorphine (Chapter 6). Together with the diﬀ erential apomorphine susceptibility 
of the APO-SUS and -UNSUS rat lines, this suggests that the γ-secretase complex is 
somehow involved in generating susceptibility to the dopamine receptor agonist.
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Functional studies on Xenopi transgenic for Aph-1a 
In Chapter 6, we employed stable Xenopus laevis transgenesis in combination with 
a cell-speciﬁ c POMC gene promoter fragment as a tool to express Aph-1a carboxy-
terminally tagged with the green ﬂ uorescent protein (Aph1a-GFP) speciﬁ cally in the 
melanotrope cells. Th ese cells produce large amounts of the prohormone POMC when 
the animal is placed on a black background, whereby a POMC-derived hormone causes 
the dispersion of skin melanophores. Conversely, on a white background these cells 
are inactive because of directly innervating inhibitory neurons of hypothalamic origin, 
including dopaminergic neurons. Th e analysis of our transgenic animals through pulse-
chase metabolic cell labelling studies revealed that, despite the high levels of transgene 
expression, POMC synthesis and processing, and the secretion of POMC-derived 
products remained unaﬀ ected in the transgenic melanotrope cells. Surprisingly, we 
found that fully black-adapted transgenic animals showed a signiﬁ cantly more rapid 
adaptation to a white background compared to wild-type animals. Furthermore, the 
transgenic melanotrope cells appeared to be more sensitive to apomorphine, i.e. their 
regulated secretion of newly synthesised POMC-derived products was more inhibited 
than secretion from wild-type cells. Th ese results suggest a modiﬁ ed sensitivity of the 
dopaminergic system in the transgenic Xenopi. However, it has to be stressed that the 
ﬁ ndings described in Chapter 6 are only preliminary. Th us far, only one Xenopus F1 line 
transgenic for Aph-1a has been analysed and a limited number of experiments have been 
performed on these frogs. It will be essential to study multiple transgenic lines in more 
detail to draw more deﬁ nitive conclusions. Such experiments will have to prove that 
the observed eﬀ ects were not caused by mere line-speciﬁ c diﬀ erences or by the site of 
integration of the transgene DNA fragment into the genome of the frog (position eﬀ ect). 
Furthermore, it has to be examined whether the eﬀ ect is dopamine-speciﬁ c or if other 
inhibitory mechanisms of melanotrope secretion (e.g. neuropeptide Y or GABA) are also 
aﬀ ected in these animals.
Recombination of the rat Aph-1b locus
Th e data presented in Chapters 3 to 5 provide evidence that in APO-SUS rats the reduced 
number of Aph-1b genes is directly related to their phenotype. First, the APO-SUS/
-UNSUS rat lines were generated twice, independently and with a ten-year interval. In 
both the original and the replicated APO-SUS and -UNSUS lines, the same Aph-1b gene 
copy number distribution was observed: one (I) or two (II) genes in APO-SUS rats and 
three (III) gene copies in APO-UNSUS rats. Second, the I/I and II/II rats from the APO-
SUS line and the III/III rats from the APO-UNSUS line were tested separately for their 
behaviour (Chapter 3) revealing some features of a gene-dosage eﬀ ect (e.g. locomotor 
activity in the open ﬁ eld or open arm entries in the elevated plus maze test), while for 
other behavioural characteristics a threshold in Aph-1b gene copy number appears to 
exist, i.e. a similar increase in gnawing score (apomorphine test) or in habituation time 
in the open ﬁ eld test is observed in the I/I and II/II rats compared to the III/III rats. And 
third, by crossing I/I rats of the APO-SUS line with III/III rats of the APO-UNSUS line, 
as performed in Chapter 5, we mixed the genetic background of both lines. By reselection 
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of the various Aph-1b genotypes, new lines were created with otherwise a highly similar 
general genetic backgrounds. We showed that the apomorphine susceptibility segregated 
with the Aph-1b genotypes, clearly indicating a correlation between genotype and 
phenotype. Correlations for other phenotypic characteristics are likely to be observed 
in future experiments. Similar to the I/I and III/III crossing experiments, the II/II rats 
of the APO-SUS line have recently been crossed with III/III rats of the APO-UNSUS 
line for future phenotyping (see also Chapter 4). A detailed gene-dosage dependency of 
various characteristics can now be determined using the I/I, II/II and III/III rats that 
only diﬀ er in Aph-1b copy numbers. 
Aph-1b and the gamma-secretase complex
In mammals, together with the Aph-1aS and -1aL proteins, the Aph-1b protein is part of 
the family of anterior pharynx defective 1 (Aph-1) proteins. Recently, it has been shown 
that this family is a component of the minimal molecular subunit composition of the γ-
secretase complex that includes presenilin (either PS-1 or PS-2), nicastrin (Nct), presenilin 
enhancer 2 (PEN-2) as well (De Strooper et al., 1998; Edbauer et al., 2003; Francis et al., 
2002; Yu et al., 2000). Th e γ-secretase complex belongs to the family of aspartyl proteases 
and cleaves many type I transmembrane proteins within their membrane domain (Figure 
1A). In general, the proteolytic processing of a γ-secretase substrate is initiated by the 
binding of the substrate to its ligand and subsequent shedding of its extracellular domain 
by a disintegrin metalloprotease, leaving a membrane-bound C-terminal fragment 
(CTF) that is subsequently cleaved by γ-secretase within its transmembrane domain. 
Th e resulting intracellular domain (ICD) is released into the cytoplasm and translocates 
to the nucleus, where it is involved in transcriptional regulation. In this thesis, we have 
shown that in APO-SUS rats the reduced Aph-1b mRNA levels caused a reduction of γ-
secretase cleavage activity towards multiple substrates (Figure 1B). Th us far, thirty-three
Figure 1. Model of substrate cleavage by gamma-secretase
(A) Upon ligand binding, the ectodomain of the substrate is shed, resulting in the generation of a 
membrane-bound C-terminal fragment (CTF). This CTF is subsequently cleaved by the γ-secretase 
complex within its membrane region and the released intracellular domain (ICD) translocates to 
the nucleus, where it is involved in transcriptional regulation (after Kopan and Ilagan, 2004). (B) The 
reduction of the Aph-1b levels (in I/I compared to III/III rats) causes a decrease in Aph-1b-containing γ-
secretase complexes, whereas the levels of Aph-1a-containing complexes remain unaffected (depicted 
by number of Aph-1a [white] and -1b [grey] particles). The various γ-secretase substrates can show 
differences in selectivity towards either Aph-1b or -1a containing complexes (left column). Substrates 
with a preference for Aph-1b will show the most severely affected γ-secretase processing in I/I rats 
(upper part of scheme), whereas substrates with a high affinity for Aph-1a-containing γ-secretase 
complexes may not be affected by the reduced Aph-1b levels (lower part of scheme). In this thesis, 
we have shown the direct consequences of the reduced Aph-1b levels in I/I rats for several substrates. 
We hypothesise the occurrence of downstream changes. For clarity, only two types of γ-secretase 
complexes (Aph-1a and -1b) are shown, whereas six complexes with different subunit compositions can 
be formed (containing one of the three Aph-1 proteins, and one of the two PS proteins). Differences in 
expression levels of the various components over time and place will add another layer of complexity 
to the situation in I/I rats (see Chapters 4 and 5 for examples).
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γ-secretase substrates have been discovered, each of which is part of a speciﬁ c signalling 
pathway (Table 1).
Th e Aph-1b gene is present in all mammalian species, while the Aph-1b duplication 
(and thus the presence of the Aph-1b’ gene) is rodent speciﬁ c. Sequence comparisons 
suggest that Aph-1a is the closest orthologue to the ancestral Aph-1 gene, which can 
be found in plants, worms and insects (Figure 2). Th e amino acid sequence alignment 
reveals a strong evolutionary conservation, suggesting an important basal function for 
Aph-1 proteins. Th e Aph-1a gene is transcribed as two splice variants, Aph-1aS and 
-1aL, and all transcript of the Aph-1 family are ubiquitously expressed. Th e restricted 
presence of Aph-1b in mammals could imply a specialized function for this protein 
in the γ-secretase complex of higher organisms.  In vertebrates as well as in plants and 
invertebrates, the presenilin family consists of two members, PS1 and PS2 (Ponting 
et al., 2002). Th is makes the Aph-1b protein the only mammalian-speciﬁ c γ-secretase 
complex subunit. Mice with a Aph-1a knock-out have been shown to be lethal, whereas 
the deletion of both the Aph-1b and -1b’ gene yielded viable animals with only localized 
signs of aﬀ ected γ-secretase functioning (Ma et al., 2005; Serneels et al., 2005). Th is 
suggests that γ-secretase complexes containing Aph-1b have a diﬀ erent, perhaps more 
specialized, function than complexes containing Aph-1a. Future mutation analysis and 
domain swapping may reveal further functional diﬀ erences between the Aph-1 family 
members.
Th us far, no mammalian-speciﬁ c substrates of the γ-secretase complex are known, nor is 
any of the substrates exclusively processed by either Aph-1a- or -1b-containing γ-secretase 
complexes. However, the list of γ-secretase substrates is still growing, so a mammalian-
speciﬁ c (or Aph-1b-speciﬁ c) substrate could still be discovered. Th e selective presence of 
Aph-1b in mammals may point towards specialisation of the functioning of the complex 
in these organisms that show complex behavioural traits.
Table 1. The gamma-secretase components and their substrates in a number of species
Species abbreviations: Hs, Homo sapiens; Rn, Rattus norvegicus; Mm, Mus musculus; Xl; Xenopus 
laevis; Dm, Drosophila melanogaster; Ce, Caenorhabditis elegans; At, Arabidopsis thaliana. Grey: specific 
orthologue present; White: single ancestral orthologue for family. 
component (proposed) function orthologues
PS1
catalytic subunit (De Strooper, 2003; Haass, 2004; Steiner, 2004)
Hs Mm Rn Xl
Dm Ce At
PS2 Hs Mm Rn Xl
Nicastrin substrate recognition (Shah et al., 2005) Hs Mm Rn Xl Dm Ce At
PEN-2 endoproteolysis of PS holoprotein (Periz and Fortini, 2004) Hs Mm Rn Xl Dm Ce At
Aph-1a complex stabilisation and maturation (Lee et al., 2004; Niimura et 
al., 2005) and/or substrate selectivity? (Serneels et al., 2005, and this 
thesis)
Hs Mm Rn Xl Dm Ce At
Aph-1b Hs Mm Rn
Aph-1b’ similar to Aph-1a/-1b? Mm Rn
(continued on next page)
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(Table 1 continued)
substrate (proposed) function γ-secretase reference
APP transport or adhesion function? (De Strooper, 2003)
APLP1 unknown function (Scheinfeld et al., 2002)
APLP2 unknown function (Scheinfeld et al., 2002)
N-cadherin cell adhesion (Marambaud et al., 2003)
E-cadherin cell adhesion (Marambaud et al., 2002)
γ-protocadherin cell adhesion (Haas et al., 2005)
CD43 cell-cell interaction (Andersson et al., 2005)
CD44 cell adhesion
(Lammich et al., 2002; Murakami et 
al., 2003)
CSF-1 receptor protein tyrosine kinase (Wilhelmsen and van der Geer, 2004)
DCC netrin-1 receptor (axon guidance) (Taniguchi et al., 2003)
ErbB4 growth-factor-dependent receptor tyrosine kinase (Ni et al., 2003)
LRP endocytic receptor (May et al., 2002)
ApoER2
essential component Reelin/Disabled-mediated signal 
transduction during neuronal development
(May et al., 2003)
Megalin endocytic receptor (Zou et al., 2004)
Nectin-1α adherance-junction formation (Kim et al., 2002)
Neuregulin1,2 cell growth and differentiation
(Bao et al., 2003; Montero et al., 
2002)
Notch1-4 cell fate / signalling receptor (Schroeter et al., 1998)
Delta1 Notch ligand (Six et al., 2003)
Jagged Notch ligand (Martoglio and Golde, 2003)
Syndecan-3 cell-surface proteoglycan co-receptor (Schulz et al., 2003)
p75 NTR neurotrophin co-receptor (Kanning et al., 2003)
NRADD death domain protein (Gowrishankar et al., 2004)
VGSCβ1-4 cell-cell adhesion and migration (Kim et al., 2005; Wong et al., 2005)
Alcadein α-γ associates with APP through X11L / unknown function (Araki et al., 2004)
Our detailed longitudinal analysis of Aph-1 mRNA levels in developing I/I, II/II and 
III/III rats revealed temporal diﬀ erences in these levels, without any compensation by 
Aph-1a. In addition, the ratios between the Aph-1b and -1a mRNAs diﬀ ered signiﬁ cantly 
between tissues and over time. Th is resulted in spatio-temporally aﬀ ected γ-secretase 
functioning toward various γ-secretase substrates in I/I compared to III/III rat tissues 
(Chapters 4 and 5). Moreover, we observed that in the I/I rats the levels of some, but 
not all, γ-secretase substrates tested were aﬀ ected by the reduced Aph-1b mRNA levels. 
Th is suggests that in vivo Aph-1a and -1b are not functionally redundant but are each 
involved in the preferential cleavage of a subset of γ-secretase substrates. Since γ-secretase 
substrates are part of diverse signalling pathways (from neuronal diﬀ erentiation [notch 
and ErbB4] and synapse formation [nectin-1α] to haemotopoiesis and tumour growth 
[CD44]), cell-cell adhesion [E-cadherin], and vitamin homeostasis [LRP]), the reduced 
Aph-1b expression may well underlie the complex phenotype of the APO-SUS rats.
In Chapter 5, a reduction in p75-NTR processing by γ-secretase was found in certain 
I/I rat tissues. Th e p75 protein is known to be involved in a surprisingly diverse set of 
processes, ranging from cell death to regulation of axon elongation (Casaccia-Bonneﬁ l 
et al., 1996). A more detailed analysis of such cellular processes in the I/I and III/III rats 
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Figure 2. Amino acid sequence comparison of the Aph-1-related proteins in a number of 
species
Species abbreviations: Hs, Homo sapiens; Rn, Rattus norvegicus; Mm, Mus musculus; Xl, Xenopus laevis; 
Xt, Xenopus tropicalis; Dm, Drosophila melanogaster; Ag, Anopheles gambiae; Ce, Caenorhabditis elegans; 
At, Arabidopsis thaliana. Accession numbers: Hs_Aph1b (NP_112591); Rn_Aph1b (XP_578740); 
Mm_Aph1b (NP_808251); Rn_Aph1b’ (XP_217185); Mm_Aph1b’ (NP_080950); Hs_Aph1aL 
(AAH01230); Rn-Aph1aL (XP_345252); Mm_Aph1aL (AAH24111); Hs_Aph1aS (AAH08732); Rn_
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may reveal further evidence for a link between an aﬀ ected γ-secretase cleavage towards 
p75-NTR and the observed I/I phenotype. In addition, for various γ-secretase substrates 
the downstream targets of the intracellular domains (ICDs) are known (e.g. for notch and 
APP). Th ese ICDs translocate to the nucleus where they are involved in transcriptional 
regulation. A more in-depth analysis of the mRNA levels of these downstream targets 
could illustrate that the reduced Aph-1b levels in the I/I rats do not only aﬀ ect γ-secretase 
cleavage activity towards these substrates, but also inﬂ uence their downstream signalling 
pathways (Figure 1). Also at the behavioural level, additional phenotypic eﬀ ects may be 
observed in the rat model, which can be directly related to an aﬀ ected γ-secretase cleavage 
activity. Aberrant APP processing is known to inﬂ uence learning capabilities in mice 
(reviewed by Morgan, 2003). It would therefore be interesting to investigate the learning 
performances of the I/I and III/III rats more thoroughly in a Morris water maze test or 
via other learning paradigms.
Recently, the voltage-gated sodium channel beta 2 subunit (Scn2b) has been discovered 
as a new γ-secretase substrate (Kim et al., 2005; Wong et al., 2005). Scn2b is expressed 
only in central neurons (Jones et al., 1996) and although brain development in Scn2b-
null mice was grossly normal the knock-out mice displayed increased susceptibility to 
epileptic seizures (Chen et al., 2002). Similarly, APO-SUS rats show a signiﬁ cantly 
increased incidence of bursts of bilateral synchronous spike wave discharges (SWDs) in 
their electro-encephalogram (EEG) which is associated with absence epilepsy (de Bruin 
et al., 2000). It is therefore well worth studying the Scn2b pathway in the rat lines. 
In addition, several groups have reported that the γ-secretase substrate neuregulin-1 
(NRG1) is a candidate gene for schizophrenia (Li et al., 2006; Stefansson et al., 2002; 
Tosato et al., 2005). Furthermore, heterozygous NRG1 knock-out mice are hyperactive 
in an open-ﬁ eld test and show an impaired prepulse inhibition, and these behavioural 
phenotypes are partially reversible with clozapine, an atypical antipsychotic drug used to 
treat schizophrenia (Stefansson et al., 2002). Also, mutations in the NRG1 gene can cause 
impaired latent inhibition in mice (Rimer et al., 2005). Th us, analysis of the γ-secretase 
cleavage activity towards NRG1 in the I/I and III/III rats will be very informative and may 
reveal further similarities between the rat model and schizophrenic patients. Recently, 
the NRG1 receptor ErbB4 has also been directly linked to schizophrenia (Silberberg 
et al., 2006). A linkage disequilibrium block within the ErbB4 gene revealed a strong 
association with schizophrenia. In addition, increased ErbB4 transcript levels were found 
in the dorsolateral prefrontal cortex of patients compared to controls. Furthermore, ErbB4 
heterozygous knock-out mice show a behavioural phenotype that overlaps with mouse 
models for schizophrenia (Stefansson et al., 2002). Th us, strong arguments exist for an 
involvement of the γ-secretase-mediated NRG1-ErbB4 pathway in the pathophysiology 
of schizophrenia.
Aph1aS (NP_001014277); Mm_Aph1aS (NP_666216); Xl_Aph1 (AAH89044); Xt_Aph1 (AAH90132); 
Dm_Aph1 (NP_608710); Ag_Aph1 (XP_318923); Ce_Aph1 (NP_492469); At_Aph1 (NP_565724). A 
black background indicates identical and a grey background indicates conserved amino acid residues; 
horizontal bars are indicative of the seven putative transmembrane regions (TMs) in human and rodent 
sequences.
Chapter 7
140
In Chapter 5, we described that γ-secretase cleavage activity towards multiple substrates 
is severely aﬀ ected in the olfactory bulb. It will be of interest to analyse the functioning 
of the olfactory system in the diﬀ erent rat lines, by studying synaptic transmission or 
via behavioural experiments testing odour preference or performance. As an example 
of an odour preference test, the Y-maze could be used in which female rats of either 
line are examined for their preference to odours of males vs. oestrous females (Bakker 
et al., 2002). Furthermore, the cookie test could be used as an olfactory performance 
test (Dawson et al., 2005). An observed olfactory deﬁ cit would prove further similarity 
between the rat model and schizophrenia, where deﬁ cits in odour identiﬁ cation, detection 
threshold sensitivity, discrimination and memory have been reported (Brewer et al., 
1996; Hurwitz et al., 1988; Malaspina et al., 1994; Moberg et al., 1997). Furthermore, 
this would further support our hypothesis that the γ-secretase complex is involved in the 
schizophrenic phenotype.
Interestingly, during early postnatal development of the APO-SUS/UNSUS rats diﬀ erent 
environmental stressors, such as maternal deprivation or cross fostering, have various 
eﬀ ects on the adult phenotype (Degen et al., 2004; Ellenbroek et al., 2000). It would 
therefore be interesting to further analyse the possible eﬀ ects of these environmental 
factors on Aph-1b mRNA levels, γ-secretase activity or certain γ-secretase substrate levels. 
By not only analysing the end situation in the adult rats, but especially during and 
shortly after the stress application, a more detailed understanding of the mechanisms 
underlying the origin of the complex adult phenotype may be obtained.
Extrapolation to schizophrenia in humans
At present, no evidence for an aﬀ ected γ-secretase functioning in schizophrenic patients 
is available. As stated before, opposed to rodents, in humans only one gene encodes the 
Aph-1b protein, so an unequal crossing-over event in this genetic locus cannot occur. 
Initial results of an analysis of the Aph-1b locus in schizophrenic patients did not reveal 
duplications or large deletions in this genomic region (data not shown). However, other 
factors could inﬂ uence the expression levels of the Aph-1b gene in human. Polymorphisms, 
mutations, epigenetic factors, aﬀ ected levels of transcription factors involved in Aph-1b 
mRNA synthesis, and increased Aph-1b protein degradation are just a few ways in which 
the Aph-1b levels could be aﬀ ected in schizophrenics. Furthermore, it must be born 
Figure 3. General model on how a complex phenotype can be generated
Especially proteins that are part of complex, developmentally important networks (e.g. the Aph-1b 
protein) are prime suspects to be the causal factor for a complex stress phenotype, as observed in 
disorders like schizophrenia or depression. The expression of these (neuro-)developmentally important 
genes can be affected in various ways. Genetic mutations and/or epigenetic dysregulations can be either 
inherited or induced during early development, resulting in an affected protein functioning or expression 
level at critical developmental time points. Alternatively, stressful early-life events can directly influence 
protein functioning or expression levels, without the involvement of (epi-)genetic factors. Once protein 
levels or functioning are affected, a direct effect on the phenotype may be observed, but often additional 
stressors will trigger the actual onset of the disorder. The timing and type of stressor is critical for the 
phenotypic outcome. For clarity, not all possible combinations of events are shown. 
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in mind that the signalling pathway in which Aph-1b is involved can also be aﬀ ected 
at numerous other entry points. Th us, variations in other genes that feed into these 
pathways could also lead to similar phenotypes. Together, our ﬁ ndings on the molecular 
basis of the complex phenotype of the APO-SUS/-UNSUS rat model and the phenotypic 
observations in the I/I, II/II and III/III rat lines suggest a general model for the origin 
of a complex phenotype that may be applicable to human (Figure 3). In this model, a 
subtle defect in a (neuro)developmentally important gene may aﬀ ect diverse signalling 
pathways, ultimately resulting in a complex phenotype that is generally thought to be 
caused by multiple aﬀ ected genes. Th e expression or function of such a gene can be 
aﬀ ected in various ways and at various time points during development. In addition, this 
model speculates on the inﬂ uence of environmental stressors on the (epi-)genome, further 
emphasising the interaction between the genome and environment in the aetiology of a 
complex disorder. Th e results presented in this thesis may shed new light on the origin of 
complex disorders, like schizophrenia, and encourage further research into the possible 
involvement of the γ-secretase complex in these devastating disorders.
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Summary
Schizophrenia is a complex neurodevelopmental disorder aﬀ ecting about 1% of the world’s population. It is characterised by abnormal mental functions and 
disturbed behaviour, mostly appearing after puberty as a diverse mixture of positive 
and negative symptoms, and cognitive impairment. Th e severity of the symptoms and 
the chronic pattern of schizophrenia often cause a high degree of disability. Although 
many researchers try to ﬁ nd the origin of this disease, little progress is being made, 
most likely because of the complexity and diversity of the symptoms combined with the 
fact that most symptoms of schizophrenia are usually noticed quite late in the disease 
process. In this respect, heuristic animal models could help greatly to further analyse the 
neurodevelopmental hypothesis of schizophrenia. An example of such a heuristic animal 
model is the APO-SUS/-UNSUS rat model. APO-SUS rats show a range of symptoms 
that are remarkably similar to those observed in schizophrenic patients. Th e goal of the 
research described in this thesis was to understand the molecular mechanism underlying 
the APO-SUS/-UNSUS complex phenotype, which might aid in ﬁ nding the cause of 
schizophrenia in human.
Chapter one gives an introduction to the characteristics and aetiology of schizophrenia, 
the diﬀ erent approaches researchers use to elucidate its cause, and the rationale for using 
animal models, in particular the APO-SUS/-UNSUS rat model.
In chapter two, we describe the use of cDNA and oligonucleotide microarray expression 
proﬁ ling to establish diﬀ erences at the mRNA level between APO-SUS and -UNSUS 
rats in their juvenile and adult state. Remarkably few transcript levels were found to be 
aﬀ ected. Upon validation, the largest diﬀ erences observed turned out to be caused by 
a dissection artefact, namely partial co-dissection of the choroid plexus with some of 
the hippocampal samples analysed. Th e only reproducible mRNA expression diﬀ erence 
concerned the reduction of Aph-1b mRNA in APO-SUS rats; Aph-1b is a component 
of the γ-secretase enzyme complex that is involved in multiple (neuro)developmental 
signalling pathways. Th ese diﬀ erences were found in all tissues, in male and female 
rats, and in the original as well as in an independent replication of the APO-SUS and 
-UNSUS rat lines. Th is strongly suggested that the reduced Aph-1b mRNA expression 
may be causative of the observed phenotype. However, the cause of the reduced expression 
remained a matter of speculation.
Chapter three reports a detailed genomic analysis of the genetic locus of Aph-1b in 
APO-SUS and -UNSUS rats revealing diﬀ erences in gene copy numbers. APO-SUS rats 
harbour only one or two gene copies of Aph-1b, whereas APO-UNSUS rats contain three 
gene copies. Th is gene-dosage imbalance was caused by an unequal crossing-over event 
and the site of recombination was identiﬁ ed as a direct repeat (a segmental duplication) 
within the Aph-1b locus in the rat genome. Th e expression levels of the other γ-secretase 
components were analysed, but no diﬀ erences were found. However, γ-secretase cleavage 
activity towards several substrates was aﬀ ected and, furthermore, the Aph-1b genotypes 
segregated with a number of behavioural phenotypes.
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In chapter four, we describe - through crossing and genetic re-selection - the generation 
of new rat lines with one (I/I), two (II/II) or three (III/III) Aph-1b gene copies against 
otherwise similar general genetic backgrounds. Subsequently, a detailed longitudinal 
expression analysis of the mRNA levels of the Aph-1 family members (Aph-1b, and its 
paralogues Aph-1aS and -1aL) was performed in developing I/I, II/II and III/III rats. 
Th ese analyses revealed gene-dosage dependent diﬀ erences in Aph-1b, but not Aph-1a, 
mRNA expression throughout pre- and post-natal development. We were able to assign 
relative activities to the various Aph-1a and -1b gene promoters. In addition, in the three 
rat lines we observed both tissue-speciﬁ c and temporal alterations in γ-secretase cleavage 
activity towards one of its best-known substrates, the amyloid-β precursor protein APP.
Th e tissue-speciﬁ c changes in γ-secretase activity are further addressed in chapter ﬁ ve, 
where we ﬁ rst analysed the tissue distributions of the Aph-1 family members in the I/I, 
II/II and III/III rats. We observed that the ratios between the Aph-1b and Aph-1a mRNA 
levels greatly varied among III/III rat tissues. A subsequent analysis of the γ-secretase 
cleavage activity towards the three APP superfamily members, p75 neurotrophin receptor, 
ErbB4 and neuregulin-2 in various I/I and III/III rat tissues showed that the cleavage of 
only a subset of the substrates was changed. Furthermore, the observed diﬀ erences were 
restricted to tissues that normally express relatively high Aph-1b compared to Aph-1a 
levels. We thus provided in vivo evidence that subtle alterations in γ-secretase subunit 
composition may lead to both tissue- and substrate-speciﬁ c changes in γ-secretase activity, 
which are likely to contribute to the complexity of the observed phenotype.
In chapter six, we describe a functional analysis of the rat Aph-1a protein by using 
stable transgenesis of the amphibian Xenopus laevis. We generated frogs that expressed 
the ﬂ uorescently tagged Aph-1a protein speciﬁ cally in the melanotrope cells of the 
intermediate pituitary, and analysed the transgenic animals at the protein, cellular, 
physiological and organismal levels. Th e melanotrope cells are involved in the adaptation 
of the frogs skin colour to its background through the production of the prohormone 
proopiomelanocortin (POMC), the precursor of the α-melanophore-stimulating 
hormone. We observed no eﬀ ect of the fusion protein on the processing of POMC 
in the intermediate pituitary cells. Intriguingly, the transgenic melanotrope cells were 
more sensitive to the inhibition of regulated secretion by the dopamine receptor agonist 
apomorphine than wild-type cells. Furthermore, the transgenic frogs adapted more rapidly 
to a white background than wild-type animals. Together, the results of these preliminary 
studies suggest that manipulation of Aph-1 expression in Xenopus melanotrope cells leads 
to a modiﬁ ed sensitivity of the dopaminergic system. Such a link between Aph-1 and 
the Xenopus dopaminergic system is in line with the observed diﬀ erence in apomorphine 
susceptibility of the APO-SUS and -UNSUS rats. Future experiments will have to be 
performed to substantiate this conclusion. 
Finally, in chapter seven the results described in this thesis are discussed and put in 
a broader perspective. Based on our ﬁ ndings in the APO-SUS and -UNSUS rats, we 
present a model explaining how a complex phenotype may arise from a defect in a single 
developmentally important gene, such as Aph-1b. Th is model is not only applicable to the 
APO-SUS and -UNSUS rats, but may also help in the understanding of human complex 
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diseases, such as schizophrenia. Furthermore, recommendations are provided for future 
fundamental research on the I/I, II/II and III/III rat lines as well as for translational 
research on schizophrenic patient material.
In conclusion, the studies described in this thesis suggest that a subtle change in the 
expression of a (neuro)developmentally important protein may spatio-temporally aﬀ ect 
diverse signalling pathways, ultimately resulting in a complex phenotype that is generally 
thought to be caused by multiple aﬀ ected genes. Furthermore, we implicate the possible 
involvement of the γ-secretase enzyme in complex disorders, such as schizophrenia.
Samenvatting
Schizofrenie is een complexe neurobiologische aandoening die ongeveer 1% van de wereldbevolking treft. Karakteristieke kenmerken van schizofrenie zijn 
abnormale mentale functies en een verstoord gedrag, welke meestal tot uiting komen 
na de pubertijd als een combinatie van positieve en negatieve symptomen en cognitieve 
tekortkomingen. Zowel de ernst van de symptomen als het chronische patroon van 
schizofrenie zorgen vaak voor een grote handicap bij de patiënt. Vele onderzoekers pogen 
de oorzaak van deze ziekte te doorgronden, maar er wordt weinig vooruitgang geboekt. 
Dit wordt mede veroorzaakt door de complexiteit en diversiteit van de symptomen, 
samen met het feit dat de meeste symptomen pas tot uiting komen nadat de ziekte zich 
heeft ontwikkeld. Daarom kunnen zogenaamde heuristische diermodellen helpen bij het 
verder analyseren van de neurobiologische hypothese van schizofrenie. Een voorbeeld 
van een dergelijk heuristisch diermodel is het APO-SUS/-UNSUS rattenmodel. APO-
SUS ratten vertonen een scala aan symptomen die opvallend overeenkomen met de 
symptomen van schizofrenie. Het doel van het onderzoek beschreven in dit proefschrift 
was het achterhalen van het moleculaire mechanisme dat ten grondslag ligt aan het 
complexe APO-SUS/-UNSUS fenotype. De gevonden resultaten kunnen bijdragen aan 
het doorgronden van de oorzaak van schizofrenie bij de mens.
Hoofdstuk 1 beschrijft de kenmerken van schizofrenie, wat tot nu toe bekend is over het 
ontstaan van deze ziekte, en op welke manieren naar de oorzaken ervan wordt gezocht, 
inclusief het gebruik van diermodellen en in het bijzonder van het APO-SUS/-UNSUS 
rattenmodel.
In hoofdstuk 2 beschrijven we het gebruik van cDNA en oligonucleotide microarrays 
om verschillen in mRNA niveaus te ontdekken in weefsels van APO-SUS en -UNSUS 
ratten, zowel in pups als in volwassen ratten. Opvallend weinig transcripten vertoonden 
verschillen tussen beide lijnen en na validatie bleken de grootste verschillen veroorzaakt 
te worden door een dissectie-artefact, namelijk een verontreiniging van het hippocampus 
extract met fragmenten van omringend epitheelweefsel, het choroid plexus. Het enige 
reproduceerbare verschil bleek een reductie van de hoeveelheid Aph-1b mRNA in de 
APO-SUS ratten te zijn. Aph-1b is een component van het γ-secretase enzym complex 
dat betrokken is bij vele (neuro-)ontwikkelingsbiologische signaaltransductie- routes. 
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De verschillen in mRNA werden gedetecteerd in alle weefsels, in mannelijke en 
vrouwelijke ratten, en zowel in de originele APO-SUS en -UNSUS rattenlijnen als in een 
onafhankelijke replicatie van deze lijnen. Dit impliceert dat het verlaagde Aph-1b mRNA 
niveau een causale rol speelt bij het ontstaan van het fenotype van de ratten. 
Hoofdstuk 3 beschrijft een gedetailleerde analyse van het Aph-1b gen in de APO-SUS en 
-UNSUS ratten, waarbij een verschil in het aantal gencopieën werd gevonden. APO-SUS 
ratten dragen slechts één of twee Aph-1b genen in hun genoom, terwijl APO-UNSUS 
ratten drie copieën bezitten. Dit verschil in het aantal genen werd veroorzaakt door 
een ongelijke paring tussen chromosoom-armen en de plaats van de recombinatie bleek 
een directe sequentieherhaling in de Aph-1b locus van het rattengenoom. Analyse van 
de expressieniveaus van de andere γ-secretase componenten leverde geen verschillen op. 
Echter, verscheidene γ-secretase substraten bleken minder eﬃ  cient door het γ-secretase 
complex gekliefd te worden. Bovendien segregeerden de verschillende Aph-1b genotypes 
met een aantal fenotypische gedragskenmerken.
In hoofdstuk 4 beschrijven we – via kruisingen en daaropvolgend genetische selectie – het 
maken van nieuwe rattenlijnen met vergelijkbare genetische achtergronden, behalve dat 
ze één (I/I), twee (II/II) of drie (III/III) Aph-1b gencopieën bevatten. Vervolgens werd een 
gedetailleerde longitudinale expressie-analyse uitgevoerd van de mRNA niveaus van de 
Aph-1 familieleden (Aph-1b, en de paralogen Aph-1aS en -1aL) tijdens de ontwikkeling 
van de I/I, II/II en III/III ratten. Deze analyse liet zien dat tijdens de gehele pre- en 
postnatale ontwikkeling er gendosis-afhankelijke verschillen in het mRNA niveau van 
Aph-1b, maar niet van Aph-1a, aanwezig waren. Aan de promotoren van de Aph-1a en 
-1b genen konden relatieve activiteiten worden toegewezen. Daarnaast werden in de drie 
rattenlijnen zowel weefselspeciﬁ eke als tijdsafhankelijke veranderingen in de γ-secretase 
klievingsactiviteit gevonden voor één van de meest bekende substraten, het amyloid-β
voorloper eiwit APP.
In hoofdstuk 5 wordt eveneens aandacht besteed aan de weefselspeciﬁ citeit van de 
verschillen in γ-secretase activiteit. Allereerst werd de mRNA weefseldistributie van de 
Aph-1 familieleden in de I/I, II/II en III/III ratten bepaald. In de weefsels van III/III 
ratten bleken de ratios tussen de Aph-1b en Aph-1a mRNA niveaus sterk te variëren. 
Daarna werd in verscheidene I/I en III/III rattenweefsels een analyse uitgevoerd van de 
γ-secretase klievingsactiviteiten voor de drie APP superfamilieleden, de p75 neurotroﬁ ne 
receptor, ErbB4 en neureguline-2. De klieving van slechts een deel van deze substraten 
was veranderd. Bovendien bleken de gevonden verschillen alleen aanwezig te zijn in 
weefsels die, ten opzichte van Aph-1a,  normaal een relatief hoog Aph-1b niveau hebben. 
Hiermee hebben we in vivo bewijs geleverd dat subtiele verschillen in de samenstelling 
van het γ-secretase complex kunnen leiden tot zowel weefsel- als substraatspeciﬁ eke 
veranderingen in γ-secretase activiteit. Deze veranderingen dragen waarschijnlijk bij aan 
de vorming van het waargenomen complexe fenotype.
In hoofdstuk 6 beschrijven we de functionele analyse van het ratten Aph-1a eiwit via 
stabiele transgenese van de amﬁ bie Xenopus laevis. Kikkers werden gegenereerd die het 
ﬂ uorescerend gemerkte Aph-1a eiwit speciﬁ ek aanmaakten in de melanotrope cellen van 
de hypofyse middenkwab, en deze transgene dieren werden geanalyseerd op het eiwit-, 
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cellulair, fysiologisch en organismaal niveau. De melanotrope cellen uit de hypofyse 
middenkwab van de kikker zijn betrokken bij de aanpassing van de huidskleur aan de 
omgeving, namelijk door de aanmaak van het prohormoon pro-opiomelanocortine 
(POMC), het voorloper-eiwit van het α-melanofoor-stimulerend hormoon. We vonden 
geen eﬀ ect van de overexpressie van het fusie-eiwit op de klieving van POMC in de 
cellen van de hypofyse middenkwab. In vergelijking met wild-type cellen, bleken de 
transgene melanotrope cellen wel gevoeliger te zijn voor de inhibitie van de gereguleerde 
secretieroute middels de dopamine receptor agonist apomorﬁ ne. Daarnaast adapteerden 
de transgene kikkers sneller aan een witte achtergrond dan wild-type dieren. De resultaten 
van deze voorlopige studies suggereren dat de manupulatie van de Aph-1 expressie in de 
Xenopus melanotrope cellen leidt tot een veranderde gevoeligheid van het dopaminerge 
systeem. Een dergelijke link tussen Aph-1 en het Xenopus dopaminerge systeem is in 
overeenstemming met de gevonden verschillen in apomorﬁ ne gevoeligheid van de APO-
SUS en -UNSUS ratten. Verdere experimenten zullen moeten worden uitgevoerd om 
deze conclusie te versterken.
Tot slot worden in hoofdstuk 7 de resultaten, die beschreven zijn in dit proefschrift, 
bediscussiëerd en in een breder perspectief geplaatst. Gebaseerd op onze bevindingen 
in de APO-SUS en -UNSUS ratten presenteren we een model dat verklaart hoe een 
complex fenotype kan ontstaan door een defect in één enkel gen dat belangrijk is voor de 
ontwikkeling van het organisme, zoals het Aph-1b gen. Dit model is niet alleen toepasbaar 
op de APO-SUS en -UNSUS ratten, maar het kan ook helpen bij het doorgronden 
van complexe humane ziekten, zoals schizofrenie. Verder worden er in dit hoofdstuk 
aanbevelingen gedaan voor vervolgonderzoek aan de I/I, II/II en III/III rattenlijnen, 
maar ook aan patiënten met schizofrenie.
Samenvattend suggereert het onderzoek beschreven in dit proefschrift, dat een subtiele 
verandering in de expressie van één eiwit dat (neuro-)ontwikkelingsbiologisch van belang 
is een scala aan signaaltransductieroutes kan beïnvloeden op een zowel weefselspeciﬁ eke 
als tijdsafhankelijke manier. Het uiteindelijke resultaat is een complex fenotype, waarvan 
in het algemeen wordt verondersteld dat het veroorzaakt zou worden door de aantasting 
van meerdere genen. Daarnaast geven de resultaten aan dat het γ-secretase enzym mogelijk 
betrokken is bij complexe ziekten, zoals schizofrenie.
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